Compounds for immunotherapy of prostate cancer and methods for their use

ABSTRACT

Compounds and methods for treating prostate cancer are provided. The inventive compounds include polypeptides containing at least a portion of a prostate tumor protein. Vaccines and pharmaceutical compositions for immunotherapy of prostate cancer comprising such polypeptides, or DNA molecules encoding such polypeptides, are also provided, together with DNA molecules for preparing the inventive polypeptides.

REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of U.S. patent application Ser. No. 08/904,804, filed Aug. 1, 1997, which is a continuation-in-part of U.S. patent application Ser. No. 08/806,099, filed Feb. 25, 1997.

TECHNICAL FIELD

The present invention relates generally to compositions and methods for the treatment of prostate cancer. The invention is more particularly related to polypeptides comprising at least a portion of a prostate protein and to DNA molecules encoding such polypeptides. Such polypeptides may be used in vaccines and pharmaceutical compositions for treatment of prostate cancer.

BACKGROUND OF THE INVENTION

Prostate cancer is the most common form of cancer among males, with an estimated incidence of 30% in men over the age of 50. Overwhelming clinical evidence shows that human prostate cancer has the propensity to metastasize to bone, and the disease appears to progress inevitably from androgen dependent to androgen refractory status, leading to increased patient mortality. This prevalent disease is currently the second leading cause of cancer death among men in the U.S.

In spite of considerable research into therapies for the disease, prostate cancer remains difficult to treat. Commonly, treatment is based on surgery and/or radiation therapy, but these methods are ineffective in a significant percentage of cases. Two previously identified prostate specific proteins—prostate specific antigen (PSA) and prostatic acid phosphatase (PAP)—have limited therapeutic and diagnostic potential. For example, PSA levels do not always correlate well with the presence of prostate cancer, being positive in a percentage of non-prostate cancer cases, including benign prostatic hyperplasia (BPH). Furthermore, PSA measurements correlate with prostate volume, and do not indicate the level of metastasis.

Accordingly, there remains a need in the art for improved vaccines and treatment methods for prostate cancer.

SUMMARY OF THE INVENTION

The present invention provides compounds and methods for immunotherapy of prostate cancer. In one aspect, polypeptides are provided comprising at least an immunogenic portion of a prostate tumor protein or a variant of said protein that differs only in conservative substitutions and/or modifications, wherein the prostate tumor protein comprises an amino acid sequence encoded by a DNA molecule having a sequence selected from the group consisting of nucleotide sequences recited in SEQ ID NO: 2, 3, 8-29, 41-45, 47-52, 54-65, 70, 73-74, 79, 81, 87, 90, 92, 93, 97, 103, 104, 107, 109-111, 115-160, 171, 173-175, 177, the complements of said nucleotide sequences and variants thereof.

In related aspects, DNA molecules encoding the above polypeptides are provided. In specific embodiments, such DNA molecules include sequences provided in SEQ ID NO: 2, 3, 8-29, 41-45, 47-52, 54-65, 70, 73-74, 79, 81, 87, 90, 92, 93, 97, 103, 104, 107, 109-111, 115-160, 171, 173-175, 177. The present invention further provides expression vectors comprising the above DNA molecules and host cells transformed or transfected with such expression vectors. In preferred embodiments, the host cells are selected from the group consisting of E coli, yeast and mammalian cells.

In another aspect, the present invention provides fusion proteins comprising a first and a second inventive polypeptide or, alternatively, an inventive polypeptide and a known prostate antigen.

The present invention also provides pharmaceutical compositions comprising one or more of the above polypeptides, or a DNA molecule encoding such polypeptides, and a physiologically acceptable carrier, together with vaccines comprising one or more of such polypeptide or DNA molecules in combination with a non-specific immune response enhancer.

In related aspects, pharmaceutical compositions for the treatment of prostate cancer comprising one or more polypeptides and a physiologically acceptable carrier are provided, wherein the polypeptide comprises an immunogenic portion of a prostate tumor protein or of a variant of said protein that differs only in conservative substitutions and/or modifications, the prostate tumor protein being encoded by a DNA molecule having a sequence selected from the group consisting of nucleotide sequences recited in SEQ ID NO: 5-7, 30-40, 46, 53, 66-69, 71, 72, 75-78, 80, 82-86, 88, 89, 91, 94-96, 98-102, 105, 106 and 161-170, the complements of said nucleotide sequences and variants thereof. The invention also provides vaccines for the treatment of prostate cancer comprising such polypeptides in combination with a non-specific immune response enhancer, together with pharmaceutical compositions and vaccines comprising one or more DNA molecules having a sequence provided in SEQ ID NO: 5-7, 30-40, 46, 53, 66-69, 71, 72, 75-78, 80, 82-86, 88, 89, 91, 94-96, 98-102, 105, 106 and 161-170. Pharmaceutical compositions and vaccines comprising one or more of the above fusion proteins are also provided.

In yet another aspect, methods are provided for inhibiting the development of prostate cancer in a patient, comprising administering an effective amount of at least one of the above pharmaceutical compositions and/or vaccines.

These and other aspects of the present invention will become apparent upon reference to the following detailed description and attached drawings. All references disclosed herein are hereby incorporated by reference in their entirety as if each was incorporated individually.

DETAILED DESCRIPTION OF THE INVENTION

As noted above, the present invention is generally directed to compositions and methods for the immunotherapy of prostate cancer. The inventive compositions are generally polypeptides that comprise at least a portion of a prostate tumor protein. Also included within the present invention are molecules (such as an antibody or fragment thereof) that bind to the inventive polypeptides. Such molecules are referred to herein as “binding agents.”

In particular, the subject invention discloses polypeptides comprising at least a portion of a human prostate tumor protein, or a variant of such a protein that differs only in conservative substitutions and/or modifications, wherein the prostate tumor protein includes an amino acid sequence encoded by a DNA molecule having a sequence selected from the group consisting of nucleotide sequences recited in SEQ ID NO: 2, 3, 8-29, 41-45, 47-52, 54-65, 70, 73-74, 79, 81, 87, 90, 92, 93, 97, 103, 104, 107, 109-111 and 115-160, the complements of said nucleotide sequences and variants thereof. As used herein, the term “polypeptide” encompasses amino acid chains of any length, including full length proteins, wherein the amino acid residues are linked by covalent peptide bonds. Thus, a polypeptide comprising a portion of one of the above prostate proteins may consist entirely of the portion, or the portion may be present within a larger polypeptide that contains additional sequences. The additional sequences may be derived from the native protein or may be heterologous, and such sequences may be immunoreactive and/or antigenic.

As used herein, an “immunogenic portion” of a human prostate tumor protein is a portion that is capable of eliciting an immune response in a patient inflicted with prostate cancer and as such binds to antibodies present within sera from a prostate cancer patient. Immunogenic portions of the proteins described herein may thus be identified in antibody binding assays. Such assays may generally be performed using any of a variety of means known to those of ordinary skill in the art, as described, for example, in Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1988. For example, a polypeptide may be immobilized on a solid support (as described below) and contacted with patient sera to allow binding of antibodies within the sera to the immobilized polypeptide. Unbound sera may then be removed and bound antibodies detected using, for example, ¹²⁵I-labeled Protein A. Alternatively, a polypeptide may be used to generate monoclonal and polyclonal antibodies for use in detection of the polypeptide in blood or other fluids of prostate cancer patients.

The compositions and methods of the present invention also encompass variants of the above polypeptides and DNA molecules. A polypeptide “variant,” as used herein, is a polypeptide that differs from the recited polypeptide only in conservative substitutions and/or modifications, such that the therapeutic, antigenic and/or immunogenic properties of the polypeptide are retained. Polypeptide variants preferably exhibit at least about 70%, more preferably at least about 90% and most preferably at least about 95% identity to the identified polypeptides. For prostate tumor polypeptides with immunoreactive properties, variants may, alternatively, be identified by modifying the amino acid sequence of one of the above polypeptides, and evaluating the immunoreactivity of the modified polypeptide. For prostate tumor polypeptides useful for the generation of diagnostic binding agents, a variant may be identified by evaluating a modified polypeptide for the ability to generate antibodies that detect the presence or absence of prostate cancer. Such modified sequences may be prepared and tested using, for example, the representative procedures described herein.

As used herein, a “conservative substitution” is one in which an amino acid is substituted for another amino acid that has similar properties, such that one skilled in the art of peptide chemistry would expect the secondary structure and hydropathic nature of the polypeptide to be substantially unchanged. In general, the following groups of amino acids represent conservative changes: (1) ala, pro, gly, glu, asp, gln, asn, ser, thr; (2) cys, ser, tyr, thr; (3) val, ile, leu, met, ala, phe; (4) lys, arg, his; and (5) phe, tyr, trp, his.

Variants may also, or alternatively, contain other modifications, including the deletion or addition of amino acids that have minimal influence on the antigenic properties, secondary structure and hydropathic nature of the polypeptide. For example, a polypeptide may be conjugated to a signal (or leader) sequence at the N-terminal end of the protein which co-translationally or post-translationally directs transfer of the protein. The polypeptide may also be conjugated to a linker or other sequence for ease of synthesis, purification or identification of the polypeptide (e.g., poly-His), or to enhance binding of the polypeptide to a solid support. For example, a polypeptide may be conjugated to an immunoglobulin Fc region.

A nucleotide “variant” is a sequence that differs from the recited nucleotide sequence in having one or more nucleotide deletions, substitutions or additions. Such modifications may be readily introduced using standard mutagenesis techniques, such as oligonucleotide-directed site-specific mutagenesis as taught, for example, by Adelman et al. (DNA, 2:183, 1983). Nucleotide variants may be naturally occurring allelic variants, or non-naturally occurring variants. Variant nucleotide sequences preferably exhibit at least about 70%, more preferably at least about 80% and most preferably at least about 90% identity to the recited sequence. Such variant nucleotide sequences will generally hybridize to the recite nucleotide sequence under stringent conditions. As used herein, “stringent conditions” refers to prewashing in a solution of 6X SSC, 0.2% SDS; hybridizing at 65° C., 6X SSC, 0.2% SDS overnight; followed by two washes of 30 minutes each in 1X SSC, 0.1% SDS at 65° C. and two washes of 30 minutes each in 0.2X SSC, 0.1% SDS at 65° C.

“Polypeptides” as used herein also include combination, or fusion, polypeptides. A “combination polypeptide” is a polypeptide comprising at least one of the above immunogenic portions and one or more additional immunogenic prostate tumor-specific sequences, which are joined via a peptide linkage into a single amino acid chain. The sequences may be joined directly (i.e., with no intervening amino acids) or may be joined by way of a linked sequence (e.g., Gly-Cys-Gly) that does not significantly diminish the immunogenic properties of the component polypeptides.

The prostate tumor proteins of the present invention, and DNA molecules encoding such proteins, may be isolated from prostate tumor tissue using any of a variety of methods well known in the art. DNA sequences corresponding to a gene (of a portion thereof) encoding one of the inventive prostate tumor proteins may be isolated from a prostate tumor cDNA library using a subtraction technique as described in detail below. Examples of such DNA sequences are provided in SEQ ID NOS: 1-107, 109-111, 115-171, 173-175 and 177. Partial DNA sequences thus obtained may be used to design oligonucleotide primers for the amplification of full-length DNA sequences in a polymerase chain reaction (PCR), using techniques well known in the art (see, for example, Mullis et al., Cold Spring Harbor Symp. Quant. Biol., 51:263, 1987; Erlich ed., PCR Technology, Stockton Press, N.Y., 1989). Once a DNA sequence encoding a polypeptide is obtained, any of the above modifications may be readily introduced using standard mutagenesis techniques, such as oligonucleotide-directed site-specific mutagenesis as taught, for example, by Adelman et al. (DNA, 2:183, 1983).

The prostate tumor polypeptides disclosed herein may also be generated by synthetic or recombinant means. Synthetic polypeptides having fewer than about 100 amino acids, and generally fewer than about 50 amino acids, may be generated using techniques well known to those of ordinary skill in the art. For example, such polypeptides may be synthesized using any of the commercially available solid-phase techniques, such as the Merrifield solid-phase synthesis method, where amino acids are sequentially added to a growing amino acid chain (see, for example, Merrifield, J. Am. Chem. Soc. 85:2149-2146, 1963). Equipment for automated synthesis of polypeptides is commercially available from suppliers such as Perkin Elmer/Applied BioSystems Division (Foster City, Calif.), and may be operated according to the manufacturer's instructions.

Alternatively, any of the above polypeptides may be produced recombinantly by inserting a DNA sequence that encodes the polypeptide into an expression vector and expressing the protein in an appropriate host. Any of a variety of expression vectors known to those of ordinary skill in the art may be employed to express recombinant polypeptides of this invention. Expression may be achieved in any appropriate host cell that has been transformed or transfected with an expression vector containing a DNA molecule that encodes a recombinant polypeptide. Suitable host cells include prokaryotes, yeast and higher eukaryotic cells. Preferably, the host cells employed are E. coli, yeast or a mammalian cell line, such as CHO cells. The DNA sequences expressed in this manner may encode naturally occurring polypeptides, portions of naturally occurring polypeptides, or other variants thereof.

In general, regardless of the method of preparation, the polypeptides disclosed herein are prepared in substantially pure form (i.e., the polypeptides are homogenous as determined by amino acid composition and primary sequence analysis). Preferably, the polypeptides are at least about 90% pure, more preferably at least about 95% pure and most preferably at least about 99% pure. In certain preferred embodiments, described in more detail below, the substantially pure polypeptides are incorporated into pharmaceutical compositions or vaccines for use in one or more of the methods disclosed herein.

In a related aspect, the present invention provides fusion proteins comprising a first and a second inventive polypeptide or, alternatively, a polypeptide of the present invention and a known prostate antigen, together with variants of such fusion proteins. The fusion proteins of the present invention may also include a linker peptide between the first and second polypeptides.

A DNA sequence encoding a fusion protein of the present invention is constructed using known recombinant DNA techniques to assemble separate DNA sequences encoding the first and second polypeptides into an appropriate expression vector. The 3′ end of a DNA sequence encoding the first polypeptide is ligated, with or without a peptide linker, to the 5′ end of a DNA sequence encoding the second polypeptide so that the reading frames of the sequences are in phase to permit mRNA translation of the two DNA sequences into a single fusion protein that retains the biological activity of both the first and the second polypeptides.

A peptide linker sequence may be employed to separate the first and the second polypeptides by a distance sufficient to ensure that each polypeptide folds into its secondary and tertiary structures. Such a peptide linker sequence is incorporated into the fusion protein using standard techniques well known in the art. Suitable peptide linker sequences may be chosen based on the following factors: (1) their ability to adopt a flexible extended conformation; (2) their inability to adopt a secondary structure that could interact with functional epitopes on the first and second polypeptides; and (3) the lack of hydrophobic or charged residues that might react with the polypeptide functional epitopes. Preferred peptide linker sequences contain Gly, Asn and Ser residues. Other near neutral amino acids, such as Thr and Ala may also be used in the linker sequence. Amino acid sequences which may be usefully employed as linkers include those disclosed in Maratea et al., Gene 40:39-46, 1985; Murphy et al., Proc. Natl. Acad. Sci. USA 83:8258-8262, 1986; U.S. Pat. No. 4,935,233 and U.S. Pat. No. 4,751,180. The linker sequence may be from 1 to about 50 amino acids in length. Peptide sequences are not required when the first and second polypeptides have non-essential N-terminal amino acid regions that can be used to separate the functional domains and prevent steric interference.

The ligated DNA sequences are operably linked to suitable transcriptional or translational regulatory elements. The regulatory elements responsible for expression of DNA are located only 5′ to the DNA sequence encoding the first polypeptides. Similarly, stop codons require to end translation and transcription termination signals are only present 3′ to the DNA sequence encoding the second polypeptide.

Polypeptides of the present invention that comprise an immunogenic portion of a prostate tumor protein may generally be used for immunotherapy of prostate cancer, wherein the polypeptide stimulates the patient's own immune response to prostate tumor cells. In further aspects, the present invention provides methods for using one or more of the immunoreactive polypeptides encoded by a DNA molecule having a sequence provided in SEQ ID NOS: 1-107, 109-111, 115-171, 173-175 and 177 (or fusion proteins comprising one or more such polypeptides and/or DNA encoding such polypeptides) for immunotherapy of prostate cancer in a patient. As used herein, a “patient” refers to any warm-blooded animal, preferably a human. A patient may be afflicted with a disease, or may be free of detectable disease. Accordingly, the above immunoreactive polypeptides (or fusion proteins or DNA molecules encoding such polypeptides) may be used to treat prostate cancer or to inhibit the development of prostate cancer. The polypeptides may be administered either prior to or following surgical removal of primary tumors and/or treatment by administration of radiotherapy and conventional chemotherapeutic drugs.

In these aspects, the polypeptide or fusion protein is generally present within a pharmaceutical composition and/or a vaccine. Pharmaceutical compositions may comprise one or more polypeptides, each of which may contain one or more of the above sequences (or variants thereof), and a physiologically acceptable carrier. The vaccines may comprise one or more of such polypeptides and a non-specific immune response enhancer, such as an adjuvant, biodegradable microsphere (e.g., polylactic galactide) or a liposome (into which the polypeptide is incorporated). Pharmaceutical compositions and vaccines may also contain other epitopes of prostate tumor antigens, either incorporated into a combination polypeptide (i.e., a single polypeptide that contains multiple epitopes) or present within a separate polypeptide.

Alternatively, a pharmaceutical composition or vaccine may contain DNA encoding one or more of the above polypeptides, such that the polypeptide is generated in situ. In such pharmaceutical compositions and vaccines, the DNA may be present within any of a variety of delivery systems known to those of ordinary skill in the art, including nucleic acid expression systems, bacteria and viral expression systems. Appropriate nucleic acid expression systems contain the necessary DNA sequences for expression in the patient (such as a suitable promoter). Bacterial delivery systems involve the administration of a bacterium (such as Bacillus-Calmette-Guerrin) that expresses an epitope of a prostate cell antigen on its cell surface. In a preferred embodiment, the DNA may be introduced using a viral expression system (e.g., vaccinia or other pox virus, retrovirus, or adenovirus), which may involve the use of a non-pathogenic (defective), replication competent virus. Suitable systems are disclosed, for example, in Fisher-Hoch et al., PNAS 86:317-321, 1989; Flexner et al., Ann. N.Y. Acad. Sci. 569:86-103, 1989; Flexner et al., Vaccine 8:17-21, 1990; U.S. Pat. Nos. 4,603,112, 4,769,330, and 5,017,487; WO 89/01973; U.S. Pat. No. 4,777,127; GB 2,200,651; EP 0,345,242; WO 91/02805; Berkner, Biotechniques 6:616-627, 1988; Rosenfeld et al., Science 252:431-434, 1991; Kolls et al., PNAS 91:215-219, 1994; Kass-Eisler et al., PNAS 90:11498-11502, 1993; Guzman et al., Circulation 88:2838-2848, 1993; and Guzman et al., Cir. Res. 73:1202-1207, 1993. Techniques for incorporating DNA into such expression systems are well known to those of ordinary skill in the art. The DNA may also be “naked,” as described, for example, in published PCT application WO 90/11092, and Ulmer et al., Science 259:1745-1749, 1993, reviewed by Cohen, Science 259:1691-1692, 1993. The uptake of naked DNA may be increased by coating the DNA onto biodegradable beads, which are efficiently transported into the cells.

Routes and frequency of administration, as well as dosage, will vary from individual to individual and may parallel those currently being used in immunotherapy of other diseases. In general, the pharmaceutical compositions and vaccines may be administered by injection (e.g., intracutaneous, intramuscular, intravenous or subcutaneous), intranasally (e.g., by aspiration) or orally. Between 1 and 10 doses may be administered over a 3-24 week period. Preferably, 4 doses are administered, at an interval of 3 months, and booster administrations may be given periodically thereafter. Alternate protocols may be appropriate for individual patients. A suitable dose is an amount of polypeptide or DNA that is effective to raise an immune response (cellular and/or humoral) against prostate tumor cells in a treated patient. A suitable immune response is at least 10-50% above the basal (i.e., untreated) level. In general, the amount of polypeptide present in a dose (or produced in situ by the DNA in a dose) ranges from about 1 pg to about 100 mg per kg of host, typically from about 10 pg to about 1 mg, and preferably from about 100 pg to about 1 μg. Suitable dose sizes will vary with the size of the patient, but will typically range from about 0.01 mL to about 5 mL.

While any suitable carrier known to those of ordinary skill in the art may be employed in the pharmaceutical compositions of this invention, the type of carrier will vary depending on the mode of administration. For parenteral administration, such as subcutaneous injection, the carrier preferably comprises water, saline, alcohol, a lipid, a wax and/or a buffer. For oral administration, any of the above carriers or a solid carrier, such as mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, glucose, sucrose, and/or magnesium carbonate, may be employed. Biodegradable microspheres (e.g., polylactic glycolide) may also be employed as carriers for the pharmaceutical compositions of this invention. Suitable biodegradable microspheres are disclosed, for example, in U.S. Pat. Nos. 4,897,268 and 5,075,109.

Any of a variety of non-specific immune response enhancers may be employed in the vaccines of this invention. For example, an adjuvant may be included. Most adjuvants contain a substance designed to protect the antigen from rapid catabolism, such as aluminum hydroxide or mineral oil, and a nonspecific stimulator of immune response, such as lipid A, Bordella pertussis or Mycobacterium tuberculosis. Such adjuvants are commercially available as, for example, Freund's Incomplete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, Mich.) and Merck Adjuvant 65 (Merck and Company, Inc., Rahway, N.J.).

Polypeptides disclosed herein may also be employed in ex vivo treatment of prostate cancer. For example, cells of the immune system, such as T cells, may be isolated from the peripheral blood of a patient, using a commercially available cell separation system, such as CellPro Incorporated's (Bothell, Wash.) CEPRATE™ system (see U.S. Pat. No. 5,240,856; U.S. Pat. No. 5,215,926; WO 89/06280; WO 91/16116 and WO 92/07243). The separated cells are stimulated with one or more of the immunoreactive polypeptides contained within a delivery vehicle, such as a microsphere, to provide antigen-specific T cells. The population of tumor antigen-specific T cells is then expanded using standard techniques and the cells are administered back to the patient.

Polypeptides of the present invention may also, or alternatively, be used to generate binding agents, such as antibodies or fragments thereof, that are capable of detecting metastatic human prostate tumors. Binding agents of the present invention may generally be prepared using methods known to those of ordinary skill in the art, including the representative procedures described herein. Binding agents are capable of differentiating between patients with and without prostate cancer, using the representative assays described herein. In other words, antibodies or other binding agents raised against a prostate tumor protein, or a suitable portion thereof, will generate a signal indicating the presence of primary or metastatic prostate cancer in at least about 20% of patients afflicted with the disease, and will generate a negative signal indicating the absence of the disease in at least about 90% of individuals without primary or metastatic prostate cancer. Suitable portions of such prostate tumor proteins are portions that are able to generate a binding agent that indicates the presence of primary or metastatic prostate cancer in substantially all (i.e. at least about 80%, and preferably at least about 90%) of the patients for which prostate cancer would be indicated using the full length protein, and that indicate the absence of prostate cancer in substantially all of those samples that would be negative when tested with full length protein. The representative assays described below, such as the two-antibody sandwich assay, may generally be employed for evaluating the ability of a binding agent to detect metastatic human prostate tumors.

The ability of a polypeptide prepared as described herein to generate antibodies capable of detecting primary or metastatic human prostate tumors may generally be evaluated by raising one or more antibodies against the polypeptide (using, for example, a representative method described herein) and determining the ability of such antibodies to detect such tumors in patients. This determination may be made by assaying biological samples from patients with and without primary or metastatic prostate cancer for the presence of a polypeptide that binds to the generated antibodies. Such test assays may be performed, for example, using a representative procedure described below. Polypeptides that generate antibodies capable of detecting at least 20% of primary or metastatic prostate tumors by such procedures are considered to be useful in assays for detecting primary or metastatic human prostate tumors. Polypeptide specific antibodies may be used alone or in combination to improve sensitivity.

Polypeptides capable of detecting primary or metastatic human prostate tumors may be used as markers for diagnosing prostate cancer or for monitoring disease progression in patients. In one embodiment, prostate cancer in a patient may be diagnosed by evaluating a biological sample obtained from the patient for the level of one or more of the above polypeptides, relative to a predetermined cut-off value. As used herein, suitable “biological samples” include blood, sera, urine and/or prostate secretions.

The level of one or more of the above polypeptides may be evaluated using any binding agent specific for the polypeptide(s). A “binding agent,” in the context of this invention, is any agent (such as a compound or a cell) that binds to a polypeptide as described above. As used herein, “binding” refers to a noncovalent association between two separate molecules (each of which may be free (i.e., in solution) or present on the surface of a cell or a solid support), such that a “complex” is formed. Such a complex may be free or immobilized (either covalently or noncovalently) on a support material. The ability to bind may generally be evaluated by determining a binding constant for the formation of the complex. The binding constant is the value obtained when the concentration of the complex is divided by the product of the component concentrations. In general, two compounds are said to “bind” in the context of the present invention when the binding constant for complex formation exceeds about 10³ L/mol. The binding constant may be determined using methods well known to those of ordinary skill in the art.

Any agent that satisfies the above requirements may be a binding agent. For example, a binding agent may be a ribosome with or without a peptide component, an RNA molecule or a peptide. In a preferred embodiment, the binding partner is an antibody, or a fragment thereof. Such antibodies may be polyclonal, or monoclonal. In addition, the antibodies may be single chain, chimeric, CDR-grafted or humanized. Antibodies may be prepared by the methods described herein and by other methods well known to those of skill in the art.

There are a variety of assay formats known to those of ordinary skill in the art for using a binding partner to detect polypeptide markers in a sample. See, e.g., Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1988. In a preferred embodiment, the assay involves the use of binding partner immobilized on a solid support to bind to and remove the polypeptide from the remainder of the sample. The bound polypeptide may then be detected using a second binding partner that contains a reporter group. Suitable second binding partners include antibodies that bind to the binding partner/polypeptide complex. Alternatively, a competitive assay may be utilized, in which a polypeptide is labeled with a reporter group and allowed to bind to the immobilized binding partner after incubation of the binding partner with the sample. The extent to which components of the sample inhibit the binding of the labeled polypeptide to the binding partner is indicative of the reactivity of the sample with the immobilized binding partner.

The solid support may be any material known to those of ordinary skill in the art to which the antigen may be attached. For example, the solid support may be a test well in a microtiter plate or a nitrocellulose or other suitable membrane. Alternatively, the support may be a bead or disc, such as glass, fiberglass, latex or a plastic material such as polystyrene or polyvinylchloride. The support may also be a magnetic particle or a fiber optic sensor, such as those disclosed, for example, in U.S. Pat. No. 5,359,681. The binding agent may be immobilized on the solid support using a variety of techniques known to those of skill in the art, which are amply described in the patent and scientific literature. In the context of the present invention, the term “immobilization” refers to both noncovalent association, such as adsorption, and covalent attachment (which may be a direct linkage between the antigen and functional groups on the support or may be a linkage by way of a cross-linking agent). Immobilization by adsorption to a well in a microtiter plate or to a membrane is preferred. In such cases, adsorption may be achieved by contacting the binding agent, in a suitable buffer, with the solid support for a suitable amount of time. The contact time varies with temperature, but is typically between about 1 hour and about 1 day. In general, contacting a well of a plastic microtiter plate (such as polystyrene or polyvinylchloride) with an amount of binding agent ranging from about 10 ng to about 10 μg and preferably about 100 ng to about 1 μg, is sufficient to immobilize an adequate amount of binding agent.

Covalent attachment of binding agent to a solid support may generally be achieved by first reacting the support with a bifinctional reagent that will react with both the support and a functional group, such as a hydroxyl or amino group, on the binding agent. For example, the binding agent may be covalently attached to supports having an appropriate polymer coating using benzoquinone or by condensation of an aldehyde group on the support with an amine and an active hydrogen on the binding partner (see, e.g., Pierce Immunotechnology Catalog and Handbook, 1991, at A12-A13).

In certain embodiments, the assay is a two-antibody sandwich assay. This assay may be performed by first contacting an antibody that has been immobilized on a solid support, commonly the well of a microtiter plate, with the sample, such that polypeptides within the sample are allowed to bind to the immobilized antibody. Unbound sample is then removed from the immobilized polypeptide-antibody complexes and a second antibody (containing a reporter group) capable of binding to a different site on the polypeptide is added. The amount of second antibody that remains bound to the solid support is then determined using a method appropriate for the specific reporter group.

More specifically, once the antibody is immobilized on the support as described above, the remaining protein binding sites on the support are typically blocked. Any suitable blocking agent known to those of ordinary skill in the art, such as bovine serum albumin or Tween 20™ (Sigma Chemical Co., St. Louis, Mo.). The immobilized antibody is then incubated with the sample, and polypeptide is allowed to bind to the antibody. The sample may be diluted with a suitable diluent, such as phosphate-buffered saline (PBS) prior to incubation. In general, an appropriate contact time (i.e., incubation time) is that period of time that is sufficient to detect the presence of polypeptide within a sample obtained from an individual with prostate cancer. Preferably, the contact time is sufficient to achieve a level of binding that is at least about 95% of that achieved at equilibrium between bound and unbound polypeptide. Those of ordinary skill in the art will recognize that the time necessary to achieve equilibrium may be readily determined by assaying the level of binding that occurs over a period of time. At room temperature, an incubation time of about 30 minutes is generally sufficient.

Unbound sample may then be removed by washing the solid support with an appropriate buffer, such as PBS containing 0.1% Tween 20™. The second antibody, which contains a reporter group, may then be added to the solid support. Preferred reporter groups include enzymes (such as horseradish peroxidase), substrates, cofactors, inhibitors, dyes, radionuclides, luminescent groups, fluorescent groups and biotin. The conjugation of antibody to reporter group may be achieved using standard methods known to those of ordinary skill in the art.

The second antibody is then incubated with the immobilized antibody-polypeptide complex for an amount of time sufficient to detect the bound polypeptide. An appropriate amount of time may generally be determined by assaying the level of binding that occurs over a period of time. Unbound second antibody is then removed and bound second antibody is detected using the reporter group. The method employed for detecting the reporter group depends upon the nature of the reporter group. For radioactive groups, scintillation counting or autoradiographic methods are generally appropriate. Spectroscopic methods may be used to detect dyes, luminescent groups and fluorescent groups. Biotin may be detected using avidin, coupled to a different reporter group (commonly a radioactive or fluorescent group or an enzyme). Enzyme reporter groups may generally be detected by the addition of substrate (generally for a specific period of time), followed by spectroscopic or other analysis of the reaction products.

To determine the presence or absence of prostate cancer, the signal detected from the reporter group that remains bound to the solid support is generally compared to a signal that corresponds to a predetermined cut-off value. In one preferred embodiment, the cut-off value is the average mean signal obtained when the immobilized antibody is incubated with samples from patients without prostate cancer. In general, a sample generating a signal that is three standard deviations above the predetermined cut-off value is considered positive for prostate cancer. In an alternate preferred embodiment, the cut-off value is determined using a Receiver Operator Curve, according to the method of Sackett et al., Clinical Epidemiology: A Basic Science for Clinical Medicine, Little Brown and Co., 1985, p. 106-7. Briefly, in this embodiment, the cut-off value may be determined from a plot of pairs of true positive rates (i.e., sensitivity) and false positive rates (100%-specificity) that correspond to each possible cut-off value for the diagnostic test result. The cut-off value on the plot that is the closest to the upper left-hand corner (i.e., the value that encloses the largest area) is the most accurate cut-off value, and a sample generating a signal that is higher than the cut-off value determined by this method may be considered positive. Alternatively, the cut-off value may be shifted to the left along the plot, to minimize the false positive rate, or to the right, to minimize the false negative rate. In general, a sample generating a signal that is higher than the cut-off value determined by this method is considered positive for prostate cancer.

In a related embodiment, the assay is performed in a flow-through or strip test format, wherein the antibody is immobilized on a membrane, such as nitrocellulose. In the flow-through test, polypeptides within the sample bind to the immobilized antibody as the sample passes through the membrane. A second, labeled antibody then binds to the antibody-polypeptide complex as a solution containing the second antibody flows through the membrane. The detection of bound second antibody may then be performed as described above. In the strip test format, one end of the membrane to which antibody is bound is immersed in a solution containing the sample. The sample migrates along the membrane through a region containing second antibody and to the area of immobilized antibody. Concentration of second antibody at the area of immobilized antibody indicates the presence of prostate cancer. Typically, the concentration of second antibody at that site generates a pattern, such as a line, that can be read visually. The absence of such a pattern indicates a negative result. In general, the amount of antibody immobilized on the membrane is selected to generate a visually discernible pattern when the biological sample contains a level of polypeptide that would be sufficient to generate a positive signal in the two-antibody sandwich assay, in the format discussed above. Preferably, the amount of antibody immobilized on the membrane ranges from about 25 ng to about 1 μg, and more preferably from about 50 ng to about 500 ng. Such tests can typically be performed with a very small amount of biological sample.

Of course, numerous other assay protocols exist that are suitable for use with the antigens or antibodies of the present invention. The above descriptions are intended to be exemplary only.

In another embodiment, the above polypeptides may be used as markers for the progression of prostate cancer. In this embodiment, assays as described above for the diagnosis of prostate cancer may be performed over time, and the change in the level of reactive polypeptide(s) evaluated. For example, the assays may be performed every 24-72 hours for a period of 6 months to 1 year, and thereafter performed as needed. In general, prostate cancer is progressing in those patients in whom the level of polypeptide detected by the binding agent increases over time. In contrast, prostate cancer is not progressing when the level of reactive polypeptide either remains constant or decreases with time.

Antibodies for use in the above methods may be prepared by any of a variety of techniques known to those of ordinary skill in the art. See, e.g., Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1988. In one such technique, an immunogen comprising the antigenic polypeptide is initially injected into any of a wide variety of mammals (e.g., mice, rats, rabbits, sheep and goats). In this step, the polypeptides of this invention may serve as the immunogen without modification. Alternatively, particularly for relatively short polypeptides, a superior immune response may be elicited if the polypeptide is joined to a carrier protein, such as bovine serum albumin or keyhole limpet hemocyanin. The immunogen is injected into the animal host, preferably according to a predetermined schedule incorporating one or more booster immunizations, and the animals are bled periodically. Polyclonal antibodies specific for the polypeptide may then be purified from such antisera by, for example, affinity chromatography using the polypeptide coupled to a suitable solid support.

Monoclonal antibodies specific for the antigenic polypeptide of interest may be prepared, for example, using the technique of Kohler and Milstein, Eur. J. Immunol. 6:511-519, 1976, and improvements thereto. Briefly, these methods involve the preparation of immortal cell lines capable of producing antibodies having the desired specificity (i.e., reactivity with the polypeptide of interest). Such cell lines may be produced, for example, from spleen cells obtained from an animal immunized as described above. The spleen cells are then immortalized by, for example, fusion with a myeloma cell fusion partner, preferably one that is syngeneic with the immunized animal. A variety of fusion techniques may be employed. For example, the spleen cells and myeloma cells may be combined with a nonionic detergent for a few minutes and then plated at low density on a selective medium that supports the growth of hybrid cells, but not myeloma cells. A preferred selection technique uses HAT (hypoxanthine, aminopterin, thymidine) selection. After a sufficient time, usually about 1 to 2 weeks, colonies of hybrids are observed. Single colonies are selected and tested for binding activity against the polypeptide. Hybridomas having high reactivity and specificity are preferred.

Monoclonal antibodies may be isolated from the supernatants of growing hybridoma colonies. In addition, various techniques may be employed to enhance the yield, such as injection of the hybridoma cell line into the peritoneal cavity of a suitable vertebrate host, such as a mouse. Monoclonal antibodies may then be harvested from the ascites fluid or the blood. Contaminants may be removed from the antibodies by conventional techniques, such as chromatography, gel filtration, precipitation, and extraction. The polypeptides of this invention may be used in the purification process in, for example, an affinity chromatography step.

Monoclonal antibodies of the present invention may also be used as therapeutic reagents, to diminish or eliminate prostate tumors. The antibodies may be used on their own (for instance, to inhibit metastases) or coupled to one or more therapeutic agents. Suitable agents in this regard include radionuclides, differentiation inducers, drugs, toxins, and derivatives thereof. Preferred radionuclides include ⁹⁰Y, ¹²³I, ¹²⁵I, ¹³¹I, ¹⁸⁶Re, ¹⁸⁸Re, ²¹¹At, and ²¹²Bi. Preferred drugs include methotrexate, and pyrimidine and purine analogs. Preferred differentiation inducers include phorbol esters and butyric acid. Preferred toxins include ricin, abrin, diptheria toxin, cholera toxin, gelonin, Pseudomonas exotoxin, Shigella toxin, and pokeweed antiviral protein.

A therapeutic agent may be coupled (e.g., covalently bonded) to a suitable monoclonal antibody either directly or indirectly (e.g., via a linker group). A direct reaction between an agent and an antibody is possible when each possesses a substituent capable of reacting with the other. For example, a nucleophilic group, such as an amino or sulfhydryl group, on one may be capable of reacting with a carbonyl-containing group, such as an anhydride or an acid halide, or with an alkyl group containing a good leaving group (e.g., a halide) on the other.

Alternatively, it may be desirable to couple a therapeutic agent and an antibody via a linker group. A linker group can function as a spacer to distance an antibody from an agent in order to avoid interference with binding capabilities. A linker group can also serve to increase the chemical reactivity of a substituent on an agent or an antibody, and thus increase the coupling efficiency. An increase in chemical reactivity may also facilitate the use of agents, or functional groups on agents, which otherwise would not be possible.

It will be evident to those skilled in the art that a variety of bifunctional or polyfunctional reagents, both homo- and hetero-functional (such as those described in the catalog of the Pierce Chemical Co., Rockford, Ill.), may be employed as the linker group. Coupling may be effected, for example, through amino groups, carboxyl groups, sulfhydryl groups or oxidized carbohydrate residues. There are numerous references describing such methodology, e.g., U.S. Pat. No. 4,671,958, to Rodwell et al.

Where a therapeutic agent is more potent when free from the antibody portion of the immunoconjugates of the present invention, it may be desirable to use a linker group which is cleavable during or upon internalization into a cell. A number of different cleavable linker groups have been described. The mechanisms for the intracellular release of an agent from these linker groups include cleavage by reduction of a disulfide bond (e.g., U.S. Pat. No. 4,489,710, to Spitler), by irradiation of a photolabile bond (e.g., U.S. Pat. No. 4,625,014, to Senter et al.), by hydrolysis of derivatized amino acid side chains (e.g., U.S. Pat. No. 4,638,045, to Kohn et al.), by serum complement-mediated hydrolysis (e.g., U.S. Pat. No. 4,671,958, to Rodwell et al.), and acid-catalyzed hydrolysis (e.g., U.S. Pat. No. 4,569,789, to Blattler et al.).

It may be desirable to couple more than one agent to an antibody. In one embodiment, multiple molecules of an agent are coupled to one antibody molecule. In another embodiment, more than one type of agent may be coupled to one antibody. Regardless of the particular embodiment, immunoconjugates with more than one agent may be prepared in a variety of ways. For example, more than one agent may be coupled directly to an antibody molecule, or linkers which provide multiple sites for attachment can be used. Alternatively, a carrier can be used.

A carrier may bear the agents in a variety of ways, including covalent bonding either directly or via a linker group. Suitable carriers include proteins such as albumins (e.g., U.S. Pat. No. 4,507,234, to Kato et al.), peptides and polysaccharides such as aminodextran (e.g., U.S. Pat. No. 4,699,784, to Shih et al.). A carrier may also bear an agent by noncovalent bonding or by encapsulation, such as within a liposome vesicle (e.g, U.S. Pat. Nos. 4,429,008 and 4,873,088). Carriers specific for radionuclide agents include radiohalogenated small molecules and chelating compounds. For example, U.S. Pat. No. 4,735,792 discloses representative radiohalogenated small molecules and their synthesis. A radionuclide chelate may be formed from chelating compounds that include those containing nitrogen and sulfur atoms as the donor atoms for binding the metal, or metal oxide, radionuclide. For example, U.S. Pat. No. 4,673,562, to Davison et al. discloses representative chelating compounds and their synthesis.

A variety of routes of administration for the antibodies and immunoconjugates may be used. Typically, administration will be intravenous, intramuscular, subcutaneous or in the bed of a resected tumor. It will be evident that the precise dose of the antibody/immunoconjugate will vary depending upon the antibody used, the antigen density on the tumor, and the rate of clearance of the antibody.

Diagnostic reagents of the present invention may also comprise DNA sequences encoding one or more of the above polypeptides, or one or more portions thereof. For example, at least two oligonucleotide primers may be employed in a polymerase chain reaction (PCR) based assay to amplify prostate tumor-specific cDNA derived from a biological sample, wherein at least one of the oligonucleotide primers is specific for a DNA molecule encoding a prostate tumor protein of the present invention. The presence of the amplified cDNA is then detected using techniques well known in the art, such as gel electrophoresis. Similarly, oligonucleotide probes specific for a DNA molecule encoding a prostate tumor protein of the present invention may be used in a hybridization assay to detect the presence of an inventive polypeptide in a biological sample.

As used herein, the term “oligonucleotide primer/probe specific for a DNA molecule” means an oligonucleotide sequence that has at least about 80%, preferably at least about 90% and more preferably at least about 95%, identity to the DNA molecule in question. Oligonucleotide primers and/or probes which may be usefully employed in the inventive diagnostic methods preferably have at least about 10-40 nucleotides. In a preferred embodiment, the oligonucleotide primers comprise at least about 10 contiguous nucleotides of a DNA molecule having a sequence selected from SEQ ID NOS: 1-107, 109-111, 115-171, 173-175 and 177. Preferably, oligonucleotide probes for use in the inventive diagnostic methods comprise at least about 15 contiguous oligonucleotides of a DNA molecule having a sequence provided in SEQ ID NOS: 1-107, 109-111, 115-171, 173-175 and 177. Techniques for both PCR based assays and hybridization assays are well known in the art (see, for example, Mullis et al. Ibid; Ehrlich, Ibid). Primers or probes may thus be used to detect prostate tumor-specific sequences in biological samples, including blood, semen, prostate tissue and/or prostate tumor tissue.

The following Examples are offered by way of illustration and not by way of limitation.

EXAMPLES Example 1 ISOLATION AND CHARACTERIZATION OF PROSTATE TUMOR POLYPEPTIDES

This Example describes the isolation of prostate tumor polypeptides from a prostate tumor cDNA library.

A human prostate tumor cDNA expression library was constructed from prostate tumor poly A+ RNA using a Superscript Plasmid System for cDNA Synthesis and Plasmid Cloning kit (BRL Life Technologies, Gaithersburg, Md. 20897) following the manufacturer's protocol. Specifically, prostate tumor tissues were homogenized with polytron (Kinematica, Switzerland) and total RNA was extracted using Trizol reagent (BRL Life Technologies) as directed by the manufacturer. The poly A+ RNA was then purified using a Qiagen oligotex spin column mRNA purification kit (Qiagen, Santa Clarita, Calif. 91355) according to the manufacturer's protocol. First-strand cDNA was synthesized using the NotI/Oligo-dT18 primer. Double-stranded cDNA was synthesized, ligated with EcoRI/BAXI adaptors (Invitrogen, San Diego, Calif.) and digested with NotI. Following size fractionation with Chroma Spin-1000 columns (Clontech, Palo Alto, Calif. 94303), the cDNA was ligated into the EcoRI/NotI site of pCDNA3.1 (Invitrogen) and transformed into ElectroMax E. coli DH10B cells (BRL Life Technologies) by electroporation.

Using the same procedure, a normal human pancreas cDNA expression library was prepared from a pool of six tissue specimens (Clontech). The cDNA libraries were characterized by determining the number of independent colonies, the percentage of clones that carried insert, the average insert size and by sequence analysis. The prostate tumor library contained 1.64×10⁷ independent colonies, with 70% of clones having an insert and the average insert size being 1745 base pairs. The normal pancreas cDNA library contained 3.3×10⁶ independent colonies, with 69% of clones having inserts and the average insert size being 1120 base pairs. For both libraries, sequence analysis showed that the majority of clones had a full length cDNA sequence and were synthesized from mRNA, with minimal rRNA and mitochondrial DNA contamination.

cDNA library subtraction was performed using the above prostate tumor and normal pancreas cDNA libraries, as described by Hara et al. (Blood, 84:189-199, 1994) with some modifications. Specifically, a prostate tumor-specific subtracted cDNA library was generated as follows. Normal pancreas cDNA library (70 μg) was digested with EcoRI, NotI, and SfuI, followed by a filling-in reaction with DNA polymerase Klenow fragment. After phenol-chloroform extraction and ethanol precipitation, the DNA was dissolved in 100 μl of H₂O, heat-denatured and mixed with 100 μl (100 μg) of Photoprobe biotin (Vector Laboratories, Burlingame, Calif.). As recommended by the manufacturer, the resulting mixture was irradiated with a 270 W sunlamp on ice for 20 minutes. Additional Photoprobe biotin (50 μl) was added and the biotinylation reaction was repeated. After extraction with butanol five times, the DNA was ethanol-precipitated and dissolved in 23 μl H₂O to form the driver DNA.

To form the tracer DNA, 10 μg prostate tumor cDNA library was digested with BamHI and XhoI, phenol chloroform extracted and passed through Chroma spin-400 columns (Clontech). Following ethanol precipitation, the tracer DNA was dissolved in 5 μl H₂O. Tracer DNA was mixed with 15 μl driver DNA and 20 μl of 2× hybridization buffer (1.5 M NaCl/10 mM EDTA/50 mM HEPES pH 7.5/0.2% sodium dodecyl sulfate), overlaid with mineral oil, and heat-denatured completely. The sample was immediately transferred into a 68° C. water bath and incubated for 20 hours (long hybridization [LH]). The reaction mixture was then subjected to a streptavidin treatment followed by phenol/chloroform extraction. This process was repeated three more times. Subtracted DNA was precipitated, dissolved in 12 μl H₂O, mixed with 8 μl driver DNA and 20 μl of 2× hybridization buffer, and subjected to a hybridization at 68° C. for 2 hours (short hybridization [SH]). After removal of biotinylated double-stranded DNA, subtracted cDNA was ligated into BamHI/XhoI site of chloramphenicol resistant pBCSK+ (Stratagene, La Jolla, Calif. 92037) and transformed into ElectroMax E. coli DH10B cells by electroporation to generate a prostate tumor specific subtracted cDNA library (prostate subtraction 1).

To analyze the subtracted CDNA library, plasmid DNA was prepared from 100 independent clones, randomly picked from the subtracted prostate tumor specific library and grouped based on insert size. Representative cDNA clones were further characterized by DNA sequencing with a Perkin Elmer/Applied Biosystems Division Automated Sequencer Model 373A (Foster City, Calif.). Six CDNA clones, hereinafter referred to as F1-13, F1-12, F1-16, H1-1, H1-9 and H1-4, were shown to be abundant in the subtracted prostate-specific cDNA library. The determined 3′ and 5′ CDNA sequences for F1-12 are provided in SEQ ID NO: 2 and 3, respectively, with determined 3′ cDNA sequences for F1-13, F1-16, H1-1, H1-9 and H1-4 being provided in SEQ ID NO: 1 and 4-7, respectively.

The cDNA sequences for the isolated clones were compared to known sequences in the gene bank using the EMBL and GenBank databases (release 96). Four of the prostate tumor cDNA clones, F1-13, F1-16, H1-1, and H1-4, were determined to encode the following previously identified proteins: prostate specific antigen (PSA), human glandular kallikrein, human tumor expression enhanced gene, and mitochondria cytochrome C oxidase subunit II. H1-9 was found to be identical to a previously identified human autonomously replicating sequence. No significant homologies to the cDNA sequence for F1-12 were found.

Subsequent studies led to the isolation of a full-length cDNA sequence for F1-12. This sequence is provided in SEQ ID NO: 107, with the corresponding predicted amino acid sequence being provided in SEQ ID NO: 108.

To clone less abundant prostate tumor specific genes, cDNA library subtraction was performed by subtracting the prostate tumor cDNA library described above with the normal pancreas cDNA library and with the three most abundant genes in the previously subtracted prostate tumor specific cDNA library: human glandular kallikrein, prostate specific antigen (PSA), and mitochondria cytochrome C oxidase subunit II. Specifically, 1 μg each of human glandular kallikrein, PSA and mitochondria cytochrome C oxidase subunit II cDNAs in pCDNA3.1 were added to the driver DNA and subtraction was performed as described above to provide a second subtracted cDNA library hereinafter referred to as the “subtracted prostate tumor specific cDNA library with spike”.

Twenty-two cDNA clones were isolated from the subtracted prostate tumor specific cDNA library with spike. The determined 3′ and 5′ cDNA sequences for the clones referred to as J1-17, L1-12, N1-1862, J1-13, J1-19, J1-25, J1-24, K1-58, K1-63, L1-4 and L1-14 are provided in SEQ ID NOS: 8-9, 10-11, 12-13, 14-15, 16-17, 18-19, 20-21, 22-23, 24-25, 26-27 and 28-29, respectively. The determined 3′ cDNA sequences for the clones referred to as J1-12, J1-16, J1-21, K1-48, K1-55, L1-2, L1-6, N1-1858, N1-1860, N1-1861, N1-1864 are provided in SEQ ID NOS: 30-40, respectively. Comparison of these sequences with those in the gene bank as described above, revealed no significant homologies to three of the five most abundant DNA species, (J1-17, L1-12 and N1-1862; SEQ ID NOS: 8-9, 10-11 and 12-13, respectively). Of the remaining two most abundant species, one (J1-12; SEQ ID NO:30) was found to be identical to the previously identified human pulmonary surfactant-associated protein, and the other (K1-48; SEQ ID NO:33) was determined to have some homology to R. norvegicus mRNA for 2-arylpropionyl-CoA epimerase. Of the 17 less abundant cDNA clones isolated from the subtracted prostate tumor specific cDNA library with spike, four (J1-16, K1-55, L1-6 and N1-1864; SEQ ID NOS:31, 34, 36 and 40, respectively) were found to be identical to previously identified sequences, two (J1-21 and N1-1860; SEQ ID NOS: 32 and 38, respectively) were found to show some homology to non-human sequences, and two (L1-2 and N1-1861; SEQ ID NOS: 35 and 39, respectively) were found to show some homology to known human sequences. No significant homologies were found to the polypeptides J1-13, J1-19, J1-24, J1-25, K1-58, K1-63, L1-4, L1-14 (SEQ ID NOS: 14-15, 16-17, 20-21, 18-19, 22-23, 24-25, 26-27, 28-29, respectively).

Subsequent studies led to the isolation of full length cDNA sequences for J1-17, L1-12 and N1-1862 (SEQ ID NOS: 109-111, respectively). The corresponding predicted amino acid sequences are provided in SEQ ID NOS: 112-114.

In a further experiment, four additional clones were identified by subtracting a prostate tumor cDNA library with normal prostate cDNA prepared from a pool of three normal prostate poly A+ RNA (prostate subtraction 2). The determined cDNA sequences for these clones, hereinafter referred to as U1-3064, U1-3065, V1-3692 and 1A-3905, are provided in SEQ ID NO: 69-72, respectively. Comparison of the determined sequences with those in the gene bank revealed no significant homologies to U1-3065.

A second subtraction with spike (prostate subtraction spike 2) was performed by subtracting a prostate tumor specific cDNA library with spike with normal pancreas cDNA library and further spiked with PSA, J1-17, pulmonary surfactant-associated protein, mitochondrial DNA, cytochrome c oxidase subunit II, N1-1862, autonomously replicating sequence, L1-12 and tumor expression enhanced gene. Four additional clones, hereinafter referred to as V1-3686, R1-2330, 1B-3976 and V1-3679, were isolated. The determined cDNA sequences for these clones are provided in SEQ ID NO:73-76, respectively. Comparison of these sequences with those in the gene bank revealed no significant homologies to V1-3686 and R1-2330.

Further analysis of the three prostate subtractions described above (prostate subtraction 2, subtracted prostate tumor specific cDNA library with spike, and prostate subtraction spike 2) resulted in the identification of sixteen additional clones, referred to as 1G-4736, 1G-4738, 1G-4741, 1G-4744, 1G-4734, 1H-4774, 1H4781, 1H-4785, 1H-4787, 1H-4796, 1I-4810, 1I-4811, 1J-4876, 1K-4884 and 1K-4896. The determined cDNA sequences for these clones are provided in SEQ ID NOS: 77-92, respectively. Comparison of these sequences with those in the gene bank as described above, revealed no significant homologies to 1G-4741, 1G-4734, 1I-4807, 1J-4876 and 1K-4896 (SEQ ID NOS: 79, 81, 87, 90 and 92, respectively).

An additional subtraction was performed by subtracting a normal prostate cDNA library with normal pancreas cDNA (prostate subtraction 3). This led to the identification of six additional clones referred to as 1G-4761, 1G-4762, 1H-4766, 1H-4770, 1H-4771 and 1H-4772 (SEQ ID NOS: 93-98). Comparison of these sequences with those in the gene bank revealed no significant homologies to 1G-4761 and 1H-4771 (SEQ ID NOS: 93 and 97, respectively).

Subtraction of a prostate tumor cDNA library, prepared from a pool of polyA+ RNA from three prostate cancer patients, with a normal pancreas cDNA library (prostate subtraction 4) led to the identification of eight clones, referred to as 1D-4297, 1D-4309, 1D.1-4278, 1D-4288, 1D-4283, 1D-4304, 1D-4296 and 1D-4280 (SEQ ID NOS: 99-107). These sequences were compared to those in the gene bank as described above. No significant homologies were found to 1D-4283 and 1D-4304 (SEQ ID NOS: 103 and 104, respectively).

Example 2 DETERMINATION OF TISSUE SPECIFICITY OF PROSTATE TUMOR POLYPEPTIDES

Using gene specific primers, mRNA expression levels for the representative prostate tumor polypeptides F1-16, H1-1, J1-17, L1-12, F1-12 and N1-1862 were examined in a variety of normal and tumor tissues using RT-PCR.

Briefly, total RNA was extracted from a variety of normal and tumor tissues using Trizol reagent as described above. First strand synthesis was carried out using 1-2 μg of total RNA with SuperScript II reverse transcriptase (BRL Life Technologies) at 42° C. for one hour. The cDNA was then amplified by PCR with gene-specific primers. To ensure the semi-quantitative nature of the RT-PCR, β-actin was used as an internal control for each of the tissues examined. First, serial dilutions of the first strand cDNAs were prepared and RT-PCR assays were performed using β-actin specific primers. A dilution was then chosen that enabled the linear range amplification of the β-actin template and which was sensitive enough to reflect the differences in the initial copy numbers. Using these conditions, the β-actin levels were determined for each reverse transcription reaction from each tissue. DNA contamination was minimized by DNase treatment and by assuring a negative PCR result when using first strand cDNA that was prepared without adding reverse transcriptase.

mRNA Expression levels were examined in four different types of tumor tissue (prostate tumor from 2 patients, breast tumor from 3 patients, colon tumor, lung tumor), and sixteen different normal tissues, including prostate, colon, kidney, liver, lung, ovary, pancreas, skeletal muscle, skin, stomach, testes, bone marrow and brain. F1-16 was found to be expressed at high levels in prostate tumor tissue, colon tumor and normal prostate, and at lower levels in normal liver, skin and testes, with expression being undetectable in the other tissues examined. H1-1 was found to be expressed at high levels in prostate tumor, lung tumor, breast tumor, normal prostate, normal colon and normal brain, at much lower levels in normal lung, pancreas, skeletal muscle, skin, small intestine, bone marrow, and was not detected in the other tissues tested. J1-17 and L1-12 appear to be specifically over-expressed in prostate, with both genes being expressed at high levels in prostate tumor and normal prostate but at low to undetectable levels in all the other tissues examined. N1-1862 was found to be over-expressed in 60% of prostate tumors and detectable in normal colon and kidney. The RT-PCR results thus indicate that F1-16, H1-1, J1-17, N1-1862 and L1-12 are either prostate specific or are expressed at significantly elevated levels in prostate.

Further RT-PCR studies showed that F1-12 is over-expressed in 60% of prostate tumors, detectable in normal kidney but not detectable in all other tissues tested. Similarly, R1-2330 was shown to be over-expressed in 40% of prostate tumors, detectable in normal kidney and liver, but not detectable in all other tissues tested. U1-3064 was found to be over-expressed in 60% of prostate tumors, and also expressed in breast and colon tumors, but was not detectable in normal tissues.

RT-PCR characterization of R1-2330, U1-3064 and 1D-4279 showed that these three antigens are overexpressed in prostate and/or prostate tumors.

Example 3 ISOLATION AND CHARACTERIZATION OF PROSTATE TUMOR POLYPEPTIDES BY PCR-BASED SUBTRACTION

A cDNA subtraction library, containing cDNA from normal prostate subtracted with ten other normal tissue cDNAs (brain, heart, kidney, liver, lung, ovary, placenta, skeletal muscle, spleen and thymus) and then submitted to a first round of PCR amplification, was purchased from Clontech. This library was subjected to a second round of PCR amplification, following the manufacturer's protocol. The resulting cDNA fragments were subcloned into the vector pT7 Blue T-vector (Novagen, Madison, Wis.) and transformed into XL-1 Blue MRF' E. coli (Stratagene). DNA was isolated from independent clones and sequenced using a Perkin Elmer/Applied Biosystems Division Automated Sequencer Model 373A.

Fifty-nine positive clones were sequenced. Comparison of the DNA sequences of these clones with those in the gene bank, as described above, revealed no significant homologies to 25 of these clones, hereinafter referred to as P5, P8, P9, P18, P20, P30, P34, P36, P38, P39, P42, P49, P50, P53, P55, P60, P64, P65, P73, P75, P76, P79 and P84. The determined cDNA sequences for these clones are provided in SEQ ID NO:41-45, 47-52 and 54-65, respectively. P29, P47, P68, P80 and P82 (SEQ ID NO:46, 53 and 66-68, respectively) were found to show some degree of homology to previously identified DNA sequences. To the best of the inventors' knowledge, none of these sequences have been previously shown to be present in prostate.

Further studies using the PCR-based methodology described above resulted in the isolation of more than 180 additional clones, of which 23 clones were found to show no significant homologies to known sequences. The determined cDNA sequences for these clones are provided in SEQ ID NO: 115-123, 127, 131, 137, 145, 147-151, 153, 156-158 and 160. Twenty-three clones (SEQ ID NO: 124-126, 128-130, 132-136, 138-144, 146, 152, 154, 155 and 159) were found to show some homology to previously identified ESTs. An additional ten clones (SEQ ID NO: 161-170) were found to have some degree of homology to known genes. An additional clone, referred to as P703, was found to have five splice variants. The determined DNA sequence for the variants referred to as DE1, DE13 and DE14 are provided in SEQ ID NOS: 171, 175 and 177, respectively, with the corresponding predicted amino acid sequences being provided in SEQ ID NO: 172, 176 and 178, respectively. The DNA sequences for the splice variants referred to as DE2 and DE6 are provided in SEQ ID NOS: 173 and 174, respectively.

mRNA Expression levels for representative clones in tumor tissues (prostate (n=5), breast (n=2), colon and lung) normal tissues (prostate (n=5), colon, kidney, liver, lung (n=2), ovary (n=2), skeletal muscle, skin, stomach, small intestine and brain), and activated and non-activated PBMC was determined by RT-PCT as described above. Expression was examined in one sample of each tissue type unless otherwise indicated.

P9 was found to be highly expressed in normal prostate and prostate tumor compared to all normal tissues tested except for normal colon which showed comparable expression. P20 was found to be highly expressed in normal prostate and prostate tumor, compared to all twelve normal tissues tested. A modest increase in expression of P20 in breast tumor (n=2), colon tumor and lung tumor was seen compared to all normal tissues except lung (1 of 2). Increased expression of P18 was found in normal prostate, prostate tumor and breast tumor compared to other normal tissues except lung and stomach. A modest increase in expression of P5 was observed in normal prostate compared to most other normal tissues. However, some elevated expression was seen in normal lung and PBMC. Elevated expression of P5 was also observed in prostate tumors (2 of 5), breast tumor and one lung tumor sample. For P30, similar expression levels were seen in normal prostate and prostate tumor, compared to six of twelve other normal tissues tested. Increased expression was seen in breast tumors, one lung tumor sample and one colon tumor sample, and also in normal PBMC. P29 was found to be over-expressed in prostate tumor (5 of 5) and normal prostate (5 of 5) compared to the majority of normal tissues. However, substantial expression of P29 was observed in normal colon and normal lung (2 of 2). P80 was found to be over-expressed in prostate tumor (5 of 5) and normal prostate (5 of 5) compared to all other normal tissues tested, with increased expression also being seen in colon tumor.

Example 4 SYNTHESIS OF POLYPEPTIDES

Polypeptides may be synthesized on a Perkin Elmer/Applied Biosystems 430A peptide synthesizer using FMOC chemistry with HPTU (O-Benzotriazole-N,N,N′,N′-tetramethyluronium hexafluorophosphate) activation. A Gly-Cys-Gly sequence may be attached to the amino terminus of the peptide to provide a method of conjugation, binding to an immobilized surface, or labeling of the peptide. Cleavage of the peptides from the solid support may be carried out using the following cleavage mixture: trifluoroacetic acid:ethanedithiol:thioanisole:water:phenol (40:1:2:2:3). After cleaving for 2 hours, the peptides may be precipitated in cold methyl-t-butyl-ether. The peptide pellets may then be dissolved in water containing 0.1% trifluoroacetic acid (TFA) and lyophilized prior to purification by C18 reverse phase HPLC. A gradient of 0%-60% acetonitrile (containing 0.1% TFA) in water (containing 0.1% TFA) may be used to elute the peptides. Following lyophilization of the pure fractions, the peptides may be characterized using electrospray or other types of mass spectrometry and by amino acid analysis.

From the foregoing, it will be appreciated that, although specific embodiments of the invention have been described herein for the purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention.

178 814 base pairs nucleic acid single linear cDNA not provided 1 TTTTTTTTTT TTTTTCACAG TATAACAGCT CTTTATTTCT GTGAGTTCTA CTAGGAAATC 60 ATCAAATCTG AGGGTTGTCT GGAGGACTTC AATACACCTC CCCCCATAGT GAATCAGCTT 120 CCAGGGGGTC CAGTCCCTCT CCTTACTTCA TCCCCATCCC ATGCCAAAGG AAGACCCTCC 180 CTCCTTGGCT CACAGCCTTC TCTAGGCTTC CCAGTGCCTC CAGGACAGAG TGGGTTATGT 240 TTTCAGCTCC ATCCTTGCTG TGAGTGTCTG GTGCGTTGTG CCTCCAGCTT CTGCTCAGTG 300 CTTCATGGAC AGTGTCCAGC ACATGTCACT CTCCACTCTC TCAGTGTGGA TCCACTAGTT 360 CTAGAGCGGC CGCCACCGCG GTGGAGCTCC AGCTTTTGTT CCCTTTAGTG AGGGTTAATT 420 GCGCGCTTGG CGTAATCATG GTCATAACTG TTTCCTGTGT GAAATTGTTA TCCGCTCACA 480 ATTCCACACA ACATACGAGC CGGAAGCATA AAGTGTAAAG CCTGGGGTGC CTAATGAGTG 540 ANCTAACTCA CATTAATTGC GTTGCGCTCA CTGNCCGCTT TCCAGTCNGG AAAACTGTCG 600 TGCCAGCTGC ATTAATGAAT CGGCCAACGC NCGGGGAAAA GCGGTTTGCG TTTTGGGGGC 660 TCTTCCGCTT CTCGCTCACT NANTCCTGCG CTCGGTCNTT CGGCTGCGGG GAACGGTATC 720 ACTCCTCAAA GGNGGTATTA CGGTTATCCN NAAATCNGGG GATACCCNGG AAAAAANTTT 780 AACAAAAGGG CANCAAAGGG CNGAAACGTA AAAA 814 816 base pairs nucleic acid single linear cDNA not provided 2 ACAGAAATGT TGGATGGTGG AGCACCTTTC TATACGACTT ACAGGACAGC AGATGGGGAA 60 TTCATGGCTG TTGGAGCAAT AGAACCCCAG TTCTACGAGC TGCTGATCAA AGGACTTGGA 120 CTAAAGTCTG ATGAACTTCC CAATCAGATG AGCATGGATG ATTGGCCAGA AATGAAGAAG 180 AAGTTTGCAG ATGTATTTGC AAAGAAGACG AAGGCAGAGT GGTGTCAAAT CTTTGACGGC 240 ACAGATGCCT GTGTGACTCC GGTTCTGACT TTTGAGGAGG TTGTTCATCA TGATCACAAC 300 AAGGAACGGG GCTCGTTTAT CACCAGTGAG GAGCAGGACG TGAGCCCCCG CCCTGCACCT 360 CTGCTGTTAA ACACCCCAGC CATCCCTTCT TTCAAAAGGG ATCCACTAGT TCTAGAAGCG 420 GCCGCCACCG CGGTGGAGCT CCAGCTTTTG TTCCCTTTAG TGAGGGTTAA TTGCGCGCTT 480 GGCGTAATCA TGGTCATAGC TGTTTCCTGT GTGAAATTGT TATCCGCTCA CAATTCCCCC 540 AACATACGAG CCGGAACATA AAGTGTTAAG CCTGGGGTGC CTAATGANTG AGCTAACTCN 600 CATTAATTGC GTTGCGCTCA CTGCCCGCTT TCCAGTCGGG AAAACTGTCG TGCCACTGCN 660 TTANTGAATC NGCCACCCCC CGGGAAAAGG CGGTTGCNTT TTGGGCCTCT TCCGCTTTCC 720 TCGCTCATTG ATCCTNGCNC CCGGTCTTCG GCTGCGGNGA ACGGTTCACT CCTCAAAGGC 780 GGTNTNCCGG TTATCCCCAA ACNGGGGATA CCCNGA 816 773 base pairs nucleic acid single linear cDNA not provided 3 CTTTTGAAAG AAGGGATGGC TGGGGTGTTT AACAGCAGAG GTGCAGGGCG GGGGCTCACG 60 TCCTGCTCCT CACTGGTGAT AAACGAGCCC CGTTCCTTGT TGTGATCATG ATGAACAACC 120 TCCTCAAAAG TCAGAACCGG AGTCACACAG GCATCTGTGC CGTCAAAGAT TTGACACCAC 180 TCTGCCTTCG TCTTCTTTGC AAATACATCT GCAAACTTCT TCTTCATTTC TGGCCAATCA 240 TCCATGCTCA TCTGATTGGG AAGTTCATCA GACTTTAGTC CANNTCCTTT GATCAGCAGC 300 TCGTAGAACT GGGGTTCTAT TGCTCCAACA GCCATGAATT CCCCATCTGC TGTCCTGTAA 360 GTCGTATAGA AAGGTGCTCC ACCATCCAAC ATGTTCTGTC CTCGAGGGGG GGCCCGGTAC 420 CCAATTCGCC CTATANTGAG TCGTATTACG CGCGCTCACT GGCCGTCGTT TTACAACGTC 480 GTGACTGGGA AAACCCTGGG CGTTACCAAC TTAATCGCCT TGCAGCACAT CCCCCTTTCG 540 CCAGCTGGGC GTAATANCGA AAAGGCCCGC ACCGATCGCC CTTCCAACAG TTGCGCACCT 600 GAATGGGNAA ATGGGACCCC CCTGTTACCG CGCATTNAAC CCCCGCNGGG TTTNGTTGTT 660 ACCCCCACNT NNACCGCTTA CACTTTGCCA GCGCCTTANC GCCCGCTCCC TTTCNCCTTT 720 CTTCCCTTCC TTTCNCNCCN CTTTCCCCCG GGGTTTCCCC CNTCAAACCC CNA 773 828 base pairs nucleic acid single linear cDNA not provided 4 CCTCCTGAGT CCTACTGACC TGTGCTTTCT GGTGTGGAGT CCAGGGCTGC TAGGAAAAGG 60 AATGGGCAGA CACAGGTGTA TGCCAATGTT TCTGAAATGG GTATAATTTC GTCCTCTCCT 120 TCGGAACACT GGCTGTCTCT GAAGACTTCT CGCTCAGTTT CAGTGAGGAC ACACACAAAG 180 ACGTGGGTGA CCATGTTGTT TGTGGGGTGC AGAGATGGGA GGGGTGGGGC CCACCCTGGA 240 AGAGTGGACA GTGACACAAG GTGGACACTC TCTACAGATC ACTGAGGATA AGCTGGAGCC 300 ACAATGCATG AGGCACACAC ACAGCAAGGA TGACNCTGTA AACATAGCCC ACGCTGTCCT 360 GNGGGCACTG GGAAGCCTAN ATNAGGCCGT GAGCANAAAG AAGGGGAGGA TCCACTAGTT 420 CTANAGCGGC CGCCACCGCG GTGGANCTCC ANCTTTTGTT CCCTTTAGTG AGGGTTAATT 480 GCGCGCTTGG CNTAATCATG GTCATANCTN TTTCCTGTGT GAAATTGTTA TCCGCTCACA 540 ATTCCACACA ACATACGANC CGGAAACATA AANTGTAAAC CTGGGGTGCC TAATGANTGA 600 CTAACTCACA TTAATTGCGT TGCGCTCACT GCCCGCTTTC CAATCNGGAA ACCTGTCTTG 660 CCNCTTGCAT TNATGAATCN GCCAACCCCC GGGGAAAAGC GTTTGCGTTT TGGGCGCTCT 720 TCCGCTTCCT CNCTCANTTA NTCCCTNCNC TCGGTCATTC CGGCTGCNGC AAACCGGTTC 780 ACCNCCTCCA AAGGGGGTAT TCCGGTTTCC CCNAATCCGG GGANANCC 828 834 base pairs nucleic acid single linear cDNA not provided 5 TTTTTTTTTT TTTTTACTGA TAGATGGAAT TTATTAAGCT TTTCACATGT GATAGCACAT 60 AGTTTTAATT GCATCCAAAG TACTAACAAA AACTCTAGCA ATCAAGAATG GCAGCATGTT 120 ATTTTATAAC AATCAACACC TGTGGCTTTT AAAATTTGGT TTTCATAAGA TAATTTATAC 180 TGAAGTAAAT CTAGCCATGC TTTTAAAAAA TGCTTTAGGT CACTCCAAGC TTGGCAGTTA 240 ACATTTGGCA TAAACAATAA TAAAACAATC ACAATTTAAT AAATAACAAA TACAACATTG 300 TAGGCCATAA TCATATACAG TATAAGGAAA AGGTGGTAGT GTTGAGTAAG CAGTTATTAG 360 AATAGAATAC CTTGGCCTCT ATGCAAATAT GTCTAGACAC TTTGATTCAC TCAGCCCTGA 420 CATTCAGTTT TCAAAGTAGG AGACAGGTTC TACAGTATCA TTTTACAGTT TCCAACACAT 480 TGAAAACAAG TAGAAAATGA TGAGTTGATT TTTATTAATG CATTACATCC TCAAGAGTTA 540 TCACCAACCC CTCAGTTATA AAAAATTTTC AAGTTATATT AGTCATATAA CTTGGTGTGC 600 TTATTTTAAA TTAGTGCTAA ATGGATTAAG TGAAGACAAC AATGGTCCCC TAATGTGATT 660 GATATTGGTC ATTTTTACCA GCTTCTAAAT CTNAACTTTC AGGCTTTTGA ACTGGAACAT 720 TGNATNACAG TGTTCCANAG TTNCAACCTA CTGGAACATT ACAGTGTGCT TGATTCAAAA 780 TGTTATTTTG TTAAAAATTA AATTTTAACC TGGTGGAAAA ATAATTTGAA ATNA 834 818 base pairs nucleic acid single linear cDNA not provided 6 TTTTTTTTTT TTTTTTTTTT AAGACCCTCA TCAATAGATG GAGACATACA GAAATAGTCA 60 AACCACATCT ACAAAATGCC AGTATCAGGC GGCGGCTTCG AAGCCAAAGT GATGTTTGGA 120 TGTAAAGTGA AATATTAGTT GGCGGATGAA GCAGATAGTG AGGAAAGTTG AGCCAATAAT 180 GACGTGAAGT CCGTGGAAGC CTGTGGCTAC AAAAAATGTT GAGCCGTAGA TGCCGTCGGA 240 AATGGTGAAG GGAGACTCGA AGTACTCTGA GGCTTGTAGG AGGGTAAAAT AGAGACCCAG 300 TAAAATTGTA ATAAGCAGTG CTTGAATTAT TTGGTTTCGG TTGTTTTCTA TTAGACTATG 360 GTGAGCTCAG GTGATTGATA CTCCTGATGC GAGTAATACG GATGTGTTTA GGAGTGGGAC 420 TTCTAGGGGA TTTAGCGGGG TGATGCCTGT TGGGGGCCAG TGCCCTCCTA GTTGGGGGGT 480 AGGGGCTAGG CTGGAGTGGT AAAAGGCTCA GAAAAATCCT GCGAAGAAAA AAACTTCTGA 540 GGTAATAAAT AGGATTATCC CGTATCGAAG GCCTTTTTGG ACAGGTGGTG TGTGGTGGCC 600 TTGGTATGTG CTTTCTCGTG TTACATCGCG CCATCATTGG TATATGGTTA GTGTGTTGGG 660 TTANTANGGC CTANTATGAA GAACTTTTGG ANTGGAATTA AATCAATNGC TTGGCCGGAA 720 GTCATTANGA NGGCTNAAAA GGCCCTGTTA NGGGTCTGGG CTNGGTTTTA CCCNACCCAT 780 GGAATNCNCC CCCCGGACNA NTGNATCCCT ATTCTTAA 818 817 base pairs nucleic acid single linear cDNA not provided 7 TTTTTTTTTT TTTTTTTTTT TGGCTCTAGA GGGGGTAGAG GGGGTGCTAT AGGGTAAATA 60 CGGGCCCTAT TTCAAAGATT TTTAGGGGAA TTAATTCTAG GACGATGGGT ATGAAACTGT 120 GGTTTGCTCC ACAGATTTCA GAGCATTGAC CGTAGTATAC CCCCGGTCGT GTAGCGGTGA 180 AAGTGGTTTG GTTTAGACGT CCGGGAATTG CATCTGTTTT TAAGCCTAAT GTGGGGACAG 240 CTCATGAGTG CAAGACGTCT TGTGATGTAA TTATTATACN AATGGGGGCT TCAATCGGGA 300 GTACTACTCG ATTGTCAACG TCAAGGAGTC GCAGGTCGCC TGGTTCTAGG AATAATGGGG 360 GAAGTATGTA GGAATTGAAG ATTAATCCGC CGTAGTCGGT GTTCTCCTAG GTTCAATACC 420 ATTGGTGGCC AATTGATTTG ATGGTAAGGG GAGGGATCGT TGAACTCGTC TGTTATGTAA 480 AGGATNCCTT NGGGATGGGA AGGCNATNAA GGACTANGGA TNAATGGCGG GCANGATATT 540 TCAAACNGTC TCTANTTCCT GAAACGTCTG AAATGTTAAT AANAATTAAN TTTNGTTATT 600 GAATNTTNNG GAAAAGGGCT TACAGGACTA GAAACCAAAT ANGAAAANTA ATNNTAANGG 660 CNTTATCNTN AAAGGTNATA ACCNCTCCTA TNATCCCACC CAATNGNATT CCCCACNCNN 720 ACNATTGGAT NCCCCANTTC CANAAANGGC CNCCCCCCGG TGNANNCCNC CTTTTGTTCC 780 CTTNANTGAN GGTTATTCNC CCCTNGCNTT ATCANCC 817 799 base pairs nucleic acid single linear cDNA not provided 8 CATTTCCGGG TTTACTTTCT AAGGAAAGCC GAGCGGAAGC TGCTAACGTG GGAATCGGTG 60 CATAAGGAGA ACTTTCTGCT GGCACGCGCT AGGGACAAGC GGGAGAGCGA CTCCGAGCGT 120 CTGAAGCGCA CGTCCCAGAA GGTGGACTTG GCACTGAAAC AGCTGGGACA CATCCGCGAG 180 TACGAACAGC GCCTGAAAGT GCTGGAGCGG GAGGTCCAGC AGTGTAGCCG CGTCCTGGGG 240 TGGGTGGCCG ANGCCTGANC CGCTCTGCCT TGCTGCCCCC ANGTGGGCCG CCACCCCCTG 300 ACCTGCCTGG GTCCAAACAC TGAGCCCTGC TGGCGGACTT CAAGGANAAC CCCCACANGG 360 GGATTTTGCT CCTANANTAA GGCTCATCTG GGCCTCGGCC CCCCCACCTG GTTGGCCTTG 420 TCTTTGANGT GAGCCCCATG TCCATCTGGG CCACTGTCNG GACCACCTTT NGGGAGTGTT 480 CTCCTTACAA CCACANNATG CCCGGCTCCT CCCGGAAACC ANTCCCANCC TGNGAAGGAT 540 CAAGNCCTGN ATCCACTNNT NCTANAACCG GCCNCCNCCG CNGTGGAACC CNCCTTNTGT 600 TCCTTTTCNT TNAGGGTTAA TNNCGCCTTG GCCTTNCCAN NGTCCTNCNC NTTTTCCNNT 660 GTTNAAATTG TTANGCNCCC NCCNNTCCCN CNNCNNCNAN CCCGACCCNN ANNTTNNANN 720 NCCTGGGGGT NCCNNCNGAT TGACCCNNCC NCCCTNTANT TGCNTTNGGG NNCNNTGCCC 780 CTTTCCCTCT NGGGANNCG 799 801 base pairs nucleic acid single linear cDNA not provided 9 ACGCCTTGAT CCTCCCAGGC TGGGACTGGT TCTGGGAGGA GCCGGGCATG CTGTGGTTTG 60 TAANGATGAC ACTCCCAAAG GTGGTCCTGA CAGTGGCCCA GATGGACATG GGGCTCACCT 120 CAAGGACAAG GCCACCAGGT GCGGGGGCCG AAGCCCACAT GATCCTTACT CTATGAGCAA 180 AATCCCCTGT GGGGGCTTCT CCTTGAAGTC CGCCANCAGG GCTCAGTCTT TGGACCCANG 240 CAGGTCATGG GGTTGTNGNC CAACTGGGGG CCNCAACGCA AAANGGCNCA GGGCCTCNGN 300 CACCCATCCC ANGACGCGGC TACACTNCTG GACCTCCCNC TCCACCACTT TCATGCGCTG 360 TTCNTACCCG CGNATNTGTC CCANCTGTTT CNGTGCCNAC TCCANCTTCT NGGACGTGCG 420 CTACATACGC CCGGANTCNC NCTCCCGCTT TGTCCCTATC CACGTNCCAN CAACAAATTT 480 CNCCNTANTG CACCNATTCC CACNTTTNNC AGNTTTCCNC NNCGNGCTTC CTTNTAAAAG 540 GGTTGANCCC CGGAAAATNC CCCAAAGGGG GGGGGCCNGG TACCCAACTN CCCCCTNATA 600 GCTGAANTCC CCATNACCNN GNCTCNATGG ANCCNTCCNT TTTAANNACN TTCTNAACTT 660 GGGAANANCC CTCGNCCNTN CCCCCNTTAA TCCCNCCTTG CNANGNNCNT CCCCCNNTCC 720 NCCCNNNTNG GCNTNTNANN CNAAAAAGGC CCNNNANCAA TCTCCTNNCN CCTCANTTCG 780 CCANCCCTCG AAATCGGCCN C 801 789 base pairs nucleic acid single linear cDNA not provided 10 CAGTCTATNT GGCCAGTGTG GCAGCTTTCC CTGTGGCTGC CGGTGCCACA TGCCTGTCCC 60 ACAGTGTGGC CGTGGTGACA GCTTCAGCCG CCCTCACCGG GTTCACCTTC TCAGCCCTGC 120 AGATCCTGCC CTACACACTG GCCTCCCTCT ACCACCGGGA GAAGCAGGTG TTCCTGCCCA 180 AATACCGAGG GGACACTGGA GGTGCTAGCA GTGAGGACAG CCTGATGACC AGCTTCCTGC 240 CAGGCCCTAA GCCTGGAGCT CCCTTCCCTA ATGGACACGT GGGTGCTGGA GGCAGTGGCC 300 TGCTCCCACC TCCACCCGCG CTCTGCGGGG CCTCTGCCTG TGATGTCTCC GTACGTGTGG 360 TGGTGGGTGA GCCCACCGAN GCCAGGGTGG TTCCGGGCCG GGGCATCTGC CTGGACCTCG 420 CCATCCTGGA TAGTGCTTCC TGCTGTCCCA NGTGGCCCCA TCCCTGTTTA TGGGCTCCAT 480 TGTCCAGCTC AGCCAGTCTG TCACTGCCTA TATGGTGTCT GCCGCAGGCC TGGGTCTGGT 540 CCCATTTACT TTGCTACACA GGTANTATTT GACAAGAACG ANTTGGCCAA ATACTCAGCG 600 TTAAAAAATT CCAGCAACAT TGGGGGTGGA AGGCCTGCCT CACTGGGTCC AACTCCCCGC 660 TCCTGTTAAC CCCATGGGGC TGCCGGCTTG GCCGCCAATT TCTGTTGCTG CCAAANTNAT 720 GTGGCTCTCT GCTGCCACCT GTTGCTGGCT GAAGTGCNTA CNGCNCANCT NGGGGGGTNG 780 GGNGTTCCC 789 772 base pairs nucleic acid single linear cDNA not provided 11 CCCACCCTAC CCAAATATTA GACACCAACA CAGAAAAGCT AGCAATGGAT TCCCTTCTAC 60 TTTGTTAAAT AAATAAGTTA AATATTTAAA TGCCTGTGTC TCTGTGATGG CAACAGAAGG 120 ACCAACAGGC CACATCCTGA TAAAAGGTAA GAGGGGGGTG GATCAGCAAA AAGACAGTGC 180 TGTGGGCTGA GGGGACCTGG TTCTTGTGTG TTGCCCCTCA GGACTCTTCC CCTACAAATA 240 ACTTTCATAT GTTCAAATCC CATGGAGGAG TGTTTCATCC TAGAAACTCC CATGCAAGAG 300 CTACATTAAA CGAAGCTGCA GGTTAAGGGG CTTANAGATG GGAAACCAGG TGACTGAGTT 360 TATTCAGCTC CCAAAAACCC TTCTCTAGGT GTGTCTCAAC TAGGAGGCTA GCTGTTAACC 420 CTGAGCCTGG GTAATCCACC TGCAGAGTCC CCGCATTCCA GTGCATGGAA CCCTTCTGGC 480 CTCCCTGTAT AAGTCCAGAC TGAAACCCCC TTGGAAGGNC TCCAGTCAGG CAGCCCTANA 540 AACTGGGGAA AAAAGAAAAG GACGCCCCAN CCCCCAGCTG TGCANCTACG CACCTCAACA 600 GCACAGGGTG GCAGCAAAAA AACCACTTTA CTTTGGCACA AACAAAAACT NGGGGGGGCA 660 ACCCCGGCAC CCCNANGGGG GTTAACAGGA ANCNGGGNAA CNTGGAACCC AATTNAGGCA 720 GGCCCNCCAC CCCNAATNTT GCTGGGAAAT TTTTCCTCCC CTAAATTNTT TC 772 751 base pairs nucleic acid single linear cDNA not provided 12 GCCCCAATTC CAGCTGCCAC ACCACCCACG GTGACTGCAT TAGTTCGGAT GTCATACAAA 60 AGCTGATTGA AGCAACCCTC TACTTTTTGG TCGTGAGCCT TTTGCTTGGT GCAGGTTTCA 120 TTGGCTGTGT TGGTGACGTT GTCATTGCAA CAGAATGGGG GAAAGGCACT GTTCTCTTTG 180 AAGTANGGTG AGTCCTCAAA ATCCGTATAG TTGGTGAAGC CACAGCACTT GAGCCCTTTC 240 ATGGTGGTGT TCCACACTTG AGTGAAGTCT TCCTGGGAAC CATAATCTTT CTTGATGGCA 300 GGCACTACCA GCAACGTCAG GGAAGTGCTC AGCCATTGTG GTGTACACCA AGGCGACCAC 360 AGCAGCTGCN ACCTCAGCAA TGAAGATGAN GAGGANGATG AAGAAGAACG TCNCGAGGGC 420 ACACTTGCTC TCAGTCTTAN CACCATANCA GCCCNTGAAA ACCAANANCA AAGACCACNA 480 CNCCGGCTGC GATGAAGAAA TNACCCCNCG TTGACAAACT TGCATGGCAC TGGGANCCAC 540 AGTGGCCCNA AAAATCTTCA AAAAGGATGC CCCATCNATT GACCCCCCAA ATGCCCACTG 600 CCAACAGGGG CTGCCCCACN CNCNNAACGA TGANCCNATT GNACAAGATC TNCNTGGTCT 660 TNATNAACNT GAACCCTGCN TNGTGGCTCC TGTTCAGGNC CNNGGCCTGA CTTCTNAANN 720 AANGAACTCN GAAGNCCCCA CNGGANANNC G 751 729 base pairs nucleic acid single linear cDNA not provided 13 GAGCCAGGCG TCCCTCTGCC TGCCCACTCA GTGGCAACAC CCGGGAGCTG TTTTGTCCTT 60 TGTGGANCCT CAGCAGTNCC CTCTTTCAGA ACTCANTGCC AAGANCCCTG AACAGGAGCC 120 ACCATGCAGT GCTTCAGCTT CATTAAGACC ATGATGATCC TCTTCAATTT GCTCATCTTT 180 CTGTGTGGTG CAGCCCTGTT GGCAGTGGGC ATCTGGGTGT CAATCGATGG GGCATCCTTT 240 CTGAAGATCT TCGGGCCACT GTCGTCCAGT GCCATGCAGT TTGTCAACGT GGGCTACTTC 300 CTCATCGCAG CCGGCGTTGT GGTCTTAGCT CTAGGTTTCC TGGGCTGCTA TGGTGCTAAG 360 ACTGAGAGCA AGTGTGCCCT CGTGACGTTC TTCTTCATCC TCCTCCTCAT CTTCATTGCT 420 GAGGTTGCAA TGCTGTGGTC GCCTTGGTGT ACACCACAAT GGCTGAGCAC TTCCTGACGT 480 TGCTGGTAAT GCCTGCCATC AANAAAAGAT TATGGGTTCC CAGGAANACT TCACTCAAGT 540 GTTGGAACAC CACCATGAAA GGGCTCAAGT GCTGTGGCTT CNNCCAACTA TACGGATTTT 600 GAAGANTCAC CTACTTCAAA GAAAANAGTG CCTTTCCCCC ATTTCTGTTG CAATTGACAA 660 ACGTCCCCAA CACAGCCAAT TGAAAACCTG CACCCAACCC AAANGGGTCC CCAACCANAA 720 ATTNAAGGG 729 816 base pairs nucleic acid single linear cDNA not provided 14 TGCTCTTCCT CAAAGTTGTT CTTGTTGCCA TAACAACCAC CATAGGTAAA GCGGGCGCAG 60 TGTTCGCTGA AGGGGTTGTA GTACCAGCGC GGGATGCTCT CCTTGCAGAG TCCTGTGTCT 120 GGCAGGTCCA CGCAGTGCCC TTTGTCACTG GGGAAATGGA TGCGCTGGAG CTCGTCAAAG 180 CCACTCGTGT ATTTTTCACA GGCAGCCTCG TCCGACGCGT CGGGGCAGTT GGGGGTGTCT 240 TCACACTCCA GGAAACTGTC NATGCAGCAG CCATTGCTGC AGCGGAACTG GGTGGGCTGA 300 CANGTGCCAG AGCACACTGG ATGGCGCCTT TCCATGNNAN GGGCCCTGNG GGAAAGTCCC 360 TGANCCCCAN ANCTGCCTCT CAAANGCCCC ACCTTGCACA CCCCGACAGG CTAGAATGGA 420 ATCTTCTTCC CGAAAGGTAG TTNTTCTTGT TGCCCAANCC ANCCCCNTAA ACAAACTCTT 480 GCANATCTGC TCCGNGGGGG TCNTANTACC ANCGTGGGAA AAGAACCCCA GGCNGCGAAC 540 CAANCTTGTT TGGATNCGAA GCNATAATCT NCTNTTCTGC TTGGTGGACA GCACCANTNA 600 CTGTNNANCT TTAGNCCNTG GTCCTCNTGG GTTGNNCTTG AACCTAATCN CCNNTCAACT 660 GGGACAAGGT AANTNGCCNT CCTTTNAATT CCCNANCNTN CCCCCTGGTT TGGGGTTTTN 720 CNCNCTCCTA CCCCAGAAAN NCCGTGTTCC CCCCCAACTA GGGGCCNAAA CCNNTTNTTC 780 CACAACCCTN CCCCACCCAC GGGTTCNGNT GGTTNG 816 783 base pairs nucleic acid single linear cDNA not provided 15 CCAAGGCCTG GGCAGGCATA NACTTGAAGG TACAACCCCA GGAACCCCTG GTGCTGAAGG 60 ATGTGGAAAA CACAGATTGG CGCCTACTGC GGGGTGACAC GGATGTCAGG GTAGAGAGGA 120 AAGACCCAAA CCAGGTGGAA CTGTGGGGAC TCAAGGAANG CACCTACCTG TTCCAGCTGA 180 CAGTGACTAG CTCAGACCAC CCAGAGGACA CGGCCAACGT CACAGTCACT GTGCTGTCCA 240 CCAAGCAGAC AGAAGACTAC TGCCTCGCAT CCAACAANGT GGGTCGCTGC CGGGGCTCTT 300 TCCCACGCTG GTACTATGAC CCCACGGAGC AGATCTGCAA GAGTTTCGTT TATGGAGGCT 360 GCTTGGGCAA CAAGAACAAC TACCTTCGGG AAGAAGAGTG CATTCTANCC TGTCNGGGTG 420 TGCAAGGTGG GCCTTTGANA NGCANCTCTG GGGCTCANGC GACTTTCCCC CAGGGCCCCT 480 CCATGGAAAG GCGCCATCCA NTGTTCTCTG GCACCTGTCA GCCCACCCAG TTCCGCTGCA 540 NCAATGGCTG CTGCATCNAC ANTTTCCTNG AATTGTGACA ACACCCCCCA NTGCCCCCAA 600 CCCTCCCAAC AAAGCTTCCC TGTTNAAAAA TACNCCANTT GGCTTTTNAC AAACNCCCGG 660 CNCCTCCNTT TTCCCCNNTN AACAAAGGGC NCTNGCNTTT GAACTGCCCN AACCCNGGAA 720 TCTNCCNNGG AAAAANTNCC CCCCCTGGTT CCTNNAANCC CCTCCNCNAA ANCTNCCCCC 780 CCC 783 801 base pairs nucleic acid single linear cDNA not provided 16 GCCCCAATTC CAGCTGCCAC ACCACCCACG GTGACTGCAT TAGTTCGGAT GTCATACAAA 60 AGCTGATTGA AGCAACCCTC TACTTTTTGG TCGTGAGCCT TTTGCTTGGT GCAGGTTTCA 120 TTGGCTGTGT TGGTGACGTT GTCATTGCAA CAGAATGGGG GAAAGGCACT GTTCTCTTTG 180 AAGTAGGGTG AGTCCTCAAA ATCCGTATAG TTGGTGAAGC CACAGCACTT GAGCCCTTTC 240 ATGGTGGTGT TCCACACTTG AGTGAAGTCT TCCTGGGAAC CATAATCTTT CTTGATGGCA 300 GGCACTACCA GCAACGTCAG GAAGTGCTCA GCCATTGTGG TGTACACCAA GGCGACCACA 360 GCAGCTGCAA CCTCAGCAAT GAAGATGAGG AGGAGGATGA AGAAGAACGT CNCGAGGGCA 420 CACTTGCTCT CCGTCTTAGC ACCATAGCAG CCCANGAAAC CAAGAGCAAA GACCACAACG 480 CCNGCTGCGA ATGAAAGAAA NTACCCACGT TGACAAACTG CATGGCCACT GGACGACAGT 540 TGGCCCGAAN ATCTTCAGAA AAGGGATGCC CCATCGATTG AACACCCANA TGCCCACTGC 600 CNACAGGGCT GCNCCNCNCN GAAAGAATGA GCCATTGAAG AAGGATCNTC NTGGTCTTAA 660 TGAACTGAAA CCNTGCATGG TGGCCCCTGT TCAGGGCTCT TGGCAGTGAA TTCTGANAAA 720 AAGGAACNGC NTNAGCCCCC CCAAANGANA AAACACCCCC GGGTGTTGCC CTGAATTGGC 780 GGCCAAGGAN CCCTGCCCCN G 801 740 base pairs nucleic acid single linear cDNA not provided 17 GTGAGAGCCA GGCGTCCCTC TGCCTGCCCA CTCAGTGGCA ACACCCGGGA GCTGTTTTGT 60 CCTTTGTGGA GCCTCAGCAG TTCCCTCTTT CAGAACTCAC TGCCAAGAGC CCTGAACAGG 120 AGCCACCATG CAGTGCTTCA GCTTCATTAA GACCATGATG ATCCTCTTCA ATTTGCTCAT 180 CTTTCTGTGT GGTGCAGCCC TGTTGGCAGT GGGCATCTGG GTGTCAATCG ATGGGGCATC 240 CTTTCTGAAG ATCTTCGGGC CACTGTCGTC CAGTGCCATG CAGTTTGTCA ACGTGGGCTA 300 CTTCCTCATC GCAGCCGGCG TTGTGGTCTT TGCTCTTGGT TTCCTGGGCT GCTATGGTGC 360 TAAGACGGAG AGCAAGTGTG CCCTCGTGAC GTTCTTCTTC ATCCTCCTCC TCATCTTCAT 420 TGCTGAAGTT GCAGCTGCTG TGGTCGCCTT GGTGTACACC ACAATGGCTG AACCATTCCT 480 GACGTTGCTG GTANTGCCTG CCATCAANAA AGATTATGGG TTCCCAGGAA AAATTCACTC 540 AANTNTGGAA CACCNCCATG AAAAGGGCTC CAATTTCTGN TGGCTTCCCC AACTATACCG 600 GAATTTTGAA AGANTCNCCC TACTTCCAAA AAAAAANANT TGCCTTTNCC CCCNTTCTGT 660 TGCAATGAAA ACNTCCCAAN ACNGCCAATN AAAACCTGCC CNNNCAAAAA GGNTCNCAAA 720 CAAAAAAANT NNAAGGGTTN 740 802 base pairs nucleic acid single linear cDNA not provided 18 CCGCTGGTTG CGCTGGTCCA GNGNAGCCAC GAAGCACGTC AGCATACACA GCCTCAATCA 60 CAAGGTCTTC CAGCTGCCGC ACATTACGCA GGGCAAGAGC CTCCAGCAAC ACTGCATATG 120 GGATACACTT TACTTTAGCA GCCAGGGTGA CAACTGAGAG GTGTCGAAGC TTATTCTTCT 180 GAGCCTCTGT TAGTGGAGGA AGATTCCGGG CTTCAGCTAA GTAGTCAGCG TATGTCCCAT 240 AAGCAAACAC TGTGAGCAGC CGGAAGGTAG AGGCAAAGTC ACTCTCAGCC AGCTCTCTAA 300 CATTGGGCAT GTCCAGCAGT TCTCCAAACA CGTAGACACC AGNGGCCTCC AGCACCTGAT 360 GGATGAGTGT GGCCAGCGCT GCCCCCTTGG CCGACTTGGC TAGGAGCAGA AATTGCTCCT 420 GGTTCTGCCC TGTCACCTTC ACTTCCGCAC TCATCACTGC ACTGAGTGTG GGGGACTTGG 480 GCTCAGGATG TCCAGAGACG TGGTTCCGCC CCCTCNCTTA ATGACACCGN CCANNCAACC 540 GTCGGCTCCC GCCGANTGNG TTCGTCGTNC CTGGGTCAGG GTCTGCTGGC CNCTACTTGC 600 AANCTTCGTC NGGCCCATGG AATTCACCNC ACCGGAACTN GTANGATCCA CTNNTTCTAT 660 AACCGGNCGC CACCGCNNNT GGAACTCCAC TCTTNTTNCC TTTACTTGAG GGTTAAGGTC 720 ACCCTTNNCG TTACCTTGGT CCAAACCNTN CCNTGTGTCG ANATNGTNAA TCNGGNCCNA 780 TNCCANCCNC ATANGAAGCC NG 802 731 base pairs nucleic acid single linear cDNA not provided 19 CNAAGCTTCC AGGTNACGGG CCGCNAANCC TGACCCNAGG TANCANAANG CAGNCNGCGG 60 GAGCCCACCG TCACGNGGNG GNGTCTTTAT NGGAGGGGGC GGAGCCACAT CNCTGGACNT 120 CNTGACCCCA ACTCCCCNCC NCNCANTGCA GTGATGAGTG CAGAACTGAA GGTNACGTGG 180 CAGGAACCAA GANCAAANNC TGCTCCNNTC CAAGTCGGCN NAGGGGGCGG GGCTGGCCAC 240 GCNCATCCNT CNAGTGCTGN AAAGCCCCNN CCTGTCTACT TGTTTGGAGA ACNGCNNNGA 300 CATGCCCAGN GTTANATAAC NGGCNGAGAG TNANTTTGCC TCTCCCTTCC GGCTGCGCAN 360 CGNGTNTGCT TAGNGGACAT AACCTGACTA CTTAACTGAA CCCNNGAATC TNCCNCCCCT 420 CCACTAAGCT CAGAACAAAA AACTTCGACA CCACTCANTT GTCACCTGNC TGCTCAAGTA 480 AAGTGTACCC CATNCCCAAT GTNTGCTNGA NGCTCTGNCC TGCNTTANGT TCGGTCCTGG 540 GAAGACCTAT CAATTNAAGC TATGTTTCTG ACTGCCTCTT GCTCCCTGNA ACAANCNACC 600 CNNCNNTCCA AGGGGGGGNC GGCCCCCAAT CCCCCCAACC NTNAATTNAN TTTANCCCCN 660 CCCCCNGGCC CGGCCTTTTA CNANCNTCNN NNACNGGGNA AAACCNNNGC TTTNCCCAAC 720 NNAATCCNCC T 731 754 base pairs nucleic acid single linear cDNA not provided 20 TTTTTTTTTT TTTTTTTTTT TAAAAACCCC CTCCATTNAA TGNAAACTTC CGAAATTGTC 60 CAACCCCCTC NTCCAAATNN CCNTTTCCGG GNGGGGGTTC CAAACCCAAN TTANNTTTGG 120 ANNTTAAATT AAATNTTNNT TGGNGGNNNA ANCCNAATGT NANGAAAGTT NAACCCANTA 180 TNANCTTNAA TNCCTGGAAA CCNGTNGNTT CCAAAAATNT TTAACCCTTA ANTCCCTCCG 240 AAATNGTTNA NGGAAAACCC AANTTCTCNT AAGGTTGTTT GAAGGNTNAA TNAAAANCCC 300 NNCCAATTGT TTTTNGCCAC GCCTGAATTA ATTGGNTTCC GNTGTTTTCC NTTAAAANAA 360 GGNNANCCCC GGTTANTNAA TCCCCCCNNC CCCAATTATA CCGANTTTTT TTNGAATTGG 420 GANCCCNCGG GAATTAACGG GGNNNNTCCC TNTTGGGGGG CNGGNNCCCC CCCCNTCGGG 480 GGTTNGGGNC AGGNCNNAAT TGTTTAAGGG TCCGAAAAAT CCCTCCNAGA AAAAAANCTC 540 CCAGGNTGAG NNTNGGGTTT NCCCCCCCCC CANGGCCCCT CTCGNANAGT TGGGGTTTGG 600 GGGGCCTGGG ATTTTNTTTC CCCTNTTNCC TCCCCCCCCC CCNGGGANAG AGGTTNGNGT 660 TTTGNTCNNC GGCCCCNCCN AAGANCTTTN CCGANTTNAN TTAAATCCNT GCCTNGGCGA 720 AGTCCNTTGN AGGGNTAAAN GGCCCCCTNN CGGG 754 755 base pairs nucleic acid single linear cDNA not provided 21 ATCANCCCAT GACCCCNAAC NNGGGACCNC TCANCCGGNC NNNCNACCNC CGGCCNATCA 60 NNGTNAGNNC ACTNCNNTTN NATCACNCCC CNCCNACTAC GCCCNCNANC CNACGCNCTA 120 NNCANATNCC ACTGANNGCG CGANGTNGAN NGAGAAANCT NATACCANAG NCACCANACN 180 CCAGCTGTCC NANAANGCCT NNNATACNGG NNNATCCAAT NTGNANCCTC CNAAGTATTN 240 NNCNNCANAT GATTTTCCTN ANCCGATTAC CCNTNCCCCC TANCCCCTCC CCCCCAACNA 300 CGAAGGCNCT GGNCCNAAGG NNGCGNCNCC CCGCTAGNTC CCCNNCAAGT CNCNCNCCTA 360 AACTCANCCN NATTACNCGC TTCNTGAGTA TCACTCCCCG AATCTCACCC TACTCAACTC 420 AAAAANATCN GATACAAAAT AATNCAAGCC TGNTTATNAC ACTNTGACTG GGTCTCTATT 480 TTAGNGGTCC NTNAANCNTC CTAATACTTC CAGTCTNCCT TCNCCAATTT CCNAANGGCT 540 CTTTCNGACA GCATNTTTTG GTTCCCNNTT GGGTTCTTAN NGAATTGCCC TTCNTNGAAC 600 GGGCTCNTCT TTTCCTTCGG TTANCCTGGN TTCNNCCGGC CAGTTATTAT TTCCCNTTTT 660 AAATTCNTNC CNTTTANTTT TGGCNTTCNA AACCCCCGGC CTTGAAAACG GCCCCCTGGT 720 AAAAGGTTGT TTTGANAAAA TTTTTGTTTT GTTCC 755 849 base pairs nucleic acid single linear cDNA not provided 22 TTTTTTTTTT TTTTTANGTG TNGTCGTGCA GGTAGAGGCT TACTACAANT GTGAANACGT 60 ACGCTNGGAN TAANGCGACC CGANTTCTAG GANNCNCCCT AAAATCANAC TGTGAAGATN 120 ATCCTGNNNA CGGAANGGTC ACCGGNNGAT NNTGCTAGGG TGNCCNCTCC CANNNCNTTN 180 CATAACTCNG NGGCCCTGCC CACCACCTTC GGCGGCCCNG NGNCCGGGCC CGGGTCATTN 240 GNNTTAACCN CACTNNGCNA NCGGTTTCCN NCCCCNNCNG ACCCNGGCGA TCCGGGGTNC 300 TCTGTCTTCC CCTGNAGNCN ANAAANTGGG CCNCGGNCCC CTTTACCCCT NNACAAGCCA 360 CNGCCNTCTA NCCNCNGCCC CCCCTCCANT NNGGGGGACT GCCNANNGCT CCGTTNCTNG 420 NNACCCCNNN GGGTNCCTCG GTTGTCGANT CNACCGNANG CCANGGATTC CNAAGGAAGG 480 TGCGTTNTTG GCCCCTACCC TTCGCTNCGG NNCACCCTTC CCGACNANGA NCCGCTCCCG 540 CNCNNCGNNG CCTCNCCTCG CAACACCCGC NCTCNTCNGT NCGGNNNCCC CCCCACCCGC 600 NCCCTCNCNC NGNCGNANCN CTCCNCCNCC GTCTCANNCA CCACCCCGCC CCGCCAGGCC 660 NTCANCCACN GGNNGACNNG NAGCNCNNTC GCNCCGCGCN GCGNCNCCCT CGCCNCNGAA 720 CTNCNTCNGG CCANTNNCGC TCAANCCNNA CNAAACGCCG CTGCGCGGCC CGNAGCGNCC 780 NCCTCCNCGA GTCCTCCCGN CTTCCNACCC ANGNNTTCCN CGAGGACACN NNACCCCGCC 840 NNCANGCGG 849 872 base pairs nucleic acid single linear cDNA not provided 23 GCGCAAACTA TACTTCGCTC GNACTCGTGC GCCTCGCTNC TCTTTTCCTC CGCAACCATG 60 TCTGACNANC CCGATTNGGC NGATATCNAN AAGNTCGANC AGTCCAAACT GANTAACACA 120 CACACNCNAN AGANAAATCC NCTGCCTTCC ANAGTANACN ATTGAACNNG AGAACCANGC 180 NGGCGAATCG TAATNAGGCG TGCGCCGCCA ATNTGTCNCC GTTTATTNTN CCAGCNTCNC 240 CTNCCNACCC TACNTCTTCN NAGCTGTCNN ACCCCTNGTN CGNACCCCCC NAGGTCGGGA 300 TCGGGTTTNN NNTGACCGNG CNNCCCCTCC CCCCNTCCAT NACGANCCNC CCGCACCACC 360 NANNGCNCGC NCCCCGNNCT CTTCGCCNCC CTGTCCTNTN CCCCTGTNGC CTGGCNCNGN 420 ACCGCATTGA CCCTCGCCNN CTNCNNGAAA NCGNANACGT CCGGGTTGNN ANNANCGCTG 480 TGGGNNNGCG TCTGCNCCGC GTTCCTTCCN NCNNCTTCCA CCATCTTCNT TACNGGGTCT 540 CCNCGCCNTC TCNNNCACNC CCTGGGACGC TNTCCTNTGC CCCCCTTNAC TCCCCCCCTT 600 CGNCGTGNCC CGNCCCCACC NTCATTTNCA NACGNTCTTC ACAANNNCCT GGNTNNCTCC 660 CNANCNGNCN GTCANCCNAG GGAAGGGNGG GGNNCCNNTG NTTGACGTTG NGGNGANGTC 720 CGAANANTCC TCNCCNTCAN CNCTACCCCT CGGGCGNNCT CTCNGTTNCC AACTTANCAA 780 NTCTCCCCCG NGNGCNCNTC TCAGCCTCNC CCNCCCCNCT CTCTGCANTG TNCTCTGCTC 840 TNACCNNTAC GANTNTTCGN CNCCCTCTTT CC 872 815 base pairs nucleic acid single linear cDNA not provided 24 GCATGCAAGC TTGAGTATTC TATAGNGTCA CCTAAATANC TTGGCNTAAT CATGGTCNTA 60 NCTGNCTTCC TGTGTCAAAT GTATACNAAN TANATATGAA TCTNATNTGA CAAGANNGTA 120 TCNTNCATTA GTAACAANTG TNNTGTCCAT CCTGTCNGAN CANATTCCCA TNNATTNCGN 180 CGCATTCNCN GCNCANTATN TAATNGGGAA NTCNNNTNNN NCACCNNCAT CTATCNTNCC 240 GCNCCCTGAC TGGNAGAGAT GGATNANTTC TNNTNTGACC NACATGTTCA TCTTGGATTN 300 AANANCCCCC CGCNGNCCAC CGGTTNGNNG CNAGCCNNTC CCAAGACCTC CTGTGGAGGT 360 AACCTGCGTC AGANNCATCA AACNTGGGAA ACCCGCNNCC ANGTNNAAGT NGNNNCANAN 420 GATCCCGTCC AGGNTTNACC ATCCCTTCNC AGCGCCCCCT TTNGTGCCTT ANAGNGNAGC 480 GTGTCCNANC CNCTCAACAT GANACGCGCC AGNCCANCCG CAATTNGGCA CAATGTCGNC 540 GAACCCCCTA GGGGGANTNA TNCAAANCCC CAGGATTGTC CNCNCANGAA ATCCCNCANC 600 CCCNCCCTAC CCNNCTTTGG GACNGTGACC AANTCCCGGA GTNCCAGTCC GGCCNGNCTC 660 CCCCACCGGT NNCCNTGGGG GGGTGAANCT CNGNNTCANC CNGNCGAGGN NTCGNAAGGA 720 ACCGGNCCTN GGNCGAANNG ANCNNTCNGA AGNGCCNCNT CGTATAACCC CCCCTCNCCA 780 NCCNACNGNT AGNTCCCCCC CNGGGTNCGG AANGG 815 775 base pairs nucleic acid single linear cDNA not provided 25 CCGAGATGTC TCGCTCCGTG GCCTTAGCTG TGCTCGCGCT ACTCTCTCTT TCTGGCCTGG 60 AGGCTATCCA GCGTACTCCA AAGATTCAGG TTTACTCACG TCATCCAGCA GAGAATGGAA 120 AGTCAAATTT CCTGAATTGC TATGTGTCTG GGTTTCATCC ATCCGACATT GAANTTGACT 180 TACTGAAGAA TGGANAGAGA ATTGAAAAAG TGGAGCATTC AGACTTGTCT TTCAGCAAGG 240 ACTGGTCTTT CTATCTCNTG TACTACACTG AATTCACCCC CACTGAAAAA GATGAGTATG 300 CCTGCCGTGT GAACCATGTG ACTTTGTCAC AGCCCAAGAT AGTTAAGTGG GATCGAGACA 360 TGTAAGCAGN CNNCATGGAA GTTTGAAGAT GCCGCATTTG GATTGGATGA ATTCCAAATT 420 CTGCTTGCTT GCNTTTTAAT ANTGATATGC NTATACACCC TACCCTTTAT GNCCCCAAAT 480 TGTAGGGGTT ACATNANTGT TCNCNTNGGA CATGATCTTC CTTTATAANT CCNCCNTTCG 540 AATTGCCCGT CNCCCNGTTN NGAATGTTTC CNNAACCACG GTTGGCTCCC CCAGGTCNCC 600 TCTTACGGAA GGGCCTGGGC CNCTTTNCAA GGTTGGGGGA ACCNAAAATT TCNCTTNTGC 660 CCNCCCNCCA CNNTCTTGNG NNCNCANTTT GGAACCCTTC CNATTCCCCT TGGCCTCNNA 720 NCCTTNNCTA ANAAAACTTN AAANCGTNGC NAAANNTTTN ACTTCCCCCC TTACC 775 820 base pairs nucleic acid single linear cDNA not provided 26 ANATTANTAC AGTGTAATCT TTTCCCAGAG GTGTGTANAG GGAACGGGGC CTAGAGGCAT 60 CCCANAGATA NCTTATANCA ACAGTGCTTT GACCAAGAGC TGCTGGGCAC ATTTCCTGCA 120 GAAAAGGTGG CGGTCCCCAT CACTCCTCCT CTCCCATAGC CATCCCAGAG GGGTGAGTAG 180 CCATCANGCC TTCGGTGGGA GGGAGTCANG GAAACAACAN ACCACAGAGC ANACAGACCA 240 NTGATGACCA TGGGCGGGAG CGAGCCTCTT CCCTGNACCG GGGTGGCANA NGANAGCCTA 300 NCTGAGGGGT CACACTATAA ACGTTAACGA CCNAGATNAN CACCTGCTTC AAGTGCACCC 360 TTCCTACCTG ACNACCAGNG ACCNNNAACT GCNGCCTGGG GACAGCNCTG GGANCAGCTA 420 ACNNAGCACT CACCTGCCCC CCCATGGCCG TNCGCNTCCC TGGTCCTGNC AAGGGAAGCT 480 CCCTGTTGGA ATTNCGGGGA NACCAAGGGA NCCCCCTCCT CCANCTGTGA AGGAAAAANN 540 GATGGAATTT TNCCCTTCCG GCCNNTCCCC TCTTCCTTTA CACGCCCCCT NNTACTCNTC 600 TCCCTCTNTT NTCCTGNCNC ACTTTTNACC CCNNNATTTC CCTTNATTGA TCGGANNCTN 660 GANATTCCAC TNNCGCCTNC CNTCNATCNG NAANACNAAA NACTNTCTNA CCCNGGGGAT 720 GGGNNCCTCG NTCATCCTCT CTTTTTCNCT ACCNCCNNTT CTTTGCCTCT CCTTNGATCA 780 TCCAACCNTC GNTGGCCNTN CCCCCCCNNN TCCTTTNCCC 820 818 base pairs nucleic acid single linear cDNA not provided 27 TCTGGGTGAT GGCCTCTTCC TCCTCAGGGA CCTCTGACTG CTCTGGGCCA AAGAATCTCT 60 TGTTTCTTCT CCGAGCCCCA GGCAGCGGTG ATTCAGCCCT GCCCAACCTG ATTCTGATGA 120 CTGCGGATGC TGTGACGGAC CCAAGGGGCA AATAGGGTCC CAGGGTCCAG GGAGGGGCGC 180 CTGCTGAGCA CTTCCGCCCC TCACCCTGCC CAGCCCCTGC CATGAGCTCT GGGCTGGGTC 240 TCCGCCTCCA GGGTTCTGCT CTTCCANGCA NGCCANCAAG TGGCGCTGGG CCACACTGGC 300 TTCTTCCTGC CCCNTCCCTG GCTCTGANTC TCTGTCTTCC TGTCCTGTGC ANGCNCCTTG 360 GATCTCAGTT TCCCTCNCTC ANNGAACTCT GTTTCTGANN TCTTCANTTA ACTNTGANTT 420 TATNACCNAN TGGNCTGTNC TGTCNNACTT TAATGGGCCN GACCGGCTAA TCCCTCCCTC 480 NCTCCCTTCC ANTTCNNNNA ACCNGCTTNC CNTCNTCTCC CCNTANCCCG CCNGGGAANC 540 CTCCTTTGCC CTNACCANGG GCCNNNACCG CCCNTNNCTN GGGGGGCNNG GTNNCTNCNC 600 CTGNTNNCCC CNCTCNCNNT TNCCTCGTCC CNNCNNCGCN NNGCANNTTC NCNGTCCCNN 660 TNNCTCTTCN NGTNTCGNAA NGNTCNCNTN TNNNNNGNCN NGNTNNTNCN TCCCTCTCNC 720 CNNNTGNANG TNNTTNNNNC NCNGNNCCCC NNNNCNNNNN NGGNNNTNNN TCTNCNCNGC 780 CCCNNCCCCC NGNATTAAGG CCTCCNNTCT CCGGCCNC 818 731 base pairs nucleic acid single linear cDNA not provided 28 AGGAAGGGCG GAGGGATATT GTANGGGATT GAGGGATAGG AGNATAANGG GGGAGGTGTG 60 TCCCAACATG ANGGTGNNGT TCTCTTTTGA ANGAGGGTTG NGTTTTTANN CCNGGTGGGT 120 GATTNAACCC CATTGTATGG AGNNAAAGGN TTTNAGGGAT TTTTCGGCTC TTATCAGTAT 180 NTANATTCCT GTNAATCGGA AAATNATNTT TCNNCNGGAA AATNTTGCTC CCATCCGNAA 240 ATTNCTCCCG GGTAGTGCAT NTTNGGGGGN CNGCCANGTT TCCCAGGCTG CTANAATCGT 300 ACTAAAGNTT NAAGTGGGAN TNCAAATGAA AACCTNNCAC AGAGNATCCN TACCCGACTG 360 TNNNTTNCCT TCGCCCTNTG ACTCTGCNNG AGCCCAATAC CCNNGNGNAT GTCNCCCNGN 420 NNNGCGNCNC TGAAANNNNC TCGNGGCTNN GANCATCANG GGGTTTCGCA TCAAAAGCNN 480 CGTTTCNCAT NAAGGCACTT TNGCCTCATC CAACCNCTNG CCCTCNNCCA TTTNGCCGTC 540 NGGTTCNCCT ACGCTNNTNG CNCCTNNNTN GANATTTTNC CCGCCTNGGG NAANCCTCCT 600 GNAATGGGTA GGGNCTTNTC TTTTNACCNN GNGGTNTACT AATCNNCTNC ACGCNTNCTT 660 TCTCNACCCC CCCCCTTTTT CAATCCCANC GGCNAATGGG GTCTCCCCNN CGANGGGGGG 720 NNNCCCANNC C 731 822 base pairs nucleic acid single linear cDNA not provided 29 ACTAGTCCAG TGTGGTGGAA TTCCATTGTG TTGGGGNCNC TTCTATGANT ANTNTTAGAT 60 CGCTCANACC TCACANCCTC CCNACNANGC CTATAANGAA NANNAATAGA NCTGTNCNNT 120 ATNTNTACNC TCATANNCCT CNNNACCCAC TCCCTCTTAA CCCNTACTGT GCCTATNGCN 180 TNNCTANTCT NTGCCGCCTN CNANCCACCN GTGGGCCNAC CNCNNGNATT CTCNATCTCC 240 TCNCCATNTN GCCTANANTA NGTNCATACC CTATACCTAC NCCAATGCTA NNNCTAANCN 300 TCCATNANTT ANNNTAACTA CCACTGACNT NGACTTTCNC ATNANCTCCT AATTTGAATC 360 TACTCTGACT CCCACNGCCT ANNNATTAGC ANCNTCCCCC NACNATNTCT CAACCAAATC 420 NTCAACAACC TATCTANCTG TTCNCCAACC NTTNCCTCCG ATCCCCNNAC AACCCCCCTC 480 CCAAATACCC NCCACCTGAC NCCTAACCCN CACCATCCCG GCAAGCCNAN GGNCATTTAN 540 CCACTGGAAT CACNATNGGA NAAAAAAAAC CCNAACTCTC TANCNCNNAT CTCCCTAANA 600 AATNCTCCTN NAATTTACTN NCANTNCCAT CAANCCCACN TGAAACNNAA CCCCTGTTTT 660 TANATCCCTT CTTTCGAAAA CCNACCCTTT ANNNCCCAAC CTTTNGGGCC CCCCCNCTNC 720 CCNAATGAAG GNCNCCCAAT CNANGAAACG NCCNTGAAAA ANCNAGGCNA ANANNNTCCG 780 CANATCCTAT CCCTTANTTN GGGGNCCCTT NCCCNGGGCC CC 822 787 base pairs nucleic acid single linear cDNA not provided 30 CGGCCGCCTG CTCTGGCACA TGCCTCCTGA ATGGCATCAA AAGTGATGGA CTGCCCATTG 60 CTAGAGAAGA CCTTCTCTCC TACTGTCATT ATGGAGCCCT GCAGACTGAG GGCTCCCCTT 120 GTCTGCAGGA TTTGATGTCT GAAGTCGTGG AGTGTGGCTT GGAGCTCCTC ATCTACATNA 180 GCTGGAAGCC CTGGAGGGCC TCTCTCGCCA GCCTCCCCCT TCTCTCCACG CTCTCCANGG 240 ACACCAGGGG CTCCAGGCAG CCCATTATTC CCAGNANGAC ATGGTGTTTC TCCACGCGGA 300 CCCATGGGGC CTGNAAGGCC AGGGTCTCCT TTGACACCAT CTCTCCCGTC CTGCCTGGCA 360 GGCCGTGGGA TCCACTANTT CTANAACGGN CGCCACCNCG GTGGGAGCTC CAGCTTTTGT 420 TCCCNTTAAT GAAGGTTAAT TGCNCGCTTG GCGTAATCAT NGGTCANAAC TNTTTCCTGT 480 GTGAAATTGT TTNTCCCCTC NCNATTCCNC NCNACATACN AACCCGGAAN CATAAAGTGT 540 TAAAGCCTGG GGGTNGCCTN NNGAATNAAC TNAACTCAAT TAATTGCGTT GGCTCATGGC 600 CCGCTTTCCN TTCNGGAAAA CTGTCNTCCC CTGCNTTNNT GAATCGGCCA CCCCCCNGGG 660 AAAAGCGGTT TGCNTTTTNG GGGGNTCCTT CCNCTTCCCC CCTCNCTAAN CCCTNCGCCT 720 CGGTCGTTNC NGGTNGCGGG GAANGGGNAT NNNCTCCCNC NAAGGGGGNG AGNNNGNTAT 780 CCCCAAA 787 799 base pairs nucleic acid single linear cDNA not provided 31 TTTTTTTTTT TTTTTTTGGC GATGCTACTG TTTAATTGCA GGAGGTGGGG GTGTGTGTAC 60 CATGTACCAG GGCTATTAGA AGCAAGAAGG AAGGAGGGAG GGCAGAGCGC CCTGCTGAGC 120 AACAAAGGAC TCCTGCAGCC TTCTCTGTCT GTCTCTTGGC GCAGGCACAT GGGGAGGCCT 180 CCCGCAGGGT GGGGGCCACC AGTCCAGGGG TGGGAGCACT ACANGGGGTG GGAGTGGGTG 240 GTGGCTGGTN CNAATGGCCT GNCACANATC CCTACGATTC TTGACACCTG GATTTCACCA 300 GGGGACCTTC TGTTCTCCCA NGGNAACTTC NTNNATCTCN AAAGAACACA ACTGTTTCTT 360 CNGCANTTCT GGCTGTTCAT GGAAAGCACA GGTGTCCNAT TTNGGCTGGG ACTTGGTACA 420 TATGGTTCCG GCCCACCTCT CCCNTCNAAN AAGTAATTCA CCCCCCCCCN CCNTCTNTTG 480 CCTGGGCCCT TAANTACCCA CACCGGAACT CANTTANTTA TTCATCTTNG GNTGGGCTTG 540 NTNATCNCCN CCTGAANGCG CCAAGTTGAA AGGCCACGCC GTNCCCNCTC CCCATAGNAN 600 NTTTTNNCNT CANCTAATGC CCCCCCNGGC AACNATCCAA TCCCCCCCCN TGGGGGCCCC 660 AGCCCANGGC CCCCGNCTCG GGNNNCCNGN CNCGNANTCC CCAGGNTCTC CCANTCNGNC 720 CCNNNGCNCC CCCGCACGCA GAACANAAGG NTNGAGCCNC CGCANNNNNN NGGTNNCNAC 780 CTCGCCCCCC CCNNCGNNG 799 789 base pairs nucleic acid single linear cDNA not provided 32 TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT 60 TTTTNCCNAG GGCAGGTTTA TTGACAACCT CNCGGGACAC AANCAGGCTG GGGACAGGAC 120 GGCAACAGGC TCCGGCGGCG GCGGCGGCGG CCCTACCTGC GGTACCAAAT NTGCAGCCTC 180 CGCTCCCGCT TGATNTTCCT CTGCAGCTGC AGGATGCCNT AAAACAGGGC CTCGGCCNTN 240 GGTGGGCACC CTGGGATTTN AATTTCCACG GGCACAATGC GGTCGCANCC CCTCACCACC 300 NATTAGGAAT AGTGGTNTTA CCCNCCNCCG TTGGCNCACT CCCCNTGGAA ACCACTTNTC 360 GCGGCTCCGG CATCTGGTCT TAAACCTTGC AAACNCTGGG GCCCTCTTTT TGGTTANTNT 420 NCCNGCCACA ATCATNACTC AGACTGGCNC GGGCTGGCCC CAAAAAANCN CCCCAAAACC 480 GGNCCATGTC TTNNCGGGGT TGCTGCNATN TNCATCACCT CCCGGGCNCA NCAGGNCAAC 540 CCAAAAGTTC TTGNGGCCCN CAAAAAANCT CCGGGGGGNC CCAGTTTCAA CAAAGTCATC 600 CCCCTTGGCC CCCAAATCCT CCCCCCGNTT NCTGGGTTTG GGAACCCACG CCTCTNNCTT 660 TGGNNGGCAA GNTGGNTCCC CCTTCGGGCC CCCGGTGGGC CCNNCTCTAA NGAAAACNCC 720 NTCCTNNNCA CCATCCCCCC NNGNNACGNC TANCAANGNA TCCCTTTTTT TANAAACGGG 780 CCCCCCNCG 789 793 base pairs nucleic acid single linear cDNA not provided 33 GACAGAACAT GTTGGATGGT GGAGCACCTT TCTATACGAC TTACAGGACA GCAGATGGGG 60 AATTCATGGC TGTTGGAGCA ATANAACCCC AGTTCTACGA GCTGCTGATC AAAGGACTTG 120 GACTAAAGTC TGATGAACTT CCCAATCAGA TGAGCATGGA TGATTGGCCA GAAATGAANA 180 AGAAGTTTGC AGATGTATTT GCAAAGAAGA CGAAGGCAGA GTGGTGTCAA ATCTTTGACG 240 GCACAGATGC CTGTGTGACT CCGGTTCTGA CTTTTGAGGA GGTTGTTCAT CATGATCACA 300 ACAANGAACG GGGCTCGTTT ATCACCANTG AGGAGCAGGA CGTGAGCCCC CGCCCTGCAC 360 CTCTGCTGTT AAACACCCCA GCCATCCCTT CTTTCAAAAG GGATCCACTA CTTCTAGAGC 420 GGNCGCCACC GCGGTGGAGC TCCAGCTTTT GTTCCCTTTA GTGAGGGTTA ATTGCGCGCT 480 TGGCGTAATC ATGGTCATAN CTGTTTCCTG TGTGAAATTG TTATCCGCTC ACAATTCCAC 540 ACAACATACG ANCCGGAAGC ATNAAATTTT AAAGCCTGGN GGTNGCCTAA TGANTGAACT 600 NACTCACATT AATTGGCTTT GCGCTCACTG CCCGCTTTCC AGTCCGGAAA ACCTGTCCTT 660 GCCAGCTGCC NTTAATGAAT CNGGCCACCC CCCGGGGAAA AGGCNGTTTG CTTNTTGGGG 720 CGCNCTTCCC GCTTTCTCGC TTCCTGAANT CCTTCCCCCC GGTCTTTCGG CTTGCGGCNA 780 ACGGTATCNA CCT 793 756 base pairs nucleic acid single linear cDNA not provided 34 GCCGCGACCG GCATGTACGA GCAACTCAAG GGCGAGTGGA ACCGTAAAAG CCCCAATCTT 60 ANCAAGTGCG GGGAANAGCT GGGTCGACTC AAGCTAGTTC TTCTGGAGCT CAACTTCTTG 120 CCAACCACAG GGACCAAGCT GACCAAACAG CAGCTAATTC TGGCCCGTGA CATACTGGAG 180 ATCGGGGCCC AATGGAGCAT CCTACGCAAN GACATCCCCT CCTTCGAGCG CTACATGGCC 240 CAGCTCAAAT GCTACTACTT TGATTACAAN GAGCAGCTCC CCGAGTCAGC CTATATGCAC 300 CAGCTCTTGG GCCTCAACCT CCTCTTCCTG CTGTCCCAGA ACCGGGTGGC TGANTNCCAC 360 ACGGANTTGG ANCGGCTGCC TGCCCAANGA CATACANACC AATGTCTACA TCNACCACCA 420 GTGTCCTGGA GCAATACTGA TGGANGGCAG CTACCNCAAA GTNTTCCTGG CCNAGGGTAA 480 CATCCCCCGC CGAGAGCTAC ACCTTCTTCA TTGACATCCT GCTCGACACT ATCAGGGATG 540 AAAATCGCNG GGTTGCTCCA GAAAGGCTNC AANAANATCC TTTTCNCTGA AGGCCCCCGG 600 ATNCNCTAGT NCTAGAATCG GCCCGCCATC GCGGTGGANC CTCCAACCTT TCGTTNCCCT 660 TTACTGAGGG TTNATTGCCG CCCTTGGCGT TATCATGGTC ACNCCNGTTN CCTGTGTTGA 720 AATTNTTAAC CCCCCACAAT TCCACGCCNA CATTNG 756 834 base pairs nucleic acid single linear cDNA not provided 35 GGGGATCTCT ANATCNACCT GNATGCATGG TTGTCGGTGT GGTCGCTGTC GATGAANATG 60 AACAGGATCT TGCCCTTGAA GCTCTCGGCT GCTGTNTTTA AGTTGCTCAG TCTGCCGTCA 120 TAGTCAGACA CNCTCTTGGG CAAAAAACAN CAGGATNTGA GTCTTGATTT CACCTCCAAT 180 AATCTTCNGG GCTGTCTGCT CGGTGAACTC GATGACNANG GGCAGCTGGT TGTGTNTGAT 240 AAANTCCANC ANGTTCTCCT TGGTGACCTC CCCTTCAAAG TTGTTCCGGC CTTCATCAAA 300 CTTCTNNAAN ANGANNANCC CANCTTTGTC GAGCTGGNAT TTGGANAACA CGTCACTGTT 360 GGAAACTGAT CCCAAATGGT ATGTCATCCA TCGCCTCTGC TGCCTGCAAA AAACTTGCTT 420 GGCNCAAATC CGACTCCCCN TCCTTGAAAG AAGCCNATCA CACCCCCCTC CCTGGACTCC 480 NNCAANGACT CTNCCGCTNC CCCNTCCNNG CAGGGTTGGT GGCANNCCGG GCCCNTGCGC 540 TTCTTCAGCC AGTTCACNAT NTTCATCAGC CCCTCTGCCA GCTGTTNTAT TCCTTGGGGG 600 GGAANCCGTC TCTCCCTTCC TGAANNAACT TTGACCGTNG GAATAGCCGC GCNTCNCCNT 660 ACNTNCTGGG CCGGGTTCAA ANTCCCTCCN TTGNCNNTCN CCTCGGGCCA TTCTGGATTT 720 NCCNAACTTT TTCCTTCCCC CNCCCCNCGG NGTTTGGNTT TTTCATNGGG CCCCAACTCT 780 GCTNTTGGCC ANTCCCCTGG GGGCNTNTAN CNCCCCCTNT GGTCCCNTNG GGCC 834 814 base pairs nucleic acid single linear cDNA not provided 36 CGGNCGCTTT CCNGCCGCGC CCCGTTTCCA TGACNAAGGC TCCCTTCANG TTAAATACNN 60 CCTAGNAAAC ATTAATGGGT TGCTCTACTA ATACATCATA CNAACCAGTA AGCCTGCCCA 120 NAACGCCAAC TCAGGCCATT CCTACCAAAG GAAGAAAGGC TGGTCTCTCC ACCCCCTGTA 180 GGAAAGGCCT GCCTTGTAAG ACACCACAAT NCGGCTGAAT CTNAAGTCTT GTGTTTTACT 240 AATGGAAAAA AAAAATAAAC AANAGGTTTT GTTCTCATGG CTGCCCACCG CAGCCTGGCA 300 CTAAAACANC CCAGCGCTCA CTTCTGCTTG GANAAATATT CTTTGCTCTT TTGGACATCA 360 GGCTTGATGG TATCACTGCC ACNTTTCCAC CCAGCTGGGC NCCCTTCCCC CATNTTTGTC 420 ANTGANCTGG AAGGCCTGAA NCTTAGTCTC CAAAAGTCTC NGCCCACAAG ACCGGCCACC 480 AGGGGANGTC NTTTNCAGTG GATCTGCCAA ANANTACCCN TATCATCNNT GAATAAAAAG 540 GCCCCTGAAC GANATGCTTC CANCANCCTT TAAGACCCAT AATCCTNGAA CCATGGTGCC 600 CTTCCGGTCT GATCCNAAAG GAATGTTCCT GGGTCCCANT CCCTCCTTTG TTNCTTACGT 660 TGTNTTGGAC CCNTGCTNGN ATNACCCAAN TGANATCCCC NGAAGCACCC TNCCCCTGGC 720 ATTTGANTTT CNTAAATTCT CTGCCCTACN NCTGAAAGCA CNATTCCCTN GGCNCCNAAN 780 GGNGAACTCA AGAAGGTCTN NGAAAAACCA CNCN 814 760 base pairs nucleic acid single linear cDNA not provided 37 GCATGCTGCT CTTCCTCAAA GTTGTTCTTG TTGCCATAAC AACCACCATA GGTAAAGCGG 60 GCGCAGTGTT CGCTGAAGGG GTTGTAGTAC CAGCGCGGGA TGCTCTCCTT GCAGAGTCCT 120 GTGTCTGGCA GGTCCACGCA ATGCCCTTTG TCACTGGGGA AATGGATGCG CTGGAGCTCG 180 TCNAANCCAC TCGTGTATTT TTCACANGCA GCCTCCTCCG AAGCNTCCGG GCAGTTGGGG 240 GTGTCGTCAC ACTCCACTAA ACTGTCGATN CANCAGCCCA TTGCTGCAGC GGAACTGGGT 300 GGGCTGACAG GTGCCAGAAC ACACTGGATN GGCCTTTCCA TGGAAGGGCC TGGGGGAAAT 360 CNCCTNANCC CAAACTGCCT CTCAAAGGCC ACCTTGCACA CCCCGACAGG CTAGAAATGC 420 ACTCTTCTTC CCAAAGGTAG TTGTTCTTGT TGCCCAAGCA NCCTCCANCA AACCAAAANC 480 TTGCAAAATC TGCTCCGTGG GGGTCATNNN TACCANGGTT GGGGAAANAA ACCCGGCNGN 540 GANCCNCCTT GTTTGAATGC NAAGGNAATA ATCCTCCTGT CTTGCTTGGG TGGAANAGCA 600 CAATTGAACT GTTAACNTTG GGCCGNGTTC CNCTNGGGTG GTCTGAAACT AATCACCGTC 660 ACTGGAAAAA GGTANGTGCC TTCCTTGAAT TCCCAAANTT CCCCTNGNTT TGGGTNNTTT 720 CTCCTCTNCC CTAAAAATCG TNTTCCCCCC CCNTANGGCG 760 724 base pairs nucleic acid single linear cDNA not provided 38 TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTAAAAA CCCCCTCCAT TGAATGAAAA 60 CTTCCNAAAT TGTCCAACCC CCTCNNCCAA ATNNCCATTT CCGGGGGGGG GTTCCAAACC 120 CAAATTAATT TTGGANTTTA AATTAAATNT TNATTNGGGG AANAANCCAA ATGTNAAGAA 180 AATTTAACCC ATTATNAACT TAAATNCCTN GAAACCCNTG GNTTCCAAAA ATTTTTAACC 240 CTTAAATCCC TCCGAAATTG NTAANGGAAA ACCAAATTCN CCTAAGGCTN TTTGAAGGTT 300 NGATTTAAAC CCCCTTNANT TNTTTTNACC CNNGNCTNAA NTATTTNGNT TCCGGTGTTT 360 TCCTNTTAAN CNTNGGTAAC TCCCGNTAAT GAANNNCCCT AANCCAATTA AACCGAATTT 420 TTTTTGAATT GGAAATTCCN NGGGAATTNA CCGGGGTTTT TCCCNTTTGG GGGCCATNCC 480 CCCNCTTTCG GGGTTTGGGN NTAGGTTGAA TTTTTNNANG NCCCAAAAAA NCCCCCAANA 540 AAAAAACTCC CAAGNNTTAA TTNGAATNTC CCCCTTCCCA GGCCTTTTGG GAAAGGNGGG 600 TTTNTGGGGG CCNGGGANTT CNTTCCCCCN TTNCCNCCCC CCCCCCNGGT AAANGGTTAT 660 NGNNTTTGGT TTTTGGGCCC CTTNANGGAC CTTCCGGATN GAAATTAAAT CCCCGGGNCG 720 GCCG 724 751 base pairs nucleic acid single linear cDNA not provided 39 TTTTTTTTTT TTTTTCTTTG CTCACATTTA ATTTTTATTT TGATTTTTTT TAATGCTGCA 60 CAACACAATA TTTATTTCAT TTGTTTCTTT TATTTCATTT TATTTGTTTG CTGCTGCTGT 120 TTTATTTATT TTTACTGAAA GTGAGAGGGA ACTTTTGTGG CCTTTTTTCC TTTTTCTGTA 180 GGCCGCCTTA AGCTTTCTAA ATTTGGAACA TCTAAGCAAG CTGAANGGAA AAGGGGGTTT 240 CGCAAAATCA CTCGGGGGAA NGGAAAGGTT GCTTTGTTAA TCATGCCCTA TGGTGGGTGA 300 TTAACTGCTT GTACAATTAC NTTTCACTTT TAATTAATTG TGCTNAANGC TTTAATTANA 360 CTTGGGGGTT CCCTCCCCAN ACCAACCCCN CTGACAAAAA GTGCCNGCCC TCAAATNATG 420 TCCCGGCNNT CNTTGAAACA CACNGCNGAA NGTTCTCATT NTCCCCNCNC CAGGTNAAAA 480 TGAAGGGTTA CCATNTTTAA CNCCACCTCC ACNTGGCNNN GCCTGAATCC TCNAAAANCN 540 CCCTCAANCN AATTNCTNNG CCCCGGTCNC GCNTNNGTCC CNCCCGGGCT CCGGGAANTN 600 CACCCCCNGA ANNCNNTNNC NAACNAAATT CCGAAAATAT TCCCNNTCNC TCAATTCCCC 660 CNNAGACTNT CCTCNNCNAN CNCAATTTTC TTTTNNTCAC GAACNCGNNC CNNAAAATGN 720 NNNNCNCCTC CNCTNGTCCN NAATCNCCAN C 751 753 base pairs nucleic acid single linear cDNA not provided 40 GTGGTATTTT CTGTAAGATC AGGTGTTCCT CCCTCGTAGG TTTAGAGGAA ACACCCTCAT 60 AGATGAAAAC CCCCCCGAGA CAGCAGCACT GCAACTGCCA AGCAGCCGGG GTAGGAGGGG 120 CGCCCTATGC ACAGCTGGGC CCTTGAGACA GCAGGGCTTC GATGTCAGGC TCGATGTCAA 180 TGGTCTGGAA GCGGCGGCTG TACCTGCGTA GGGGCACACC GTCAGGGCCC ACCAGGAACT 240 TCTCAAAGTT CCAGGCAACN TCGTTGCGAC ACACCGGAGA CCAGGTGATN AGCTTGGGGT 300 CGGTCATAAN CGCGGTGGCG TCGTCGCTGG GAGCTGGCAG GGCCTCCCGC AGGAAGGCNA 360 ATAAAAGGTG CGCCCCCGCA CCGTTCANCT CGCACTTCTC NAANACCATG ANGTTGGGCT 420 CNAACCCACC ACCANNCCGG ACTTCCTTGA NGGAATTCCC AAATCTCTTC GNTCTTGGGC 480 TTCTNCTGAT GCCCTANCTG GTTGCCCNGN ATGCCAANCA NCCCCAANCC CCGGGGTCCT 540 AAANCACCCN CCTCCTCNTT TCATCTGGGT TNTTNTCCCC GGACCNTGGT TCCTCTCAAG 600 GGANCCCATA TCTCNACCAN TACTCACCNT NCCCCCCCNT GNNACCCANC CTTCTANNGN 660 TTCCCNCCCG NCCTCTGGCC CNTCAAANAN GCTTNCACNA CCTGGGTCTG CCTTCCCCCC 720 TNCCCTATCT GNACCCCNCN TTTGTCTCAN TNT 753 341 base pairs nucleic acid single linear cDNA Homo sapiens 41 ACTATATCCA TCACAACAGA CATGCTTCAT CCCATAGACT TCTTGACATA GCTTCAAATG 60 AGTGAACCCA TCCTTGATTT ATATACATAT ATGTTCTCAG TATTTTGGGA GCCTTTCCAC 120 TTCTTTAAAC CTTGTTCATT ATGAACACTG AAAATAGGAA TTTGTGAAGA GTTAAAAAGT 180 TATAGCTTGT TTACGTAGTA AGTTTTTGAA GTCTACATTC AATCCAGACA CTTAGTTGAG 240 TGTTAAACTG TGATTTTTAA AAAATATCAT TTGAGAATAT TCTTTCAGAG GTATTTTCAT 300 TTTTACTTTT TGATTAATTG TGTTTTATAT ATTAGGGTAG T 341 101 base pairs nucleic acid single linear cDNA Homo sapiens 42 ACTTACTGAA TTTAGTTCTG TGCTCTTCCT TATTTAGTGT TGTATCATAA ATACTTTGAT 60 GTTTCAAACA TTCTAAATAA ATAATTTTCA GTGGCTTCAT A 101 305 base pairs nucleic acid single linear cDNA Homo spiens 43 ACATCTTTGT TACAGTCTAA GATGTGTTCT TAAATCACCA TTCCTTCCTG GTCCTCACCC 60 TCCAGGGTGG TCTCACACTG TAATTAGAGC TATTGAGGAG TCTTTACAGC AAATTAAGAT 120 TCAGATGCCT TGCTAAGTCT AGAGTTCTAG AGTTATGTTT CAGAAAGTCT AAGAAACCCA 180 CCTCTTGAGA GGTCAGTAAA GAGGACTTAA TATTTCATAT CTACAAAATG ACCACAGGAT 240 TGGATACAGA ACGAGAGTTA TCCTGGATAA CTCAGAGCTG AGTACCTGCC CGGGGGCCGC 300 TCGAA 305 852 base pairs nucleic acid single linear cDNA Homo sapiens 44 ACATAAATAT CAGAGAAAAG TAGTCTTTGA AATATTTACG TCCAGGAGTT CTTTGTTTCT 60 GATTATTTGG TGTGTGTTTT GGTTTGTGTC CAAAGTATTG GCAGCTTCAG TTTTCATTTT 120 CTCTCCATCC TCGGGCATTC TTCCCAAATT TATATACCAG TCTTCGTCCA TCCACACGCT 180 CCAGAATTTC TCTTTTGTAG TAATATCTCA TAGCTCGGCT GAGCTTTTCA TAGGTCATGC 240 TGCTGTTGTT CTTCTTTTTA CCCCATAGCT GAGCCACTGC CTCTGATTTC AAGAACCTGA 300 AGACGCCCTC AGATCGGTCT TCCCATTTTA TTAATCCTGG GTTCTTGTCT GGGTTCAAGA 360 GGATGTCGCG GATGAATTCC CATAAGTGAG TCCCTCTCGG GTTGTGCTTT TTGGTGTGGC 420 ACTTGGCAGG GGGGTCTTGC TCCTTTTTCA TATCAGGTGA CTCTGCAACA GGAAGGTGAC 480 TGGTGGTTGT CATGGAGATC TGAGCCCGGC AGAAAGTTTT GCTGTCCAAC AAATCTACTG 540 TGCTACCATA GTTGGTGTCA TATAAATAGT TCTNGTCTTT CCAGGTGTTC ATGATGGAAG 600 GCTCAGTTTG TTCAGTCTTG ACAATGACAT TGTGTGTGGA CTGGAACAGG TCACTACTGC 660 ACTGGCCGTT CCACTTCAGA TGCTGCAAGT TGCTGTAGAG GAGNTGCCCC GCCGTCCCTG 720 CCGCCCGGGT GAACTCCTGC AAACTCATGC TGCAAAGGTG CTCGCCGTTG ATGTCGAACT 780 CNTGGAAAGG GATACAATTG GCATCCAGCT GGTTGGTGTC CAGGAGGTGA TGGAGCCACT 840 CCCACACCTG GT 852 234 base pairs nucleic acid single linear cDNA Homo sapiens 45 ACAACAGACC CTTGCTCGCT AACGACCTCA TGCTCATCAA GTTGGACGAA TCCGTGTCCG 60 AGTCTGACAC CATCCGGAGC ATCAGCATTG CTTCGCAGTG CCCTACCGCG GGGAACTCTT 120 GCCTCGTTTC TGGCTGGGGT CTGCTGGCGA ACGGCAGAAT GCCTACCGTG CTGCAGTGCG 180 TGAACGTGTC GGTGGTGTCT GAGGAGGTCT GCAGTAAGCT CTATGACCCG CTGT 234 590 base pairs nucleic acid single linear cDNA Homo sapiens 46 ACTTTTTATT TAAATGTTTA TAAGGCAGAT CTATGAGAAT GATAGAAAAC ATGGTGTGTA 60 ATTTGATAGC AATATTTTGG AGATTACAGA GTTTTAGTAA TTACCAATTA CACAGTTAAA 120 AAGAAGATAA TATATTCCAA GCANATACAA AATATCTAAT GAAAGATCAA GGCAGGAAAA 180 TGANTATAAC TAATTGACAA TGGAAAATCA ATTTTAATGT GAATTGCACA TTATCCTTTA 240 AAAGCTTTCA AAANAAANAA TTATTGCAGT CTANTTAATT CAAACAGTGT TAAATGGTAT 300 CAGGATAAAN AACTGAAGGG CANAAAGAAT TAATTTTCAC TTCATGTAAC NCACCCANAT 360 TTACAATGGC TTAAATGCAN GGAAAAAGCA GTGGAAGTAG GGAAGTANTC AAGGTCTTTC 420 TGGTCTCTAA TCTGCCTTAC TCTTTGGGTG TGGCTTTGAT CCTCTGGAGA CAGCTGCCAG 480 GGCTCCTGTT ATATCCACAA TCCCAGCAGC AAGATGAAGG GATGAAAAAG GACACATGCT 540 GCCTTCCTTT GAGGAGACTT CATCTCACTG GCCAACACTC AGTCACATGT 590 774 base pairs nucleic acid single linear cDNA Homo sapiens 47 ACAAGGGGGC ATAATGAAGG AGTGGGGANA GATTTTAAAG AAGGAAAAAA AACGAGGCCC 60 TGAACAGAAT TTTCCTGNAC AACGGGGCTT CAAAATAATT TTCTTGGGGA GGTTCAAGAC 120 GCTTCACTGC TTGAAACTTA AATGGATGTG GGACANAATT TTCTGTAATG ACCCTGAGGG 180 CATTACAGAC GGGACTCTGG GAGGAAGGAT AAACAGAAAG GGGACAAAGG CTAATCCCAA 240 AACATCAAAG AAAGGAAGGT GGCGTCATAC CTCCCAGCCT ACACAGTTCT CCAGGGCTCT 300 CCTCATCCCT GGAGGACGAC AGTGGAGGAA CAACTGACCA TGTCCCCAGG CTCCTGTGTG 360 CTGGCTCCTG GTCTTCAGCC CCCAGCTCTG GAAGCCCACC CTCTGCTGAT CCTGCGTGGC 420 CCACACTCCT TGAACACACA TCCCCAGGTT ATATTCCTGG ACATGGCTGA ACCTCCTATT 480 CCTACTTCCG AGATGCCTTG CTCCCTGCAG CCTGTCAAAA TCCCACTCAC CCTCCAAACC 540 ACGGCATGGG AAGCCTTTCT GACTTGCCTG ATTACTCCAG CATCTTGGAA CAATCCCTGA 600 TTCCCCACTC CTTAGAGGCA AGATAGGGTG GTTAAGAGTA GGGCTGGACC ACTTGGAGCC 660 AGGCTGCTGG CTTCAAATTN TGGCTCATTT ACGAGCTATG GGACCTTGGG CAAGTNATCT 720 TCACTTCTAT GGGCNTCATT TTGTTCTACC TGCAAAATGG GGGATAATAA TAGT 774 124 base pairs nucleic acid single linear cDNA Homo sapiens 48 CANAAATTGA AATTTTATAA AAAGGCATTT TTCTCTTATA TCCATAAAAT GATATAATTT 60 TTGCAANTAT ANAAATGTGT CATAAATTAT AATGTTCCTT AATTACAGCT CAACGCAACT 120 TGGT 124 147 base pairs nucleic acid single linear cDNA Homo sapiens 49 GCCGATGCTA CTATTTTATT GCAGGAGGTG GGGGTGTTTT TATTATTCTC TCAACAGCTT 60 TGTGGCTACA GGTGGTGTCT GACTGCATNA AAAANTTTTT TACGGGTGAT TGCAAAAATT 120 TTAGGGCACC CATATCCCAA GCANTGT 147 107 base pairs nucleic acid single linear cDNA Homo sapiens 50 ACATTAAATT AATAAAAGGA CTGTTGGGGT TCTGCTAAAA CACATGGCTT GATATATTGC 60 ATGGTTTGAG GTTAGGAGGA GTTAGGCATA TGTTTTGGGA GAGGGGT 107 204 base pairs nucleic acid single linear cDNA Homo sapiens 51 GTCCTAGGAA GTCTAGGGGA CACACGACTC TGGGGTCACG GGGCCGACAC ACTTGCACGG 60 CGGGAAGGAA AGGCAGAGAA GTGACACCGT CAGGGGGAAA TGACAGAAAG GAAAATCAAG 120 GCCTTGCAAG GTCAGAAAGG GGACTCAGGG CTTCCACCAC AGCCCTGCCC CACTTGGCCA 180 CCTCCCTTTT GGGACCAGCA ATGT 204 491 base pairs nucleic acid single linear cDNA Homo sapiens 52 ACAAAGATAA CATTTATCTT ATAACAAAAA TTTGATAGTT TTAAAGGTTA GTATTGTGTA 60 GGGTATTTTC CAAAAGACTA AAGAGATAAC TCAGGTAAAA AGTTAGAAAT GTATAAAACA 120 CCATCAGACA GGTTTTTAAA AAACAACATA TTACAAAATT AGACAATCAT CCTTAAAAAA 180 AAAACTTCTT GTATCAATTT CTTTTGTTCA AAATGACTGA CTTAANTATT TTTAAATATT 240 TCANAAACAC TTCCTCAAAA ATTTTCAANA TGGTAGCTTT CANATGTNCC CTCAGTCCCA 300 ATGTTGCTCA GATAAATAAA TCTCGTGAGA ACTTACCACC CACCACAAGC TTTCTGGGGC 360 ATGCAACAGT GTCTTTTCTT TNCTTTTTCT TTTTTTTTTT TTACAGGCAC AGAAACTCAT 420 CAATTTTATT TGGATAACAA AGGGTCTCCA AATTATATTG AAAAATAAAT CCAAGTTAAT 480 ATCACTCTTG T 491 484 base pairs nucleic acid single linear cDNA Homo sapiens 53 ACATAATTTA GCAGGGCTAA TTACCATAAG ATGCTATTTA TTAANAGGTN TATGATCTGA 60 GTATTAACAG TTGCTGAAGT TTGGTATTTT TATGCAGCAT TTTCTTTTTG CTTTGATAAC 120 ACTACAGAAC CCTTAAGGAC ACTGAAAATT AGTAAGTAAA GTTCAGAAAC ATTAGCTGCT 180 CAATCAAATC TCTACATAAC ACTATAGTAA TTAAAACGTT AAAAAAAAGT GTTGAAATCT 240 GCACTAGTAT ANACCGCTCC TGTCAGGATA ANACTGCTTT GGAACAGAAA GGGAAAAANC 300 AGCTTTGANT TTCTTTGTGC TGATANGAGG AAAGGCTGAA TTACCTTGTT GCCTCTCCCT 360 AATGATTGGC AGGTCNGGTA AATNCCAAAA CATATTCCAA CTCAACACTT CTTTTCCNCG 420 TANCTTGANT CTGTGTATTC CAGGANCAGG CGGATGGAAT GGGCCAGCCC NCGGATGTTC 480 CANT 484 151 base pairs nucleic acid single linear cDNA Homo sapiens 54 ACTAAACCTC GTGCTTGTGA ACTCCATACA GAAAACGGTG CCATCCCTGA ACACGGCTGG 60 CCACTGGGTA TACTGCTGAC AACCGCAACA ACAAAAACAC AAATCCTTGG CACTGGCTAG 120 TCTATGTCCT CTCAAGTGCC TTTTTGTTTG T 151 91 base pairs nucleic acid single linear cDNA Homo sapiens 55 ACCTGGCTTG TCTCCGGGTG GTTCCCGGCG CCCCCCACGG TCCCCAGAAC GGACACTTTC 60 GCCCTCCAGT GGATACTCGA GCCAAAGTGG T 91 133 base pairs nucleic acid single linear cDNA Homo sapiens 56 GGCGGATGTG CGTTGGTTAT ATACAAATAT GTCATTTTAT GTAAGGGACT TGAGTATACT 60 TGGATTTTTG GTATCTGTGG GTTGGGGGGA CGGTCCAGGA ACCAATACCC CATGGATACC 120 AAGGGACAAC TGT 133 147 base pairs nucleic acid single linear cDNA Homo sapiens 57 ACTCTGGAGA ACCTGAGCCG CTGCTCCGCC TCTGGGATGA GGTGATGCAN GCNGTGGCGC 60 GACTGGGAGC TGAGCCCTTC CCTTTGCGCC TGCCTCAGAG GATTGTTGCC GACNTGCANA 120 TCTCANTGGG CTGGATNCAT GCAGGGT 147 198 base pairs nucleic acid single linear cDNA Homo sapiens 58 ACAGGGATAT AGGTTTNAAG TTATTGTNAT TGTAAAATAC ATTGAATTTT CTGTATACTC 60 TGATTACATA CATTTATCCT TTAAAAAAGA TGTAAATCTT AATTTTTATG CCATCTATTA 120 ATTTACCAAT GAGTTACCTT GTAAATGAGA AGTCATGATA GCACTGAATT TTAACTAGTT 180 TTGACTTCTA AGTTTGGT 198 330 base pairs nucleic acid single linear cDNA Homo sapiens 59 ACAACAAATG GGTTGTGAGG AAGTCTTATC AGCAAAACTG GTGATGGCTA CTGAAAAGAT 60 CCATTGAAAA TTATCATTAA TGATTTTAAA TGACAAGTTA TCAAAAACTC ACTCAATTTT 120 CACCTGTGCT AGCTTGCTAA AATGGGAGTT AACTCTAGAG CAAATATAGT ATCTTCTGAA 180 TACAGTCAAT AAATGACAAA GCCAGGGCCT ACAGGTGGTT TCCAGACTTT CCAGACCCAG 240 CAGAAGGAAT CTATTTTATC ACATGGATCT CCGTCTGTGC TCAAAATACC TAATGATATT 300 TTTCGTCTTT ATTGGACTTC TTTGAAGAGT 330 175 base pairs nucleic acid single linear cDNA Homo sapiens 60 ACCGTGGGTG CCTTCTACAT TCCTGACGGC TCCTTCACCA ACATCTGGTT CTACTTCGGC 60 GTCGTGGGCT CCTTCCTCTT CATCCTCATC CAGCTGGTGC TGCTCATCGA CTTTGCGCAC 120 TCCTGGAACC AGCGGTGGCT GGGCAAGGCC GAGGAGTGCG ATTCCCGTGC CTGGT 175 154 base pairs nucleic acid single linear cDNA Homo sapiens 61 ACCCCACTTT TCCTCCTGTG AGCAGTCTGG ACTTCTCACT GCTACATGAT GAGGGTGAGT 60 GGTTGTTGCT CTTCAACAGT ATCCTCCCCT TTCCGGATCT GCTGAGCCGG ACAGCAGTGC 120 TGGACTGCAC AGCCCCGGGG CTCCACATTG CTGT 154 30 base pairs nucleic acid single linear cDNA Homo sapiens 62 CGCTCGAGCC CTATAGTGAG TCGTATTAGA 30 89 base pairs nucleic acid single linear cDNA Homo sapiens 63 ACAAGTCATT TCAGCACCCT TTGCTCTTCA AAACTGACCA TCTTTTATAT TTAATGCTTC 60 CTGTATGAAT AAAAATGGTT ATGTCAAGT 89 97 base pairs nucleic acid single linear cDNA Homo sapiens 64 ACCGGAGTAA CTGAGTCGGG ACGCTGAATC TGAATCCACC AATAAATAAA GGTTCTGCAG 60 AATCAGTGCA TCCAGGATTG GTCCTTGGAT CTGGGGT 97 377 base pairs nucleic acid single linear cDNA Homo sapiens 65 ACAACAANAA NTCCCTTCTT TAGGCCACTG ATGGAAACCT GGAACCCCCT TTTGATGGCA 60 GCATGGCGTC CTAGGCCTTG ACACAGCGGC TGGGGTTTGG GCTNTCCCAA ACCGCACACC 120 CCAACCCTGG TCTACCCACA NTTCTGGCTA TGGGCTGTCT CTGCCACTGA ACATCAGGGT 180 TCGGTCATAA NATGAAATCC CAANGGGGAC AGAGGTCAGT AGAGGAAGCT CAATGAGAAA 240 GGTGCTGTTT GCTCAGCCAG AAAACAGCTG CCTGGCATTC GCCGCTGAAC TATGAACCCG 300 TGGGGGTGAA CTACCCCCAN GAGGAATCAT GCCTGGGCGA TGCAANGGTG CCAACAGGAG 360 GGGCGGGAGG AGCATGT 377 305 base pairs nucleic acid single linear cDNA Homo sapiens 66 ACGCCTTTCC CTCAGAATTC AGGGAAGAGA CTGTCGCCTG CCTTCCTCCG TTGTTGCGTG 60 AGAACCCGTG TGCCCCTTCC CACCATATCC ACCCTCGCTC CATCTTTGAA CTCAAACACG 120 AGGAACTAAC TGCACCCTGG TCCTCTCCCC AGTCCCCAGT TCACCCTCCA TCCCTCACCT 180 TCCTCCACTC TAAGGGATAT CAACACTGCC CAGCACAGGG GCCCTGAATT TATGTGGTTT 240 TTATATATTT TTTAATAAGA TGCACTTTAT GTCATTTTTT AATAAAGTCT GAAGAATTAC 300 TGTTT 305 385 base pairs nucleic acid single linear cDNA Homo sapiens 67 ACTACACACA CTCCACTTGC CCTTGTGAGA CACTTTGTCC CAGCACTTTA GGAATGCTGA 60 GGTCGGACCA GCCACATCTC ATGTGCAAGA TTGCCCAGCA GACATCAGGT CTGAGAGTTC 120 CCCTTTTAAA AAAGGGGACT TGCTTAAAAA AGAAGTCTAG CCACGATTGT GTAGAGCAGC 180 TGTGCTGTGC TGGAGATTCA CTTTTGAGAG AGTTCTCCTC TGAGACCTGA TCTTTAGAGG 240 CTGGGCAGTC TTGCACATGA GATGGGGCTG GTCTGATCTC AGCACTCCTT AGTCTGCTTG 300 CCTCTCCCAG GGCCCCAGCC TGGCCACACC TGCTTACAGG GCACTCTCAG ATGCCCATAC 360 CATAGTTTCT GTGCTAGTGG ACCGT 385 73 base pairs nucleic acid single linear cDNA Homo sapiens 68 ACTTAACCAG ATATATTTTT ACCCCAGATG GGGATATTCT TTGTAAAAAA TGAAAATAAA 60 GTTTTTTTAA TGG 73 536 base pairs nucleic acid single linear cDNA Homo sapiens 69 ACTAGTCCAG TGTGGTGGAA TTCCATTGTG TTGGGGGCTC TCACCCTCCT CTCCTGCAGC 60 TCCAGCTTTG TGCTCTGCCT CTGAGGAGAC CATGGCCCAG CATCTGAGTA CCCTGCTGCT 120 CCTGCTGGCC ACCCTAGCTG TGGCCCTGGC CTGGAGCCCC AAGGAGGAGG ATAGGATAAT 180 CCCGGGTGGC ATCTATAACG CAGACCTCAA TGATGAGTGG GTACAGCGTG CCCTTCACTT 240 CGCCATCAGC GAGTATAACA AGGCCACCAA AGATGACTAC TACAGACGTC CGCTGCGGGT 300 ACTAAGAGCC AGGCAACAGA CCGTTGGGGG GGTGAATTAC TTCTTCGACG TAGAGGTGGG 360 CCGAACCATA TGTACCAAGT CCCAGCCCAA CTTGGACACC TGTGCCTTCC ATGAACAGCC 420 AGAACTGCAG AAGAAACAGT TGTGCTCTTT CGAGATCTAC GAAGTTCCCT GGGGAGAACA 480 GAANGTCCCT GGGTGAAATC CAGGTGTCAA GAAATCCTAN GGATCTGTTG CCAGGC 536 477 base pairs nucleic acid single linear cDNA Homo sapiens 70 ATGACCCCTA ACAGGGGCCC TCTCAGCCCT CCTAATGACC TCCGGCCTAG CCATGTGATT 60 TCACTTCCAC TCCATAACGC TCCTCATACT AGGCCTACTA ACCAACACAC TAACCATATA 120 CCAATGATGG CGCGATGTAA CACGAGAAAG CACATACCAA GGCCACCACA CACCACCTGT 180 CCAAAAAGGC CTTCGATACG GGATAATCCT ATTTATTACC TCAGAAGTTT TTTTCTTCGC 240 AGGGATTTTT CTGAGCCTTT TACCACTCCA GCCTAGCCCC TACCCCCCAA CTAGGAGGGC 300 ACTGGCCCCC AACAGGCATC ACCCCGCTAA ATCCCCTAGA AGTCCCACTC CTAAACACAT 360 CCGTATTACT CGCATCAGGA GTATCAATCA CCTGAGCTCA CCATAGTCTA ATAGAAAACA 420 ACCGAAACCA AATTATTCAA AGCACTGCTT ATTACAATTT TACTGGGTCT CTATTTT 477 533 base pairs nucleic acid single linear cDNA Homo sapiens 71 AGAGCTATAG GTACAGTGTG ATCTCAGCTT TGCAAACACA TTTTCTACAT AGATAGTACT 60 AGGTATTAAT AGATATGTAA AGAAAGAAAT CACACCATTA ATAATGGTAA GATTGGTTTA 120 TGTGATTTTA GTGGTATTTT TGGCACCCTT ATATATGTTT TCCAAACTTT CAGCAGTGAT 180 ATTATTTCCA TAACTTAAAA AGTGAGTTTG AAAAAGAAAA TCTCCAGCAA GCATCTCATT 240 TAAATAAAGG TTTGTCATCT TTAAAAATAC AGCAATATGT GACTTTTTAA AAAAGCTGTC 300 AAATAGGTGT GACCCTACTA ATAATTATTA GAAATACATT TAAAAACATC GAGTACCTCA 360 AGTCAGTTTG CCTTGAAAAA TATCAAATAT AACTCTTAGA GAAATGTACA TAAAAGAATG 420 CTTCGTAATT TTGGAGTANG AGGTTCCCTC CTCAATTTTG TATTTTTAAA AAGTACATGG 480 TAAAAAAAAA AATTCACAAC AGTATATAAG GCTGTAAAAT GAAGAATTCT GCC 533 511 base pairs nucleic acid single linear cDNA Homo sapiens 72 TATTACGGAA AAACACACCA CATAATTCAA CTANCAAAGA ANACTGCTTC AGGGCGTGTA 60 AAATGAAAGG CTTCCAGGCA GTTATCTGAT TAAAGAACAC TAAAAGAGGG ACAAGGCTAA 120 AAGCCGCAGG ATGTCTACAC TATANCAGGC GCTATTTGGG TTGGCTGGAG GAGCTGTGGA 180 AAACATGGAN AGATTGGTGC TGGANATCGC CGTGGCTATT CCTCATTGTT ATTACANAGT 240 GAGGTTCTCT GTGTGCCCAC TGGTTTGAAA ACCGTTCTNC AATAATGATA GAATAGTACA 300 CACATGAGAA CTGAAATGGC CCAAACCCAG AAAGAAAGCC CAACTAGATC CTCAGAANAC 360 GCTTCTAGGG ACAATAACCG ATGAAGAAAA GATGGCCTCC TTGTGCCCCC GTCTGTTATG 420 ATTTCTCTCC ATTGCAGCNA NAAACCCGTT CTTCTAAGCA AACNCAGGTG ATGATGGCNA 480 AAATACACCC CCTCTTGAAG NACCNGGAGG A 511 499 base pairs nucleic acid single linear cDNA Homo sapiens 73 CAGTGCCAGC ACTGGTGCCA GTACCAGTAC CAATAACAGT GCCAGTGCCA GTGCCAGCAC 60 CAGTGGTGGC TTCAGTGCTG GTGCCAGCCT GACCGCCACT CTCACATTTG GGCTCTTCGC 120 TGGCCTTGGT GGAGCTGGTG CCAGCACCAG TGGCAGCTCT GGTGCCTGTG GTTTCTCCTA 180 CAAGTGAGAT TTTAGATATT GTTAATCCTG CCAGTCTTTC TCTTCAAGCC AGGGTGCATC 240 CTCAGAAACC TACTCAACAC AGCACTCTAG GCAGCCACTA TCAATCAATT GAAGTTGACA 300 CTCTGCATTA AATCTATTTG CCATTTCTGA AAAAAAAAAA AAAAAAAGGG CGGCCGCTCG 360 ANTCTAGAGG GCCCGTTTAA ACCCGCTGAT CAGCCTCGAC TGTGCCTTCT ANTTGCCAGC 420 CATCTGTTGT TTGCCCCTCC CCCGNTGCCT TCCTTGACCC TGGAAAGTGC CACTCCCACT 480 GTCCTTTCCT AANTAAAAT 499 537 base pairs nucleic acid single linear cDNA Homo sapiens 74 TTTCATAGGA GAACACACTG AGGAGATACT TGAAGAATTT GGATTCAGCC GCGAAGAGAT 60 TTATCAGCTT AACTCAGATA AAATCATTGA AAGTAATAAG GTAAAAGCTA GTCTCTAACT 120 TCCAGGCCCA CGGCTCAAGT GAATTTGAAT ACTGCATTTA CAGTGTAGAG TAACACATAA 180 CATTGTATGC ATGGAAACAT GGAGGAACAG TATTACAGTG TCCTACCACT CTAATCAAGA 240 AAAGAATTAC AGACTCTGAT TCTACAGTGA TGATTGAATT CTAAAAATGG TAATCATTAG 300 GGCTTTTGAT TTATAANACT TTGGGTACTT ATACTAAATT ATGGTAGTTA TACTGCCTTC 360 CAGTTTGCTT GATATATTTG TTGATATTAA GATTCTTGAC TTATATTTTG AATGGGTTCT 420 ACTGAAAAAN GAATGATATA TTCTTGAAGA CATCGATATA CATTTATTTA CACTCTTGAT 480 TCTACAATGT AGAAAATGAA GGAAATGCCC CAAATTGTAT GGTGATAAAA GTCCCGT 537 467 base pairs nucleic acid single linear cDNA Homo sapiens 75 CAAANACAAT TGTTCAAAAG ATGCAAATGA TACACTACTG CTGCAGCTCA CAAACACCTC 60 TGCATATTAC ACGTACCTCC TCCTGCTCCT CAAGTAGTGT GGTCTATTTT GCCATCATCA 120 CCTGCTGTCT GCTTAGAAGA ACGGCTTTCT GCTGCAANGG AGAGAAATCA TAACAGACGG 180 TGGCACAAGG AGGCCATCTT TTCCTCATCG GTTATTGTCC CTAGAAGCGT CTTCTGAGGA 240 TCTAGTTGGG CTTTCTTTCT GGGTTTGGGC CATTTCANTT CTCATGTGTG TACTATTCTA 300 TCATTATTGT ATAACGGTTT TCAAACCNGT GGGCACNCAG AGAACCTCAC TCTGTAATAA 360 CAATGAGGAA TAGCCACGGT GATCTCCAGC ACCAAATCTC TCCATGTTNT TCCAGAGCTC 420 CTCCAGCCAA CCCAAATAGC CGCTGCTATN GTGTAGAACA TCCCTGN 467 400 base pairs nucleic acid single linear cDNA Homo sapiens 76 AAGCTGACAG CATTCGGGCC GAGATGTCTC GCTCCGTGGC CTTAGCTGTG CTCGCGCTAC 60 TCTCTCTTTC TGGCCTGGAG GCTATCCAGC GTACTCCAAA GATTCAGGTT TACTCACGTC 120 ATCCAGCAGA GAATGGAAAG TCAAATTTCC TGAATTGCTA TGTGTCTGGG TTTCATCCAT 180 CCGACATTGA AGTTGACTTA CTGAAGAATG GAGAGAGAAT TGAAAAAGTG GAGCATTCAG 240 ACTTGTCTTT CAGCAAGGAC TGGTCTTTCT ATCTCTTGTA CTACACTGAA TTCACCCCCA 300 CTGAAAAAGA TGAGTATGCC TGCCGTGTGA ACCATGTGAC TTTGTCACAG CCCAAGATNG 360 TTNAGTGGGA TCGANACATG TAAGCAGCAN CATGGGAGGT 400 248 base pairs nucleic acid single linear cDNA Homo Sapiens 77 CTGGAGTGCC TTGGTGTTTC AAGCCCCTGC AGGAAGCAGA ATGCACCTTC TGAGGCACCT 60 CCAGCTGCCC CGGCGGGGGA TGCGAGGCTC GGAGCACCCT TGCCCGGCTG TGATTGCTGC 120 CAGGCACTGT TCATCTCAGC TTTTCTGTCC CTTTGCTCCC GGCAAGCGCT TCTGCTGAAA 180 GTTCATATCT GGAGCCTGAT GTCTTAACGA ATAAAGGTCC CATGCTCCAC CCGAAAAAAA 240 AAAAAAAA 248 201 base pairs nucleic acid single linear cDNA Homo sapiens 78 ACTAGTCCAG TGTGGTGGAA TTCCATTGTG TTGGGCCCAA CACAATGGCT ACCTTTAACA 60 TCACCCAGAC CCCGCCCTGC CCGTGCCCCA CGCTGCTGCT AACGACAGTA TGATGCTTAC 120 TCTGCTACTC GGAAACTATT TTTATGTAAT TAATGTATGC TTTCTTGTTT ATAAATGCCT 180 GATTTAAAAA AAAAAAAAAA A 201 552 base pairs nucleic acid single linear cDNA Homo sapiens 79 TCCTTTTGTT AGGTTTTTGA GACAACCCTA GACCTAAACT GTGTCACAGA CTTCTGAATG 60 TTTAGGCAGT GCTAGTAATT TCCTCGTAAT GATTCTGTTA TTACTTTCCT ATTCTTTATT 120 CCTCTTTCTT CTGAAGATTA ATGAAGTTGA AAATTGAGGT GGATAAATAC AAAAAGGTAG 180 TGTGATAGTA TAAGTATCTA AGTGCAGATG AAAGTGTGTT ATATATATCC ATTCAAAATT 240 ATGCAAGTTA GTAATTACTC AGGGTTAACT AAATTACTTT AATATGCTGT TGAACCTACT 300 CTGTTCCTTG GCTAGAAAAA ATTATAAACA GGACTTTGTT AGTTTGGGAA GCCAAATTGA 360 TAATATTCTA TGTTCTAAAA GTTGGGCTAT ACATAAANTA TNAAGAAATA TGGAATTTTA 420 TTCCCAGGAA TATGGGGTTC ATTTATGAAT ANTACCCGGG ANAGAAGTTT TGANTNAAAC 480 CNGTTTTGGT TAATACGTTA ATATGTCCTN AATNAACAAG GCNTGACTTA TTTCCAAAAA 540 AAAAAAAAAA AA 552 476 base pairs nucleic acid single linear cDNA Homo sapiens 80 ACAGGGATTT GAGATGCTAA GGCCCCAGAG ATCGTTTGAT CCAACCCTCT TATTTTCAGA 60 GGGGAAAATG GGGCCTAGAA GTTACAGAGC ATCTAGCTGG TGCGCTGGCA CCCCTGGCCT 120 CACACAGACT CCCGAGTAGC TGGGACTACA GGCACACAGT CACTGAAGCA GGCCCTGTTT 180 GCAATTCACG TTGCCACCTC CAACTTAAAC ATTCTTCATA TGTGATGTCC TTAGTCACTA 240 AGGTTAAACT TTCCCACCCA GAAAAGGCAA CTTAGATAAA ATCTTAGAGT ACTTTCATAC 300 TCTTCTAAGT CCTCTTCCAG CCTCACTTTG AGTCCTCCTT GGGGGTTGAT AGGAANTNTC 360 TCTTGGCTTT CTCAATAAAA TCTCTATCCA TCTCATGTTT AATTTGGTAC GCNTAAAAAT 420 GCTGAAAAAA TTAAAATGTT CTGGTTTCNC TTTAAAAAAA AAAAAAAAAA AAAAAA 476 232 base pairs nucleic acid single linear cDNA Homo sapiens 81 TTTTTTTTTG TATGCCNTCN CTGTGGNGTT ATTGTTGCTG CCACCCTGGA GGAGCCCAGT 60 TTCTTCTGTA TCTTTCTTTT CTGGGGGATC TTCCTGGCTC TGCCCCTCCA TTCCCAGCCT 120 CTCATCCCCA TCTTGCACTT TTGCTAGGGT TGGAGGCGCT TTCCTGGTAG CCCCTCAGAG 180 ACTCAGTCAG CGGGAATAAG TCCTAGGGGT GGGGGGTGTG GCAAGCCGGC CT 232 383 base pairs nucleic acid single linear cDNA Homo sapiens 82 AGGCGGGAGC AGAAGCTAAA GCCAAAGCCC AAGAAGAGTG GCAGTGCCAG CACTGGTGCC 60 AGTACCAGTA CCAATAACAT GCCAGTGCCA GTGCCAGCAC CAGTGGTGGC TTCAGTGCTG 120 GTGCCAGCCT GACCGCCACT CTCACATTTG GGCTCTTCGC TGGCCTTGGT GGAGCTGGTG 180 CCAGCACCAG TGGCAGCTCT GGTGCCTGTG GTTTCTCCTA CAAGTGAGAT TTTAGATATT 240 GTTAATCCTG CCAGTCTTTC TCTTCAAGCC AGGGTGCATC CTCAGAAACC TACTCAACAC 300 AGCACTCTNG GCAGCCACTA TCAATCAATT GAAGTTGACA CTCTGCATTA AATCTATTTG 360 CCATTTCAAA AAAAAAAAAA AAA 383 494 base pairs nucleic acid single linear cDNA Homo sapiens 83 ACCGAATTGG GACCGCTGGC TTATAAGCGA TCATGTCCTC CAGTATTACC TCAACGAGCA 60 GGGAGATCGA GTCTATACGC TGAAGAAATT TGACCCGATG GGACAACAGA CCTGCTCAGC 120 CCATCCTGCT CGGTTCTCCC CAGATGACAA ATACTCTCGA CACCGAATCA CCATCAAGAA 180 ACGCTTCAAG GTGCTCATGA CCCAGCAACC GCGCCCTGTC CTCTGAGGGT CCTTAAACTG 240 ATGTCTTTTC TGCCACCTGT TACCCCTCGG AGACTCCGTA ACCAAACTCT TCGGACTGTG 300 AGCCCTGATG CCTTTTTGCC AGCCATACTC TTTGGCNTCC AGTCTCTCGT GGCGATTGAT 360 TATGCTTGTG TGAGGCAATC ATGGTGGCAT CACCCATNAA GGGAACACAT TTGANTTTTT 420 TTTCNCATAT TTTAAATTAC NACCAGAATA NTTCAGAATA AATGAATTGA AAAACTCTTA 480 AAAAAAAAAA AAAA 494 380 base pairs nucleic acid single linear cDNA Homo sapiens 84 GCTGGTAGCC TATGGCGTGG CCACGGANGG GCTCCTGAGG CACGGGACAG TGACTTCCCA 60 AGTATCCTGC GCCGCGTCTT CTACCGTCCC TACCTGCAGA TCTTCGGGCA GATTCCCCAG 120 GAGGACATGG ACGTGGCCCT CATGGAGCAC AGCAACTGCT CGTCGGAGCC CGGCTTCTGG 180 GCACACCCTC CTGGGGCCCA GGCGGGCACC TGCGTCTCCC AGTATGCCAA CTGGCTGGTG 240 GTGCTGCTCC TCGTCATCTT CCTGCTCGTG GCCAACATCC TGCTGGTCAC TTGCTCATTG 300 CCATGTTCAG TTACACATTC GGCAAAGTAC AGGGCAACAG CNATCTCTAC TGGGAAGGCC 360 AGCGTTNCCG CCTCATCCGG 380 481 base pairs nucleic acid single linear cDNA Homo sapiens 85 GAGTTAGCTC CTCCACAACC TTGATGAGGT CGTCTGCAGT GGCCTCTCGC TTCATACCGC 60 TNCCATCGTC ATACTGTAGG TTTGCCACCA CCTCCTGCAT CTTGGGGCGG CTAATATCCA 120 GGAAACTCTC AATCAAGTCA CCGTCNATNA AACCTGTGGC TGGTTCTGTC TTCCGCTCGG 180 TGTGAAAGGA TCTCCAGAAG GAGTGCTCGA TCTTCCCCAC ACTTTTGATG ACTTTATTGA 240 GTCGATTCTG CATGTCCAGC AGGAGGTTGT ACCAGCTCTC TGACAGTGAG GTCACCAGCC 300 CTATCATGCC NTTGAACGTG CCGAAGAACA CCGAGCCTTG TGTGGGGGGT GNAGTCTCAC 360 CCAGATTCTG CATTACCAGA NAGCCGTGGC AAAAGANATT GACAACTCGC CCAGGNNGAA 420 AAAGAACACC TCCTGGAAGT GCTNGCCGCT CCTCGTCCNT TGGTGGNNGC GCNTNCCTTT 480 T 481 472 base pairs nucleic acid single linear cDNA Homo sapiens 86 AACATCTTCC TGTATAATGC TGTGTAATAT CGATCCGATN TTGTCTGCTG AGAATTCATT 60 ACTTGGAAAA GCAACTTNAA GCCTGGACAC TGGTATTAAA ATTCACAATA TGCAACACTT 120 TAAACAGTGT GTCAATCTGC TCCCTTACTT TGTCATCACC AGTCTGGGAA TAAGGGTATG 180 CCCTATTCAC ACCTGTTAAA AGGGCGCTAA GCATTTTTGA TTCAACATCT TTTTTTTTGA 240 CACAAGTCCG AAAAAAGCAA AAGTAAACAG TTNTTAATTT GTTAGCCAAT TCACTTTCTT 300 CATGGGACAG AGCCATTTGA TTTAAAAAGC AAATTGCATA ATATTGAGCT TTGGGAGCTG 360 ATATNTGAGC GGAAGANTAG CCTTTCTACT TCACCAGACA CAACTCCTTT CATATTGGGA 420 TGTTNACNAA AGTTATGTCT CTTACAGATG GGATGCTTTT GTGGCAATTC TG 472 413 base pairs nucleic acid single linear cDNA Homo sapiens 87 AGAAACCAGT ATCTCTNAAA ACAACCTCTC ATACCTTGTG GACCTAATTT TGTGTGCGTG 60 TGTGTGTGCG CGCATATTAT ATAGACAGGC ACATCTTTTT TACTTTTGTA AAAGCTTATG 120 CCTCTTTGGT ATCTATATCT GTGAAAGTTT TAATGATCTG CCATAATGTC TTGGGGACCT 180 TTGTCTTCTG TGTAAATGGT ACTAGAGAAA ACACCTATNT TATGAGTCAA TCTAGTTNGT 240 TTTATTCGAC ATGAAGGAAA TTTCCAGATN ACAACACTNA CAAACTCTCC CTTGACTAGG 300 GGGGACAAAG AAAAGCANAA CTGAACATNA GAAACAATTN CCTGGTGAGA AATTNCATAA 360 ACAGAAATTG GGTNGTATAT TGAAANANNG CATCATTNAA ACGTTTTTTT TTT 413 448 base pairs nucleic acid single linear cDNA Homo sapiens 88 CGCAGCGGGT CCTCTCTATC TAGCTCCAGC CTCTCGCCTG CCCCACTCCC CGCGTCCCGC 60 GTCCTAGCCN ACCATGGCCG GGCCCCTGCG CGCCCCGCTG CTCCTGCTGG CCATCCTGGC 120 CGTGGCCCTG GCCGTGAGCC CCGCGGCCGG CTCCAGTCCC GGCAAGCCGC CGCGCCTGGT 180 GGGAGGCCCA TGGACCCCGC GTGGAAGAAG AAGGTGTGCG GCGTGCACTG GACTTTGCCG 240 TCGGCNANTA CAACAAACCC GCAACNACTT TTACCNAGCN CGCGCTGCAG GTTGTGCCGC 300 CCCAANCAAA TTGTTACTNG GGGTAANTAA TTCTTGGAAG TTGAACCTGG GCCAAACNNG 360 TTTACCAGAA CCNAGCCAAT TNGAACAATT NCCCCTCCAT AACAGCCCCT TTTAAAAAGG 420 GAANCANTCC TGNTCTTTTC CAAATTTT 448 463 base pairs nucleic acid single linear cDNA Homo sapiens 89 GAATTTTGTG CACTGGCCAC TGTGATGGAA CCATTGGGCC AGGATGCTTT GAGTTTATCA 60 GTAGTGATTC TGCCAAAGTT GGTGTTGTAA CATGAGTATG TAAAATGTCA AAAAATTAGC 120 AGAGGTCTAG GTCTGCATAT CAGCAGACAG TTTGTCCGTG TATTTTGTAG CCTTGAAGTT 180 CTCAGTGACA AGTTNNTTCT GATGCGAAGT TCTNATTCCA GTGTTTTAGT CCTTTGCATC 240 TTTNATGTTN AGACTTGCCT CTNTNAAATT GCTTTTGTNT TCTGCAGGTA CTATCTGTGG 300 TTTAACAAAA TAGAANNACT TCTCTGCTTN GAANATTTGA ATATCTTACA TCTNAAAATN 360 AATTCTCTCC CCATANNAAA ACCCANGCCC TTGGGANAAT TTGAAAAANG GNTCCTTCNN 420 AATTCNNANA ANTTCAGNTN TCATACAACA NAACNGGANC CCC 463 400 base pairs nucleic acid single linear cDNA Homo sapiens 90 AGGGATTGAA GGTCTNTTNT ACTGTCGGAC TGTTCANCCA CCAACTCTAC AAGTTGCTGT 60 CTTCCACTCA CTGTCTGTAA GCNTNTTAAC CCAGACTGTA TCTTCATAAA TAGAACAAAT 120 TCTTCACCAG TCACATCTTC TAGGACCTTT TTGGATTCAG TTAGTATAAG CTCTTCCACT 180 TCCTTTGTTA AGACTTCATC TGGTAAAGTC TTAAGTTTTG TAGAAAGGAA TTTAATTGCT 240 CGTTCTCTAA CAATGTCCTC TCCTTGAAGT ATTTGGCTGA ACAACCCACC TNAAGTCCCT 300 TTGTGCATCC ATTTTAAATA TACTTAATAG GGCATTGGTN CACTAGGTTA AATTCTGCAA 360 GAGTCATCTG TCTGCAAAAG TTGCGTTAGT ATATCTGCCA 400 480 base pairs nucleic acid single linear cDNA Homo sapiens 91 GAGCTCGGAT CCAATAATCT TTGTCTGAGG GCAGCACACA TATNCAGTGC CATGGNAACT 60 GGTCTACCCC ACATGGGAGC AGCATGCCGT AGNTATATAA GGTCATTCCC TGAGTCAGAC 120 ATGCCTCTTT GACTACCGTG TGCCAGTGCT GGTGATTCTC ACACACCTCC NNCCGCTCTT 180 TGTGGAAAAA CTGGCACTTG NCTGGAACTA GCAAGACATC ACTTACAAAT TCACCCACGA 240 GACACTTGAA AGGTGTAACA AAGCGACTCT TGCATTGCTT TTTGTCCCTC CGGCACCAGT 300 TGTCAATACT AACCCGCTGG TTTGCCTCCA TCACATTTGT GATCTGTAGC TCTGGATACA 360 TCTCCTGACA GTACTGAAGA ACTTCTTCTT TTGTTTCAAA AGCAACTCTT GGTGCCTGTT 420 NGATCAGGTT CCCATTTCCC AGTCCGAATG TTCACATGGC ATATNTTACT TCCCACAAAA 480 477 base pairs nucleic acid single linear cDNA Homo sapiens 92 ATACAGCCCA NATCCCACCA CGAAGATGCG CTTGTTGACT GAGAACCTGA TGCGGTCACT 60 GGTCCCGCTG TAGCCCCAGC GACTCTCCAC CTGCTGGAAG CGGTTGATGC TGCACTCCTT 120 CCCACGCAGG CAGCAGCGGG GCCGGTCAAT GAACTCCACT CGTGGCTTGG GGTTGACGGT 180 TAANTGCAGG AAGAGGCTGA CCACCTCGCG GTCCACCAGG ATGCCCGACT GTGCGGGACC 240 TGCAGCGAAA CTCCTCGATG GTCATGAGCG GGAAGCGAAT GANGCCCAGG GCCTTGCCCA 300 GAACCTTCCG CCTGTTCTCT GGCGTCACCT GCAGCTGCTG CCGCTNACAC TCGGCCTCGG 360 ACCAGCGGAC AAACGGCGTT GAACAGCCGC ACCTCACGGA TGCCCANTGT GTCGCGCTCC 420 AGGAACGGCN CCAGCGTGTC CAGGTCAATG TCGGTGAANC CTCCGCGGGT AATGGCG 477 377 base pairs nucleic acid single linear cDNA Homo sapiens 93 GAACGGCTGG ACCTTGCCTC GCATTGTGCT GCTGGCAGGA ATACCTTGGC AAGCAGCTCC 60 AGTCCGAGCA GCCCCAGACC GCTGCCGCCC GAAGCTAAGC CTGCCTCTGG CCTTCCCCTC 120 CGCCTCAATG CAGAACCANT AGTGGGAGCA CTGTGTTTAG AGTTAAGAGT GAACACTGTN 180 TGATTTTACT TGGGAATTTC CTCTGTTATA TAGCTTTTCC CAATGCTAAT TTCCAAACAA 240 CAACAACAAA ATAACATGTT TGCCTGTTNA GTTGTATAAA AGTANGTGAT TCTGTATNTA 300 AAGAAAATAT TACTGTTACA TATACTGCTT GCAANTTCTG TATTTATTGG TNCTCTGGAA 360 ATAAATATAT TATTAAA 377 495 base pairs nucleic acid single linear cDNA Homo sapiens 94 CCCTTTGAGG GGTTAGGGTC CAGTTCCCAG TGGAAGAAAC AGGCCAGGAG AANTGCGTGC 60 CGAGCTGANG CAGATTTCCC ACAGTGACCC CAGAGCCCTG GGCTATAGTC TCTGACCCCT 120 CCAAGGAAAG ACCACCTTCT GGGGACATGG GCTGGAGGGC AGGACCTAGA GGCACCAAGG 180 GAAGGCCCCA TTCCGGGGCT GTTCCCCGAG GAGGAAGGGA AGGGGCTCTG TGTGCCCCCC 240 ACGAGGAANA GGCCCTGANT CCTGGGATCA NACACCCCTT CACGTGTATC CCCACACAAA 300 TGCAAGCTCA CCAAGGTCCC CTCTCAGTCC CTTCCCTACA CCCTGAACGG NCACTGGCCC 360 ACACCCACCC AGANCANCCA CCCGCCATGG GGAATGTNCT CAAGGAATCG CNGGGCAACG 420 TGGACTCTNG TCCCNNAAGG GGGCAGAATC TCCAATAGAN GGANNGAACC CTTGCTNANA 480 AAAAAAAANA AAAAA 495 472 base pairs nucleic acid single linear cDNA Homo sapiens 95 GGTTACTTGG TTTCATTGCC ACCACTTAGT GGATGTCATT TAGAACCATT TTGTCTGCTC 60 CCTCTGGAAG CCTTGCGCAG AGCGGACTTT GTAATTGTTG GAGAATAACT GCTGAATTTT 120 TAGCTGTTTT GAGTTGATTC GCACCACTGC ACCACAACTC AATATGAAAA CTATTTNACT 180 TATTTATTAT CTTGTGAAAA GTATACAATG AAAATTTTGT TCATACTGTA TTTATCAAGT 240 ATGATGAAAA GCAATAGATA TATATTCTTT TATTATGTTN AATTATGATT GCCATTATTA 300 ATCGGCAAAA TGTGGAGTGT ATGTTCTTTT CACAGTAATA TATGCCTTTT GTAACTTCAC 360 TTGGTTATTT TATTGTAAAT GAATTACAAA ATTCTTAATT TAAGAAAATG GTANGTTATA 420 TTTANTTCAN TAATTTCTTT CCTTGTTTAC GTTAATTTTG AAAAGAATGC AT 472 476 base pairs nucleic acid single linear cDNA Homo sapiens 96 CTGAAGCATT TCTTCAAACT TNTCTACTTT TGTCATTGAT ACCTGTAGTA AGTTGACAAT 60 GTGGTGAAAT TTCAAAATTA TATGTAACTT CTACTAGTTT TACTTTCTCC CCCAAGTCTT 120 TTTTAACTCA TGATTTTTAC ACACACAATC CAGAACTTAT TATATAGCCT CTAAGTCTTT 180 ATTCTTCACA GTAGATGATG AAAGAGTCCT CCAGTGTCTT GNGCANAATG TTCTAGNTAT 240 AGCTGGATAC ATACNGTGGG AGTTCTATAA ACTCATACCT CAGTGGGACT NAACCAAAAT 300 TGTGTTAGTC TCAATTCCTA CCACACTGAG GGAGCCTCCC AAATCACTAT ATTCTTATCT 360 GCAGGTACTC CTCCAGAAAA ACNGACAGGG CAGGCTTGCA TGAAAAAGTN ACATCTGCGT 420 TACAAAGTCT ATCTTCCTCA NANGTCTGTN AAGGAACAAT TTAATCTTCT AGCTTT 476 479 base pairs nucleic acid single linear cDNA Homo sapiens 97 ACTCTTTCTA ATGCTGATAT GATCTTGAGT ATAAGAATGC ATATGTCACT AGAATGGATA 60 AAATAATGCT GCAAACTTAA TGTTCTTATG CAAAATGGAA CGCTAATGAA ACACAGCTTA 120 CAATCGCAAA TCAAAACTCA CAAGTGCTCA TCTGTTGTAG ATTTAGTGTA ATAAGACTTA 180 GATTGTGCTC CTTCGGATAT GATTGTTTCT CANATCTTGG GCAATNTTCC TTAGTCAAAT 240 CAGGCTACTA GAATTCTGTT ATTGGATATN TGAGAGCATG AAATTTTTAA NAATACACTT 300 GTGATTATNA AATTAATCAC AAATTTCACT TATACCTGCT ATCAGCAGCT AGAAAAACAT 360 NTNNTTTTTA NATCAAAGTA TTTTGTGTTT GGAANTGTNN AAATGAAATC TGAATGTGGG 420 TTCNATCTTA TTTTTTCCCN GACNACTANT TNCTTTTTTA GGGNCTATTC TGANCCATC 479 461 base pairs nucleic acid single linear cDNA Homo sapiens 98 AGTGACTTGT CCTCCAACAA AACCCCTTGA TCAAGTTTGT GGCACTGACA ATCAGACCTA 60 TGCTAGTTCC TGTCATCTAT TCGCTACTAA ATGCAGACTG GAGGGGACCA AAAAGGGGCA 120 TCAACTCCAG CTGGATTATT TTGGAGCCTG CAAATCTATT CCTACTTGTA CGGACTTTGA 180 AGTGATTCAG TTTCCTCTAC GGATGAGAGA CTGGCTCAAG AATATCCTCA TGCAGCTTTA 240 TGAAGCCACT CTGAACACGC TGGTTATCTA GATGAGAACA GAGAAATAAA GTCAGAAAAT 300 TTACCTGGAG AAAAGAGGCT TTGGCTGGGG ACCATCCCAT TGAACCTTCT CTTAAGGACT 360 TTAAGAAAAA CTACCACATG TTGTGTATCC TGGTGCCGGC CGTTTATGAA CTGACCACCC 420 TTTGGAATAA TCTTGACGCT CCTGAACTTG CTCCTCTGCG A 461 171 base pairs nucleic acid single linear cDNA Homo sapiens 99 GTGGCCGCGC GCAGGTGTTT CCTCGTACCG CAGGGCCCCC TCCCTTCCCC AGGCGTCCCT 60 CGGCGCCTCT GCGGGCCCGA GGAGGAGCGG CTGGCGGGTG GGGGGAGTGT GACCCACCCT 120 CGGTGAGAAA AGCCTTCTCT AGCGATCTGA GAGGCGTGCC TTGGGGGTAC C 171 269 base pairs nucleic acid single linear cDNA Homo sapiens 100 CGGCCGCAAG TGCAACTCCA GCTGGGGCCG TGCGGACGAA GATTCTGCCA GCAGTTGGTC 60 CGACTGCGAC GACGGCGGCG GCGACAGTCG CAGGTGCAGC GCGGGCGCCT GGGGTCTTGC 120 AAGGCTGAGC TGACGCCGCA GAGGTCGTGT CACGTCCCAC GACCTTGACG CCGTCGGGGA 180 CAGCCGGAAC AGAGCCCGGT GAAGCGGGAG GCCTCGGGGA GCCCCTCGGG AAGGGCGGCC 240 CGAGAGATAC GCAGGTGCAG GTGGCCGCC 269 405 base pairs nucleic acid single linear cDNA Homo sapiens 101 TTTTTTTTTT TTTTGGAATC TACTGCGAGC ACAGCAGGTC AGCAACAAGT TTATTTTGCA 60 GCTAGCAAGG TAACAGGGTA GGGCATGGTT ACATGTTCAG GTCAACTTCC TTTGTCGTGG 120 TTGATTGGTT TGTCTTTATG GGGGCGGGGT GGGGTAGGGG AAACGAAGCA AATAACATGG 180 AGTGGGTGCA CCCTCCCTGT AGAACCTGGT TACAAAGCTT GGGGCAGTTC ACCTGGTCTG 240 TGACCGTCAT TTTCTTGACA TCAATGTTAT TAGAAGTCAG GATATCTTTT AGAGAGTCCA 300 CTGTTCTGGA GGGAGATTAG GGTTTCTTGC CAAATCCAAC AAAATCCACT GAAAAAGTTG 360 GATGATCAGT ACGAATACCG AGGCATATTC TCATATCGGT GGCCA 405 470 base pairs nucleic acid single linear cDNA Homo sapiens 102 TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT 60 GGCACTTAAT CCATTTTTAT TTCAAAATGT CTACAAATTT AATCCCATTA TACGGTATTT 120 TCAAAATCTA AATTATTCAA ATTAGCCAAA TCCTTACCAA ATAATACCCA AAAATCAAAA 180 ATATACTTCT TTCAGCAAAC TTGTTACATA AATTAAAAAA ATATATACGG CTGGTGTTTT 240 CAAAGTACAA TTATCTTAAC ACTGCAAACA TTTTAAGGAA CTAAAATAAA AAAAAACACT 300 CCGCAAAGGT TAAAGGGAAC AACAAATTCT TTTACAACAC CATTATAAAA ATCATATCTC 360 AAATCTTAGG GGAATATATA CTTCACACGG GATCTTAACT TTTACTCACT TTGTTTATTT 420 TTTTAAACCA TTGTTTGGGC CCAACACAAT GGAATCCCCC CTGGACTAGT 470 581 base pairs nucleic acid single linear cDNA Homo sapiens 103 TTTTTTTTTT TTTTTTTTGA CCCCCCTCTT ATAAAAAACA AGTTACCATT TTATTTTACT 60 TACACATATT TATTTTATAA TTGGTATTAG ATATTCAAAA GGCAGCTTTT AAAATCAAAC 120 TAAATGGAAA CTGCCTTAGA TACATAATTC TTAGGAATTA GCTTAAAATC TGCCTAAAGT 180 GAAAATCTTC TCTAGCTCTT TTGACTGTAA ATTTTTGACT CTTGTAAAAC ATCCAAATTC 240 ATTTTTCTTG TCTTTAAAAT TATCTAATCT TTCCATTTTT TCCCTATTCC AAGTCAATTT 300 GCTTCTCTAG CCTCATTTCC TAGCTCTTAT CTACTATTAG TAAGTGGCTT TTTTCCTAAA 360 AGGGAAAACA GGAAGAGAAA TGGCACACAA AACAAACATT TTATATTCAT ATTTCTACCT 420 ACGTTAATAA AATAGCATTT TGTGAAGCCA GCTCAAAAGA AGGCTTAGAT CCTTTTATGT 480 CCATTTTAGT CACTAAACGA TATCAAAGTG CCAGAATGCA AAAGGTTTGT GAACATTTAT 540 TCAAAAGCTA ATATAAGATA TTTCACATAC TCATCTTTCT G 581 578 base pairs nucleic acid single linear cDNA Homo sapiens 104 TTTTTTTTTT TTTTTTTTTT TTTTTCTCTT CTTTTTTTTT GAAATGAGGA TCGAGTTTTT 60 CACTCTCTAG ATAGGGCATG AAGAAAACTC ATCTTTCCAG CTTTAAAATA ACAATCAAAT 120 CTCTTATGCT ATATCATATT TTAAGTTAAA CTAATGAGTC ACTGGCTTAT CTTCTCCTGA 180 AGGAAATCTG TTCATTCTTC TCATTCATAT AGTTATATCA AGTACTACCT TGCATATTGA 240 GAGGTTTTTC TTCTCTATTT ACACATATAT TTCCATGTGA ATTTGTATCA AACCTTTATT 300 TTCATGCAAA CTAGAAAATA ATGTTTCTTT TGCATAAGAG AAGAGAACAA TATAGCATTA 360 CAAAACTGCT CAAATTGTTT GTTAAGTTAT CCATTATAAT TAGTTGGCAG GAGCTAATAC 420 AAATCACATT TACGACAGCA ATAATAAAAC TGAAGTACCA GTTAAATATC CAAAATAATT 480 AAAGGAACAT TTTTAGCCTG GGTATAATTA GCTAATTCAC TTTACAAGCA TTTATTAGAA 540 TGAATTCACA TGTTATTATT CCTAGCCCAA CACAATGG 578 538 base pairs nucleic acid single linear cDNA Homo sapiens 105 TTTTTTTTTT TTTTTCAGTA ATAATCAGAA CAATATTTAT TTTTATATTT AAAATTCATA 60 GAAAAGTGCC TTACATTTAA TAAAAGTTTG TTTCTCAAAG TGATCAGAGG AATTAGATAT 120 GTCTTGAACA CCAATATTAA TTTGAGGAAA ATACACCAAA ATACATTAAG TAAATTATTT 180 AAGATCATAG AGCTTGTAAG TGAAAAGATA AAATTTGACC TCAGAAACTC TGAGCATTAA 240 AAATCCACTA TTAGCAAATA AATTACTATG GACTTCTTGC TTTAATTTTG TGATGAATAT 300 GGGGTGTCAC TGGTAAACCA ACACATTCTG AAGGATACAT TACTTAGTGA TAGATTCTTA 360 TGTACTTTGC TAATACGTGG ATATGAGTTG ACAAGTTTCT CTTTCTTCAA TCTTTTAAGG 420 GGCGAGAAAT GAGGAAGAAA AGAAAAGGAT TACGCATACT GTTCTTTCTA TGGAAGGATT 480 AGATATGTTT CCTTTGCCAA TATTAAAAAA ATAATAATGT TTACTACTAG TGAAACCC 538 473 base pairs nucleic acid single linear cDNA Homo sapiens 106 TTTTTTTTTT TTTTTTAGTC AAGTTTCTAT TTTTATTATA ATTAAAGTCT TGGTCATTTC 60 ATTTATTAGC TCTGCAACTT ACATATTTAA ATTAAAGAAA CGTTTTAGAC AACTGTACAA 120 TTTATAAATG TAAGGTGCCA TTATTGAGTA ATATATTCCT CCAAGAGTGG ATGTGTCCCT 180 TCTCCCACCA ACTAATGAAC AGCAACATTA GTTTAATTTT ATTAGTAGAT ATACACTGCT 240 GCAAACGCTA ATTCTCTTCT CCATCCCCAT GTGATATTGT GTATATGTGT GAGTTGGTAG 300 AATGCATCAC AATCTACAAT CAACAGCAAG ATGAAGCTAG GCTGGGCTTT CGGTGAAAAT 360 AGACTGTGTC TGTCTGAATC AAATGATCTG ACCTATCCTC GGTGGCAAGA ACTCTTCGAA 420 CCGCTTCCTC AAAGGCGCTG CCACATTTGT GGCTCTTTGC ACTTGTTTCA AAA 473 1621 base pairs nucleic acid single linear cDNA Homo sapiens 107 CGCCATGGCA CTGCAGGGCA TCTCGGTCAT GGAGCTGTCC GGCCTGGCCC CGGGCCCGTT 60 CTGTGCTATG GTCCTGGCTG ACTTCGGGGC GCGTGTGGTA CGCGTGGACC GGCCCGGCTC 120 CCGCTACGAC GTGAGCCGCT TGGGCCGGGG CAAGCGCTCG CTAGTGCTGG ACCTGAAGCA 180 GCCGCGGGGA GCCGCCGTGC TGCGGCGTCT GTGCAAGCGG TCGGATGTGC TGCTGGAGCC 240 CTTCCGCCGC GGTGTCATGG AGAAACTCCA GCTGGGCCCA GAGATTCTGC AGCGGGAAAA 300 TCCAAGGCTT ATTTATGCCA GGCTGAGTGG ATTTGGCCAG TCAGGAAGCT TCTGCCGGTT 360 AGCTGGCCAC GATATCAACT ATTTGGCTTT GTCAGGTGTT CTCTCAAAAA TTGGCAGAAG 420 TGGTGAGAAT CCGTATGCCC CGCTGAATCT CCTGGCTGAC TTTGCTGGTG GTGGCCTTAT 480 GTGTGCACTG GGCATTATAA TGGCTCTTTT TGACCGCACA CGCACTGACA AGGGTCAGGT 540 CATTGATGCA AATATGGTGG AAGGAACAGC ATATTTAAGT TCTTTTCTGT GGAAAACTCA 600 GAAATCGAGT CTGTGGGAAG CACCTCGAGG ACAGAACATG TTGGATGGTG GAGCACCTTT 660 CTATACGACT TACAGGACAG CAGATGGGGA ATTCATGGCT GTTGGAGCAA TAGAACCCCA 720 GTTCTACGAG CTGCTGATCA AAGGACTTGG ACTAAAGTCT GATGAACTTC CCAATCAGAT 780 GAGCATGGAT GATTGGCCAG AAATGAAGAA GAAGTTTGCA GATGTATTTG CAAAGAAGAC 840 GAAGGCAGAG TGGTGTCAAA TCTTTGACGG CACAGATGCC TGTGTGACTC CGGTTCTGAC 900 TTTTGAGGAG GTTGTTCATC ATGATCACAA CAAGGAACGG GGCTCGTTTA TCACCAGTGA 960 GGAGCAGGAC GTGAGCCCCC GCCCTGCACC TCTGCTGTTA AACACCCCAG CCATCCCTTC 1020 TTTCAAAAGG GATCCTTTCA TAGGAGAACA CACTGAGGAG ATACTTGAAG AATTTGGATT 1080 CAGCCGCGAA GAGATTTATC AGCTTAACTC AGATAAAATC ATTGAAAGTA ATAAGGTAAA 1140 AGCTAGTCTC TAACTTCCAG GCCCACGGCT CAAGTGAATT TGAATACTGC ATTTACAGTG 1200 TAGAGTAACA CATAACATTG TATGCATGGA AACATGGAGG AACAGTATTA CAGTGTCCTA 1260 CCACTCTAAT CAAGAAAAGA ATTACAGACT CTGATTCTAC AGTGATGATT GAATTCTAAA 1320 AATGGTTATC ATTAGGGCTT TTGATTTATA AAACTTTGGG TACTTATACT AAATTATGGT 1380 AGTTATTCTG CCTTCCAGTT TGCTTGATAT ATTTGTTGAT ATTAAGATTC TTGACTTATA 1440 TTTTGAATGG GTTCTAGTGA AAAAGGAATG ATATATTCTT GAAGACATCG ATATACATTT 1500 ATTTACACTC TTGATTCTAC AATGTAGAAA ATGAGGAAAT GCCACAAATT GTATGGTGAT 1560 AAAAGTCACG TGAAACAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 1620 A 1621 382 amino acids amino acid single linear protein Homo sapiens 108 Met Ala Leu Gln Gly Ile Ser Val Met Glu Leu Ser Gly Leu Ala Pro 1 5 10 15 Gly Pro Phe Cys Ala Met Val Leu Ala Asp Phe Gly Ala Arg Val Val 20 25 30 Arg Val Asp Arg Pro Gly Ser Arg Tyr Asp Val Ser Arg Leu Gly Arg 35 40 45 Gly Lys Arg Ser Leu Val Leu Asp Leu Lys Gln Pro Arg Gly Ala Ala 50 55 60 Val Leu Arg Arg Leu Cys Lys Arg Ser Asp Val Leu Leu Glu Pro Phe 65 70 75 80 Arg Arg Gly Val Met Glu Lys Leu Gln Leu Gly Pro Glu Ile Leu Gln 85 90 95 Arg Glu Asn Pro Arg Leu Ile Tyr Ala Arg Leu Ser Gly Phe Gly Gln 100 105 110 Ser Gly Ser Phe Cys Arg Leu Ala Gly His Asp Ile Asn Tyr Leu Ala 115 120 125 Leu Ser Gly Val Leu Ser Lys Ile Gly Arg Ser Gly Glu Asn Pro Tyr 130 135 140 Ala Pro Leu Asn Leu Leu Ala Asp Phe Ala Gly Gly Gly Leu Met Cys 145 150 155 160 Ala Leu Gly Ile Ile Met Ala Leu Phe Asp Arg Thr Arg Thr Asp Lys 165 170 175 Gly Gln Val Ile Asp Ala Asn Met Val Glu Gly Thr Ala Tyr Leu Ser 180 185 190 Ser Phe Leu Trp Lys Thr Gln Lys Ser Ser Leu Trp Glu Ala Pro Arg 195 200 205 Gly Gln Asn Met Leu Asp Gly Gly Ala Pro Phe Tyr Thr Thr Tyr Arg 210 215 220 Thr Ala Asp Gly Glu Phe Met Ala Val Gly Ala Ile Glu Pro Gln Phe 225 230 235 240 Tyr Glu Leu Leu Ile Lys Gly Leu Gly Leu Lys Ser Asp Glu Leu Pro 245 250 255 sn Gln Met Ser Met Asp Asp Trp Pro Glu Met Lys Lys Lys Phe Ala 260 265 270 Asp Val Phe Ala Lys Lys Thr Lys Ala Glu Trp Cys Gln Ile Phe Asp 275 280 285 Gly Thr Asp Ala Cys Val Thr Pro Val Leu Thr Phe Glu Glu Val Val 290 295 300 His His Asp His Asn Lys Glu Arg Gly Ser Phe Ile Thr Ser Glu Glu 305 310 315 320 Gln Asp Val Ser Pro Arg Pro Ala Pro Leu Leu Leu Asn Thr Pro Ala 325 330 335 Ile Pro Ser Phe Lys Arg Asp Pro Phe Ile Gly Glu His Thr Glu Glu 340 345 350 Ile Leu Glu Glu Phe Gly Phe Ser Arg Glu Glu Ile Tyr Gln Leu Asn 355 360 365 Ser Asp Lys Ile Ile Glu Ser Asn Lys Val Lys Ala Ser Leu 370 375 380 1524 base pairs nucleic acid single linear cDNA Homo sapiens 109 GGCACGAGGC TGCGCCAGGG CCTGAGCGGA GGCGGGGGCA GCCTCGCCAG CGGGGGCCCC 60 GGGCCTGGCC ATGCCTCACT GAGCCAGCGC CTGCGCCTCT ACCTCGCCGA CAGCTGGAAC 120 CAGTGCGACC TAGTGGCTCT CACCTGCTTC CTCCTGGGCG TGGGCTGCCG GCTGACCCCG 180 GGTTTGTACC ACCTGGGCCG CACTGTCCTC TGCATCGACT TCATGGTTTT CACGGTGCGG 240 CTGCTTCACA TCTTCACGGT CAACAAACAG CTGGGGCCCA AGATCGTCAT CGTGAGCAAG 300 ATGATGAAGG ACGTGTTCTT CTTCCTCTTC TTCCTCGGCG TGTGGCTGGT AGCCTATGGC 360 GTGGCCACGG AGGGGCTCCT GAGGCCACGG GACAGTGACT TCCCAAGTAT CCTGCGCCGC 420 GTCTTCTACC GTCCCTACCT GCAGATCTTC GGGCAGATTC CCCAGGAGGA CATGGACGTG 480 GCCCTCATGG AGCACAGCAA CTGCTCGTCG GAGCCCGGCT TCTGGGCACA CCCTCCTGGG 540 GCCCAGGCGG GCACCTGCGT CTCCCAGTAT GCCAACTGGC TGGTGGTGCT GCTCCTCGTC 600 ATCTTCCTGC TCGTGGCCAA CATCCTGCTG GTCAACTTGC TCATTGCCAT GTTCAGTTAC 660 ACATTCGGCA AAGTACAGGG CAACAGCGAT CTCTACTGGA AGGCGCAGCG TTACCGCCTC 720 ATCCGGGAAT TCCACTCTCG GCCCGCGCTG GCCCCGCCCT TTATCGTCAT CTCCCACTTG 780 CGCCTCCTGC TCAGGCAATT GTGCAGGCGA CCCCGGAGCC CCCAGCCGTC CTCCCCGGCC 840 CTCGAGCATT TCCGGGTTTA CCTTTCTAAG GAAGCCGAGC GGAAGCTGCT AACGTGGGAA 900 TCGGTGCATA AGGAGAACTT TCTGCTGGCA CGCGCTAGGG ACAAGCGGGA GAGCGACTCC 960 GAGCGTCTGA AGCGCACGTC CCAGAAGGTG GACTTGGCAC TGAAACAGCT GGGACACATC 1020 CGCGAGTACG AACAGCGCCT GAAAGTGCTG GAGCGGGAGG TCCAGCAGTG TAGCCGCGTC 1080 CTGGGGTGGG TGGCCGAGGC CCTGAGCCGC TCTGCCTTGC TGCCCCCAGG TGGGCCGCCA 1140 CCCCCTGACC TGCCTGGGTC CAAAGACTGA GCCCTGCTGG CGGACTTCAA GGAGAAGCCC 1200 CCACAGGGGA TTTTGCTCCT AGAGTAAGGC TCATCTGGGC CTCGGCCCCC GCACCTGGTG 1260 GCCTTGTCCT TGAGGTGAGC CCCATGTCCA TCTGGGCCAC TGTCAGGACC ACCTTTGGGA 1320 GTGTCATCCT TACAAACCAC AGCATGCCCG GCTCCTCCCA GAACCAGTCC CAGCCTGGGA 1380 GGATCAAGGC CTGGATCCCG GGCCGTTATC CATCTGGAGG CTGCAGGGTC CTTGGGGTAA 1440 CAGGGACCAC AGACCCCTCA CCACTCACAG ATTCCTCACA CTGGGGAAAT AAAGCCATTT 1500 CAGAGGAAAA AAAAAAAAAA AAAA 1524 3410 base pairs nucleic acid single linear cDNA Homo sapiens 110 GGGAACCAGC CTGCACGCGC TGGCTCCGGG TGACAGCCGC GCGCCTCGGC CAGGATCTGA 60 GTGATGAGAC GTGTCCCCAC TGAGGTGCCC CACAGCAGCA GGTGTTGAGC ATGGGCTGAG 120 AAGCTGGACC GGCACCAAAG GGCTGGCAGA AATGGGCGCC TGGCTGATTC CTAGGCAGTT 180 GGCGGCAGCA AGGAGGAGAG GCCGCAGCTT CTGGAGCAGA GCCGAGACGA AGCAGTTCTG 240 GAGTGCCTGA ACGGCCCCCT GAGCCCTACC CGCCTGGCCC ACTATGGTCC AGAGGCTGTG 300 GGTGAGCCGC CTGCTGCGGC ACCGGAAAGC CCAGCTCTTG CTGGTCAACC TGCTAACCTT 360 TGGCCTGGAG GTGTGTTTGG CCGCAGGCAT CACCTATGTG CCGCCTCTGC TGCTGGAAGT 420 GGGGGTAGAG GAGAAGTTCA TGACCATGGT GCTGGGCATT GGTCCAGTGC TGGGCCTGGT 480 CTGTGTCCCG CTCCTAGGCT CAGCCAGTGA CCACTGGCGT GGACGCTATG GCCGCCGCCG 540 GCCCTTCATC TGGGCACTGT CCTTGGGCAT CCTGCTGAGC CTCTTTCTCA TCCCAAGGGC 600 CGGCTGGCTA GCAGGGCTGC TGTGCCCGGA TCCCAGGCCC CTGGAGCTGG CACTGCTCAT 660 CCTGGGCGTG GGGCTGCTGG ACTTCTGTGG CCAGGTGTGC TTCACTCCAC TGGAGGCCCT 720 GCTCTCTGAC CTCTTCCGGG ACCCGGACCA CTGTCGCCAG GCCTACTCTG TCTATGCCTT 780 CATGATCAGT CTTGGGGGCT GCCTGGGCTA CCTCCTGCCT GCCATTGACT GGGACACCAG 840 TGCCCTGGCC CCCTACCTGG GCACCCAGGA GGAGTGCCTC TTTGGCCTGC TCACCCTCAT 900 CTTCCTCACC TGCGTAGCAG CCACACTGCT GGTGGCTGAG GAGGCAGCGC TGGGCCCCAC 960 CGAGCCAGCA GAAGGGCTGT CGGCCCCCTC CTTGTCGCCC CACTGCTGTC CATGCCGGGC 1020 CCGCTTGGCT TTCCGGAACC TGGGCGCCCT GCTTCCCCGG CTGCACCAGC TGTGCTGCCG 1080 CATGCCCCGC ACCCTGCGCC GGCTCTTCGT GGCTGAGCTG TGCAGCTGGA TGGCACTCAT 1140 GACCTTCACG CTGTTTTACA CGGATTTCGT GGGCGAGGGG CTGTACCAGG GCGTGCCCAG 1200 AGCTGAGCCG GGCACCGAGG CCCGGAGACA CTATGATGAA GGCGTTCGGA TGGGCAGCCT 1260 GGGGCTGTTC CTGCAGTGCG CCATCTCCCT GGTCTTCTCT CTGGTCATGG ACCGGCTGGT 1320 GCAGCGATTC GGCACTCGAG CAGTCTATTT GGCCAGTGTG GCAGCTTTCC CTGTGGCTGC 1380 CGGTGCCACA TGCCTGTCCC ACAGTGTGGC CGTGGTGACA GCTTCAGCCG CCCTCACCGG 1440 GTTCACCTTC TCAGCCCTGC AGATCCTGCC CTACACACTG GCCTCCCTCT ACCACCGGGA 1500 GAAGCAGGTG TTCCTGCCCA AATACCGAGG GGACACTGGA GGTGCTAGCA GTGAGGACAG 1560 CCTGATGACC AGCTTCCTGC CAGGCCCTAA GCCTGGAGCT CCCTTCCCTA ATGGACACGT 1620 GGGTGCTGGA GGCAGTGGCC TGCTCCCACC TCCACCCGCG CTCTGCGGGG CCTCTGCCTG 1680 TGATGTCTCC GTACGTGTGG TGGTGGGTGA GCCCACCGAG GCCAGGGTGG TTCCGGGCCG 1740 GGGCATCTGC CTGGACCTCG CCATCCTGGA TAGTGCCTTC CTGCTGTCCC AGGTGGCCCC 1800 ATCCCTGTTT ATGGGCTCCA TTGTCCAGCT CAGCCAGTCT GTCACTGCCT ATATGGTGTC 1860 TGCCGCAGGC CTGGGTCTGG TCGCCATTTA CTTTGCTACA CAGGTAGTAT TTGACAAGAG 1920 CGACTTGGCC AAATACTCAG CGTAGAAAAC TTCCAGCACA TTGGGGTGGA GGGCCTGCCT 1980 CACTGGGTCC CAGCTCCCCG CTCCTGTTAG CCCCATGGGG CTGCCGGGCT GGCCGCCAGT 2040 TTCTGTTGCT GCCAAAGTAA TGTGGCTCTC TGCTGCCACC CTGTGCTGCT GAGGTGCGTA 2100 GCTGCACAGC TGGGGGCTGG GGCGTCCCTC TCCTCTCTCC CCAGTCTCTA GGGCTGCCTG 2160 ACTGGAGGCC TTCCAAGGGG GTTTCAGTCT GGACTTATAC AGGGAGGCCA GAAGGGCTCC 2220 ATGCACTGGA ATGCGGGGAC TCTGCAGGTG GATTACCCAG GCTCAGGGTT AACAGCTAGC 2280 CTCCTAGTTG AGACACACCT AGAGAAGGGT TTTTGGGAGC TGAATAAACT CAGTCACCTG 2340 GTTTCCCATC TCTAAGCCCC TTAACCTGCA GCTTCGTTTA ATGTAGCTCT TGCATGGGAG 2400 TTTCTAGGAT GAAACACTCC TCCATGGGAT TTGAACATAT GACTTATTTG TAGGGGAAGA 2460 GTCCTGAGGG GCAACACACA AGAACCAGGT CCCCTCAGCC CACAGCACTG TCTTTTTGCT 2520 GATCCACCCC CCTCTTACCT TTTATCAGGA TGTGGCCTGT TGGTCCTTCT GTTGCCATCA 2580 CAGAGACACA GGCATTTAAA TATTTAACTT ATTTATTTAA CAAAGTAGAA GGGAATCCAT 2640 TGCTAGCTTT TCTGTGTTGG TGTCTAATAT TTGGGTAGGG TGGGGGATCC CCAACAATCA 2700 GGTCCCCTGA GATAGCTGGT CATTGGGCTG ATCATTGCCA GAATCTTCTT CTCCTGGGGT 2760 CTGGCCCCCC AAAATGCCTA ACCCAGGACC TTGGAAATTC TACTCATCCC AAATGATAAT 2820 TCCAAATGCT GTTACCCAAG GTTAGGGTGT TGAAGGAAGG TAGAGGGTGG GGCTTCAGGT 2880 CTCAACGGCT TCCCTAACCA CCCCTCTTCT CTTGGCCCAG CCTGGTTCCC CCCACTTCCA 2940 CTCCCCTCTA CTCTCTCTAG GACTGGGCTG ATGAAGGCAC TGCCCAAAAT TTCCCCTACC 3000 CCCAACTTTC CCCTACCCCC AACTTTCCCC ACCAGCTCCA CAACCCTGTT TGGAGCTACT 3060 GCAGGACCAG AAGCACAAAG TGCGGTTTCC CAAGCCTTTG TCCATCTCAG CCCCCAGAGT 3120 ATATCTGTGC TTGGGGAATC TCACACAGAA ACTCAGGAGC ACCCCCTGCC TGAGCTAAGG 3180 GAGGTCTTAT CTCTCAGGGG GGGTTTAAGT GCCGTTTGCA ATAATGTCGT CTTATTTATT 3240 TAGCGGGGTG AATATTTTAT ACTGTAAGTG AGCAATCAGA GTATAATGTT TATGGTGACA 3300 AAATTAAAGG CTTTCTTATA TGTTTAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 3360 AAAAAAAARA AAAAAAAAAA AAAAAAAAAA AAAAAAATAA AAAAAAAAAA 3410 1289 base pairs nucleic acid single linear cDNA Homo sapiens 111 AGCCAGGCGT CCCTCTGCCT GCCCACTCAG TGGCAACACC CGGGAGCTGT TTTGTCCTTT 60 GTGGAGCCTC AGCAGTTCCC TCTTTCAGAA CTCACTGCCA AGAGCCCTGA ACAGGAGCCA 120 CCATGCAGTG CTTCAGCTTC ATTAAGACCA TGATGATCCT CTTCAATTTG CTCATCTTTC 180 TGTGTGGTGC AGCCCTGTTG GCAGTGGGCA TCTGGGTGTC AATCGATGGG GCATCCTTTC 240 TGAAGATCTT CGGGCCACTG TCGTCCAGTG CCATGCAGTT TGTCAACGTG GGCTACTTCC 300 TCATCGCAGC CGGCGTTGTG GTCTTTGCTC TTGGTTTCCT GGGCTGCTAT GGTGCTAAGA 360 CTGAGAGCAA GTGTGCCCTC GTGACGTTCT TCTTCATCCT CCTCCTCATC TTCATTGCTG 420 AGGTTGCAGC TGCTGTGGTC GCCTTGGTGT ACACCACAAT GGCTGAGCAC TTCCTGACGT 480 TGCTGGTAGT GCCTGCCATC AAGAAAGATT ATGGTTCCCA GGAAGACTTC ACTCAAGTGT 540 GGAACACCAC CATGAAAGGG CTCAAGTGCT GTGGCTTCAC CAACTATACG GATTTTGAGG 600 ACTCACCCTA CTTCAAAGAG AACAGTGCCT TTCCCCCATT CTGTTGCAAT GACAACGTCA 660 CCAACACAGC CAATGAAACC TGCACCAAGC AAAAGGCTCA CGACCAAAAA GTAGAGGGTT 720 GCTTCAATCA GCTTTTGTAT GACATCCGAA CTAATGCAGT CACCGTGGGT GGTGTGGCAG 780 CTGGAATTGG GGGCCTCGAG CTGGCTGCCA TGATTGTGTC CATGTATCTG TACTGCAATC 840 TACAATAAGT CCACTTCTGC CTCTGCCACT ACTGCTGCCA CATGGGAACT GTGAAGAGGC 900 ACCCTGGCAA GCAGCAGTGA TTGGGGGAGG GGACAGGATC TAACAATGTC ACTTGGGCCA 960 GAATGGACCT GCCCTTTCTG CTCCAGACTT GGGGCTAGAT AGGGACCACT CCTTTTAGCG 1020 ATGCCTGACT TTCCTTCCAT TGGTGGGTGG ATGGGTGGGG GGCATTCCAG AGCCTCTAAG 1080 GTAGCCAGTT CTGTTGCCCA TTCCCCCAGT CTATTAAACC CTTGATATGC CCCCTAGGCC 1140 TAGTGGTGAT CCCAGTGCTC TACTGGGGGA TGAGAGAAAG GCATTTTATA GCCTGGGCAT 1200 AAGTGAAATC AGCAGAGCCT CTGGGTGGAT GTGTAGAAGG CACTTCAAAA TGCATAAACC 1260 TGTTACAATG TTAAAAAAAA AAAAAAAAA 1289 315 amino acids amino acid single linear protein Homo sapiens 112 Met Val Phe Thr Val Arg Leu Leu His Ile Phe Thr Val Asn Lys Gln 1 5 10 15 Leu Gly Pro Lys Ile Val Ile Val Ser Lys Met Met Lys Asp Val Phe 20 25 30 Phe Phe Leu Phe Phe Leu Gly Val Trp Leu Val Ala Tyr Gly Val Ala 35 40 45 Thr Glu Gly Leu Leu Arg Pro Arg Asp Ser Asp Phe Pro Ser Ile Leu 50 55 60 Arg Arg Val Phe Tyr Arg Pro Tyr Leu Gln Ile Phe Gly Gln Ile Pro 65 70 75 80 Gln Glu Asp Met Asp Val Ala Leu Met Glu His Ser Asn Cys Ser Ser 85 90 95 Glu Pro Gly Phe Trp Ala His Pro Pro Gly Ala Gln Ala Gly Thr Cys 100 105 110 Val Ser Gln Tyr Ala Asn Trp Leu Val Val Leu Leu Leu Val Ile Phe 115 120 125 Leu Leu Val Ala Asn Ile Leu Leu Val Asn Leu Leu Ile Ala Met Phe 130 135 140 Ser Tyr Thr Phe Gly Lys Val Gln Gly Asn Ser Asp Leu Tyr Trp Lys 145 150 155 160 Ala Gln Arg Tyr Arg Leu Ile Arg Glu Phe His Ser Arg Pro Ala Leu 165 170 175 Ala Pro Pro Phe Ile Val Ile Ser His Leu Arg Leu Leu Leu Arg Gln 180 185 190 Leu Cys Arg Arg Pro Arg Ser Pro Gln Pro Ser Ser Pro Ala Leu Glu 195 200 205 His Phe Arg Val Tyr Leu Ser Lys Glu Ala Glu Arg Lys Leu Leu Thr 210 215 220 Trp Glu Ser Val His Lys Glu Asn Phe Leu Leu Ala Arg Ala Arg Asp 225 230 235 240 Lys Arg Glu Ser Asp Ser Glu Arg Leu Lys Arg Thr Ser Gln Lys Val 245 250 255 Asp Leu Ala Leu Lys Gln Leu Gly His Ile Arg Glu Tyr Glu Gln Arg 260 265 270 Leu Lys Val Leu Glu Arg Glu Val Gln Gln Cys Ser Arg Val Leu Gly 275 280 285 Trp Val Ala Glu Ala Leu Ser Arg Ser Ala Leu Leu Pro Pro Gly Gly 290 295 300 Pro Pro Pro Pro Asp Leu Pro Gly Ser Lys Asp 305 310 315 553 amino acids amino acid single linear protein Homo sapiens 113 Met Val Gln Arg Leu Trp Val Ser Arg Leu Leu Arg His Arg Lys Ala 1 5 10 15 Gln Leu Leu Leu Val Asn Leu Leu Thr Phe Gly Leu Glu Val Cys Leu 20 25 30 Ala Ala Gly Ile Thr Tyr Val Pro Pro Leu Leu Leu Glu Val Gly Val 35 40 45 Glu Glu Lys Phe Met Thr Met Val Leu Gly Ile Gly Pro Val Leu Gly 50 55 60 Leu Val Cys Val Pro Leu Leu Gly Ser Ala Ser Asp His Trp Arg Gly 65 70 75 80 Arg Tyr Gly Arg Arg Arg Pro Phe Ile Trp Ala Leu Ser Leu Gly Ile 85 90 95 Leu Leu Ser Leu Phe Leu Ile Pro Arg Ala Gly Trp Leu Ala Gly Leu 100 105 110 Leu Cys Pro Asp Pro Arg Pro Leu Glu Leu Ala Leu Leu Ile Leu Gly 115 120 125 Val Gly Leu Leu Asp Phe Cys Gly Gln Val Cys Phe Thr Pro Leu Glu 130 135 140 Ala Leu Leu Ser Asp Leu Phe Arg Asp Pro Asp His Cys Arg Gln Ala 145 150 155 160 Tyr Ser Val Tyr Ala Phe Met Ile Ser Leu Gly Gly Cys Leu Gly Tyr 165 170 175 Leu Leu Pro Ala Ile Asp Trp Asp Thr Ser Ala Leu Ala Pro Tyr Leu 180 185 190 Gly Thr Gln Glu Glu Cys Leu Phe Gly Leu Leu Thr Leu Ile Phe Leu 195 200 205 Thr Cys Val Ala Ala Thr Leu Leu Val Ala Glu Glu Ala Ala Leu Gly 210 215 220 Pro Thr Glu Pro Ala Glu Gly Leu Ser Ala Pro Ser Leu Ser Pro His 225 230 235 240 Cys Cys Pro Cys Arg Ala Arg Leu Ala Phe Arg Asn Leu Gly Ala Leu 245 250 255 Leu Pro Arg Leu His Gln Leu Cys Cys Arg Met Pro Arg Thr Leu Arg 260 265 270 Arg Leu Phe Val Ala Glu Leu Cys Ser Trp Met Ala Leu Met Thr Phe 275 280 285 Thr Leu Phe Tyr Thr Asp Phe Val Gly Glu Gly Leu Tyr Gln Gly Val 290 295 300 Pro Arg Ala Glu Pro Gly Thr Glu Ala Arg Arg His Tyr Asp Glu Gly 305 310 315 320 Val Arg Met Gly Ser Leu Gly Leu Phe Leu Gln Cys Ala Ile Ser Leu 325 330 335 Val Phe Ser Leu Val Met Asp Arg Leu Val Gln Arg Phe Gly Thr Arg 340 345 350 Ala Val Tyr Leu Ala Ser Val Ala Ala Phe Pro Val Ala Ala Gly Ala 355 360 365 Thr Cys Leu Ser His Ser Val Ala Val Val Thr Ala Ser Ala Ala Leu 370 375 380 Thr Gly Phe Thr Phe Ser Ala Leu Gln Ile Leu Pro Tyr Thr Leu Ala 385 390 395 400 Ser Leu Tyr His Arg Glu Lys Gln Val Phe Leu Pro Lys Tyr Arg Gly 405 410 415 Asp Thr Gly Gly Ala Ser Ser Glu Asp Ser Leu Met Thr Ser Phe Leu 420 425 430 Pro Gly Pro Lys Pro Gly Ala Pro Phe Pro Asn Gly His Val Gly Ala 435 440 445 Gly Gly Ser Gly Leu Leu Pro Pro Pro Pro Ala Leu Cys Gly Ala Ser 450 455 460 Ala Cys Asp Val Ser Val Arg Val Val Val Gly Glu Pro Thr Glu Ala 465 470 475 480 Arg Val Val Pro Gly Arg Gly Ile Cys Leu Asp Leu Ala Ile Leu Asp 485 490 495 Ser Ala Phe Leu Leu Ser Gln Val Ala Pro Ser Leu Phe Met Gly Ser 500 505 510 Ile Val Gln Leu Ser Gln Ser Val Thr Ala Tyr Met Val Ser Ala Ala 515 520 525 Gly Leu Gly Leu Val Ala Ile Tyr Phe Ala Thr Gln Val Val Phe Asp 530 535 540 Lys Ser Asp Leu Ala Lys Tyr Ser Ala 545 550 241 amino acids amino acid single linear protein Homo sapiens 114 Met Gln Cys Phe Ser Phe Ile Lys Thr Met Met Ile Leu Phe Asn Leu 1 5 10 15 Leu Ile Phe Leu Cys Gly Ala Ala Leu Leu Ala Val Gly Ile Trp Val 20 25 30 Ser Ile Asp Gly Ala Ser Phe Leu Lys Ile Phe Gly Pro Leu Ser Ser 35 40 45 Ser Ala Met Gln Phe Val Asn Val Gly Tyr Phe Leu Ile Ala Ala Gly 50 55 60 Val Val Val Phe Ala Leu Gly Phe Leu Gly Cys Tyr Gly Ala Lys Thr 65 70 75 80 Glu Ser Lys Cys Ala Leu Val Thr Phe Phe Phe Ile Leu Leu Leu Ile 85 90 95 Phe Ile Ala Glu Val Ala Ala Ala Val Val Ala Leu Val Tyr Thr Thr 100 105 110 Met Ala Glu His Phe Leu Thr Leu Leu Val Val Pro Ala Ile Lys Lys 115 120 125 Asp Tyr Gly Ser Gln Glu Asp Phe Thr Gln Val Trp Asn Thr Thr Met 130 135 140 Lys Gly Leu Lys Cys Cys Gly Phe Thr Asn Tyr Thr Asp Phe Glu Asp 145 150 155 160 Ser Pro Tyr Phe Lys Glu Asn Ser Ala Phe Pro Pro Phe Cys Cys Asn 165 170 175 Asp Asn Val Thr Asn Thr Ala Asn Glu Thr Cys Thr Lys Gln Lys Ala 180 185 190 His Asp Gln Lys Val Glu Gly Cys Phe Asn Gln Leu Leu Tyr Asp Ile 195 200 205 Arg Thr Asn Ala Val Thr Val Gly Gly Val Ala Ala Gly Ile Gly Gly 210 215 220 Leu Glu Leu Ala Ala Met Ile Val Ser Met Tyr Leu Tyr Cys Asn Leu 225 230 235 240 Gln 366 base pairs nucleic acid single linear cDNA Homo Sapiens 115 GCTCTTTCTC TCCCCTCCTC TGAATTTAAT TCTTTCAACT TGCAATTTGC AAGGATTACA 60 CATTTCACTG TGATGTATAT TGTGTTGCAA AAAAAAAAAA GTGTCTTTGT TTAAAATTAC 120 TTGGTTTGTG AATCCATCTT GCTTTTTCCC CATTGGAACT AGTCATTAAC CCATCTCTGA 180 ACTGGTAGAA AAACATCTGA AGAGCTAGTC TATCAGCATC TGACAGGTGA ATTGGATGGT 240 TCTCAGAACC ATTTCACCCA GACAGCCTGT TTCTATCCTG TTTAATAAAT TAGTTTGGGT 300 TCTCTACATG CATAACAAAC CCTGCTCCAA TCTGTCACAT AAAAGTCTGT GACTTGAAGT 360 TTAGTC 366 282 base pairs nucleic acid single linear cDNA Homo sapiens 116 ACAAAGATGA ACCATTTCCT ATATTATAGC AAAATTAAAA TCTACCCGTA TTCTAATATT 60 GAGAAATGAG ATNAAACACA ATNTTATAAA GTCTACTTAG AGAAGATCAA GTGACCTCAA 120 AGACTTTACT ATTTTCATAT TTTAAGACAC ATGATTTATC CTATTTTAGT AACCTGGTTC 180 ATACGTTAAA CAAAGGATAA TGTGAACAGC AGAGAGGATT TGTTGGCAGA AAATCTATGT 240 TCAATCTNGA ACTATCTANA TCACAGACAT TTCTATTCCT TT 282 305 base pairs nucleic acid single linear cDNA Homo sapiens 117 ACACATGTCG CTTCACTGCC TTCTTAGATG CTTCTGGTCA ACATANAGGA ACAGGGACCA 60 TATTTATCCT CCCTCCTGAA ACAATTGCAA AATAANACAA AATATATGAA ACAATTGCAA 120 AATAAGGCAA AATATATGAA ACAACAGGTC TCGAGATATT GGAAATCAGT CAATGAAGGA 180 TACTGATCCC TGATCACTGT CCTAATGCAG GATGTGGGAA ACAGATGAGG TCACCTCTGT 240 GACTGCCCCA GCTTACTGCC TGTAGAGAGT TTCTANGCTG CAGTTCAGAC AGGGAGAAAT 300 TGGGT 305 71 base pairs nucleic acid single linear cDNA Homo sapiens 118 ACCAAGGTGT NTGAATCTCT GACGTGGGGA TCTCTGATTC CCGCACAATC TGAGTGGAAA 60 AANTCCTGGG T 71 212 base pairs nucleic acid single linear cDNA Homo sapiens 119 ACTCCGGTTG GTGTCAGCAG CACGTGGCAT TGAACATNGC AATGTGGAGC CCAAACCACA 60 GAAAATGGGG TGAAATTGGC CAACTTTCTA TNAACTTATG TTGGCAANTT TGCCACCAAC 120 AGTAAGCTGG CCCTTCTAAT AAAAGAAAAT TGAAAGGTTT CTCACTAANC GGAATTAANT 180 AATGGANTCA AGANACTCCC AGGCCTCAGC GT 212 90 base pairs nucleic acid single linear cDNA Homo sapiens 120 ACTCGTTGCA NATCAGGGGC CCCCCAGAGT CACCGTTGCA GGAGTCCTTC TGGTCTTGCC 60 CTCCGCCGGC GCAGAACATG CTGGGGTGGT 90 218 base pairs nucleic acid single linear cDNA Homo sapiens 121 TGTANCGTGA ANACGACAGA NAGGGTTGTC AAAAATGGAG AANCCTTGAA GTCATTTTGA 60 GAATAAGATT TGCTAAAAGA TTTGGGGCTA AAACATGGTT ATTGGGAGAC ATTTCTGAAG 120 ATATNCANGT AAATTANGGA ATGAATTCAT GGTTCTTTTG GGAATTCCTT TACGATNGCC 180 AGCATANACT TCATGTGGGG ATANCAGCTA CCCTTGTA 218 171 base pairs nucleic acid single linear cDNA Homo sapiens 122 TAGGGGTGTA TGCAACTGTA AGGACAAAAA TTGAGACTCA ACTGGCTTAA CCAATAAAGG 60 CATTTGTTAG CTCATGGAAC AGGAAGTCGG ATGGTGGGGC ATCTTCAGTG CTGCATGAGT 120 CACCACCCCG GCGGGGTCAT CTGTGCCACA GGTCCCTGTT GACAGTGCGG T 171 76 base pairs nucleic acid single linear cDNA Homo sapiens 123 TGTAGCGTGA AGACNACAGA ATGGTGTGTG CTGTGCTATC CAGGAACACA TTTATTATCA 60 TTATCAANTA TTGTGT 76 131 base pairs nucleic acid single linear cDNA Homo sapiens 124 ACCTTTCCCC AAGGCCAATG TCCTGTGTGC TAACTGGCCG GCTGCAGGAC AGCTGCAATT 60 CAATGTGCTG GGTCATATGG AGGGGAGGAG ACTCTAAAAT AGCCAATTTT ATTCTCTTGG 120 TTAAGATTTG T 131 432 base pairs nucleic acid single linear cDNA Homo sapiens 125 ACTTTATCTA CTGGCTATGA AATAGATGGT GGAAAATTGC GTTACCAACT ATACCACTGG 60 CTTGAAAAAG AGGTGATAGC TCTTCAGAGG ACTTGTGACT TTTGCTCAGA TGCTGAAGAA 120 CTACAGTCTG CATTTGGCAG AAATGAAGAT GAATTTGGAT TAAATGAGGA TGCTGAAGAT 180 TTGCCTCACC AAACAAAAGT GAAACAACTG AGAGAAAATT TTCAGGAAAA AAGACAGTGG 240 CTCTTGAAGT ATCAGTCACT TTTGAGAATG TTTCTTAGTT ACTGCATACT TCATGGATCC 300 CATGGTGGGG GTCTTGCATC TGTAAGAATG GAATTGATTT TGCTTTTGCA AGAATCTCAG 360 CAGGAAACAT CAGAACCACT ATTTTCTAGC CCTCTGTCAG AGCAAACCTC AGTGCCTCTC 420 CTCTTTGCTT GT 432 112 base pairs nucleic acid single linear cDNA Homo sapiens 126 ACACAACTTG AATAGTAAAA TAGAAACTGA GCTGAAATTT CTAATTCACT TTCTAACCAT 60 AGTAAGAATG ATATTTCCCC CCAGGGATCA CCAAATATTT ATAAAAATTT GT 112 54 base pairs nucleic acid single linear cDNA Homo sapiens 127 ACCACGAAAC CACAAACAAG ATGGAAGCAT CAATCCACTT GCCAAGCACA GCAG 54 323 base pairs nucleic acid single linear cDNA Homo sapiens 128 ACCTCATTAG TAATTGTTTT GTTGTTTCAT TTTTTTCTAA TGTCTCCCCT CTACCAGCTC 60 ACCTGAGATA ACAGAATGAA AATGGAAGGA CAGCCAGATT TCTCCTTTGC TCTCTGCTCA 120 TTCTCTCTGA AGTCTAGGTT ACCCATTTTG GGGACCCATT ATAGGCAATA AACACAGTTC 180 CCAAAGCATT TGGACAGTTT CTTGTTGTGT TTTAGAATGG TTTTCCTTTT TCTTAGCCTT 240 TTCCTGCAAA AGGCTCACTC AGTCCCTTGC TTGCTCAGTG GACTGGGCTC CCCAGGGCCT 300 AGGCTGCCTT CTTTTCCATG TCC 323 192 base pairs nucleic acid single linear cDNA Homo sapiens 129 ACATACATGT GTGTATATTT TTAAATATCA CTTTTGTATC ACTCTGACTT TTTAGCATAC 60 TGAAAACACA CTAACATAAT TTNTGTGAAC CATGATCAGA TACAACCCAA ATCATTCATC 120 TAGCACATTC ATCTGTGATA NAAAGATAGG TGAGTTTCAT TTCCTTCACG TTGGCCAATG 180 GATAAACAAA GT 192 362 base pairs nucleic acid single linear cDNA Homo sapiens 130 CCCTTTTTTA TGGAATGAGT AGACTGTATG TTTGAANATT TANCCACAAC CTCTTTGACA 60 TATAATGACG CAACAAAAAG GTGCTGTTTA GTCCTATGGT TCAGTTTATG CCCCTGACAA 120 GTTTCCATTG TGTTTTGCCG ATCTTCTGGC TAATCGTGGT ATCCTCCATG TTATTAGTAA 180 TTCTGTATTC CATTTTGTTA ACGCCTGGTA GATGTAACCT GCTANGAGGC TAACTTTATA 240 CTTATTTAAA AGCTCTTATT TTGTGGTCAT TAAAATGGCA ATTTATGTGC AGCACTTTAT 300 TGCAGCAGGA AGCACGTGTG GGTTGGTTGT AAAGCTCTTT GCTAATCTTA AAAAGTAATG 360 GG 362 332 base pairs nucleic acid single linear cDNA Homo sapiens 131 CTTTTTGAAA GATCGTGTCC ACTCCTGTGG ACATCTTGTT TTAATGGAGT TTCCCATGCA 60 GTANGACTGG TATGGTTGCA GCTGTCCAGA TAAAAACATT TGAAGAGCTC CAAAATGAGA 120 GTTCTCCCAG GTTCGCCCTG CTGCTCCAAG TCTCAGCAGC AGCCTCTTTT AGGAGGCATC 180 TTCTGAACTA GATTAAGGCA GCTTGTAAAT CTGATGTGAT TTGGTTTATT ATCCAACTAA 240 CTTCCATCTG TTATCACTGG AGAAAGCCCA GACTCCCCAN GACNGGTACG GATTGTGGGC 300 ATANAAGGAT TGGGTGAAGC TGGCGTTGTG GT 332 322 base pairs nucleic acid single linear cDNA Homo sapiens 132 ACTTTTGCCA TTTTGTATAT ATAAACAATC TTGGGACATT CTCCTGAAAA CTAGGTGTCC 60 AGTGGCTAAG AGAACTCGAT TTCAAGCAAT TCTGAAAGGA AAACCAGCAT GACACAGAAT 120 CTCAAATTCC CAAACAGGGG CTCTGTGGGA AAAATGAGGG AGGACCTTTG TATCTCGGGT 180 TTTAGCAAGT TAAAATGAAN ATGACAGGAA AGGCTTATTT ATCAACAAAG AGAAGAGTTG 240 GGATGCTTCT AAAAAAAACT TTGGTAGAGA AAATAGGAAT GCTNAATCCT AGGGAAGCCT 300 GTAACAATCT ACAATTGGTC CA 322 278 base pairs nucleic acid single linear cDNA Homo sapiens 133 ACAAGCCTTC ACAAGTTTAA CTAAATTGGG ATTAATCTTT CTGTANTTAT CTGCATAATT 60 CTTGTTTTTC TTTCCATCTG GCTCCTGGGT TGACAATTTG TGGAAACAAC TCTATTGCTA 120 CTATTTAAAA AAAATCACAA ATCTTTCCCT TTAAGCTATG TTNAATTCAA ACTATTCCTG 180 CTATTCCTGT TTTGTCAAAG AAATTATATT TTTCAAAATA TGTNTATTTG TTTGATGGGT 240 CCCACGAAAC ACTAATAAAA ACCACAGAGA CCAGCCTG 278 121 base pairs nucleic acid single linear cDNA Homo sapiens 134 GTTTANAAAA CTTGTTTAGC TCCATAGAGG AAAGAATGTT AAACTTTGTA TTTTAAAACA 60 TGATTCTCTG AGGTTAAACT TGGTTTTCAA ATGTTATTTT TACTTGTATT TTGCTTTTGG 120 T 121 350 base pairs nucleic acid single linear cDNA Homo sapiens 135 ACTTANAACC ATGCCTAGCA CATCAGAATC CCTCAAAGAA CATCAGTATA ATCCTATACC 60 ATANCAAGTG GTGACTGGTT AAGCGTGCGA CAAAGGTCAG CTGGCACATT ACTTGTGTGC 120 AAACTTGATA CTTTTGTTCT AAGTAGGAAC TAGTATACAG TNCCTAGGAN TGGTACTCCA 180 GGGTGCCCCC CAACTCCTGC AGCCGCTCCT CTGTGCCAGN CCCTGNAAGG AACTTTCGCT 240 CCACCTCAAT CAAGCCCTGG GCCATGCTAC CTGCAATTGG CTGAACAAAC GTTTGCTGAG 300 TTCCCAAGGA TGCAAAGCCT GGTGCTCAAC TCCTGGGGCG TCAACTCAGT 350 399 base pairs nucleic acid single linear cDNA Homo sapiens 136 TGTACCGTGA AGACGACAGA AGTTGCATGG CAGGGACAGG GCAGGGCCGA GGCCAGGGTT 60 GCTGTGATTG TATCCGAATA NTCCTCGTGA GAAAAGATAA TGAGATGACG TGAGCAGCCT 120 GCAGACTTGT GTCTGCCTTC AANAAGCCAG ACAGGAAGGC CCTGCCTGCC TTGGCTCTGA 180 CCTGGCGGCC AGCCAGCCAG CCACAGGTGG GCTTCTTCCT TTTGTGGTGA CAACNCCAAG 240 AAAACTGCAG AGGCCCAGGG TCAGGTGTNA GTGGGTANGT GACCATAAAA CACCAGGTGC 300 TCCCAGGAAC CCGGGCAAAG GCCATCCCCA CCTACAGCCA GCATGCCCAC TGGCGTGATG 360 GGTGCAGANG GATGAAGCAG CCAGNTGTTC TGCTGTGGT 399 165 base pairs nucleic acid single linear cDNA Homo sapiens 137 ACTGGTGTGG TNGGGGGTGA TGCTGGTGGT ANAAGTTGAN GTGACTTCAN GATGGTGTGT 60 GGAGGAAGTG TGTGAACGTA GGGATGTAGA NGTTTTGGCC GTGCTAAATG AGCTTCGGGA 120 TTGGCTGGTC CCACTGGTGG TCACTGTCAT TGGTGGGGTT CCTGT 165 338 base pairs nucleic acid single linear cDNA Homo sapiens 138 ACTCACTGGA ATGCCACATT CACAACAGAA TCAGAGGTCT GTGAAAACAT TAATGGCTCC 60 TTAACTTCTC CAGTAAGAAT CAGGGACTTG AAATGGAAAC GTTAACAGCC ACATGCCCAA 120 TGCTGGGCAG TCTCCCATGC CTTCCACAGT GAAAGGGCTT GAGAAAAATC ACATCCAATG 180 TCATGTGTTT CCAGCCACAC CAAAAGGTGC TTGGGGTGGA GGGCTGGGGG CATANANGGT 240 CANGCCTCAG GAAGCCTCAA GTTCCATTCA GCTTTGCCAC TGTACATTCC CCATNTTTAA 300 AAAAACTGAT GCCTTTTTTT TTTTTTTTTG TAAAATTC 338 382 base pairs nucleic acid single linear cDNA Homo sapiens 139 GGGAATCTTG GTTTTTGGCA TCTGGTTTGC CTATAGCCGA GGCCACTTTG ACAGAACAAA 60 GAAAGGGACT TCGAGTAAGA AGGTGATTTA CAGCCAGCCT AGTGCCCGAA GTGAAGGAGA 120 ATTCAAACAG ACCTCGTCAT TCCTGGTGTG AGCCTGGTCG GCTCACCGCC TATCATCTGC 180 ATTTGCCTTA CTCAGGTGCT ACCGGACTCT GGCCCCTGAT GTCTGTAGTT TCACAGGATG 240 CCTTATTTGT CTTCTACACC CCACAGGGCC CCCTACTTCT TCGGATGTGT TTTTAATAAT 300 GTCAGCTATG TGCCCCATCC TCCTTCATGC CCTCCCTCCC TTTCCTACCA CTGCTGAGTG 360 GCCTGGAACT TGTTTAAAGT GT 382 200 base pairs nucleic acid single linear cDNA Homo sapiens 140 ACCAAANCTT CTTTCTGTTG TGTTNGATTT TACTATAGGG GTTTNGCTTN TTCTAAANAT 60 ACTTTTCATT TAACANCTTT TGTTAAGTGT CAGGCTGCAC TTTGCTCCAT ANAATTATTG 120 TTTTCACATT TCAACTTGTA TGTGTTTGTC TCTTANAGCA TTGGTGAAAT CACATATTTT 180 ATATTCAGCA TAAAGGAGAA 200 335 base pairs nucleic acid single linear cDNA Homo sapiens 141 ACTTTATTTT CAAAACACTC ATATGTTGCA AAAAACACAT AGAAAAATAA AGTTTGGTGG 60 GGGTGCTGAC TAAACTTCAA GTCACAGACT TTTATGTGAC AGATTGGAGC AGGGTTTGTT 120 ATGCATGTAG AGAACCCAAA CTAATTTATT AAACAGGATA GAAACAGGCT GTCTGGGTGA 180 AATGGTTCTG AGAACCATCC AATTCACCTG TCAGATGCTG ATANACTAGC TCTTCAGATG 240 TTTTTCTACC AGTTCAGAGA TNGGTTAATG ACTANTTCCA ATGGGGAAAA AGCAAGATGG 300 ATTCACAAAC CAAGTAATTT TAAACAAAGA CACTT 335 459 base pairs nucleic acid single linear cDNA Homo sapiens 142 ACCAGGTTAA TATTGCCACA TATATCCTTT CCAATTGCGG GCTAAACAGA CGTGTATTTA 60 GGGTTGTTTA AAGACAACCC AGCTTAATAT CAAGAGAAAT TGTGACCTTT CATGGAGTAT 120 CTGATGGAGA AAACACTGAG TTTTGACAAA TCTTATTTTA TTCAGATAGC AGTCTGATCA 180 CACATGGTCC AACAACACTC AAATAATAAA TCAAATATNA TCAGATGTTA AAGATTGGTC 240 TTCAAACATC ATAGCCAATG ATGCCCCGCT TGCCTATAAT CTCTCCGACA TAAAACCACA 300 TCAACACCTC AGTGGCCACC AAACCATTCA GCACAGCTTC CTTAACTGTG AGCTGTTTGA 360 AGCTACCAGT CTGAGCACTA TTGACTATNT TTTTCANGCT CTGAATAGCT CTAGGGATCT 420 CAGCANGGGT GGGAGGAACC AGCTCAACCT TGGCGTANT 459 140 base pairs nucleic acid single linear cDNA Homo sapiens 143 ACATTTCCTT CCACCAAGTC AGGACTCCTG GCTTCTGTGG GAGTTCTTAT CACCTGAGGG 60 AAATCCAAAC AGTCTCTCCT AGAAAGGAAT AGTGTCACCA ACCCCACCCA TCTCCCTGAG 120 ACCATCCGAC TTCCCTGTGT 140 164 base pairs nucleic acid single linear cDNA Homo sapiens 144 ACTTCAGTAA CAACATACAA TAACAACATT AAGTGTATAT TGCCATCTTT GTCATTTTCT 60 ATCTATACCA CTCTCCCTTC TGAAAACAAN AATCACTANC CAATCACTTA TACAAATTTG 120 AGGCAATTAA TCCATATTTG TTTTCAATAA GGAAAAAAAG ATGT 164 303 base pairs nucleic acid single linear cDNA Homo sapiens 145 ACGTAGACCA TCCAACTTTG TATTTGTAAT GGCAAACATC CAGNAGCAAT TCCTAAACAA 60 ACTGGAGGGT ATTTATACCC AATTATCCCA TTCATTAACA TGCCCTCCTC CTCAGGCTAT 120 GCAGGACAGC TATCATAAGT CGGCCCAGGC ATCCAGATAC TACCATTTGT ATAAACTTCA 180 GTAGGGGAGT CCATCCAAGT GACAGGTCTA ATCAAAGGAG GAAATGGAAC ATAAGCCCAG 240 TAGTAAAATN TTGCTTAGCT GAAACAGCCA CAAAAGACTT ACCGCCGTGG TGATTACCAT 300 CAA 303 327 base pairs nucleic acid single linear cDNA Homo sapiens 146 ACTGCAGCTC AATTAGAAGT GGTCTCTGAC TTTCATCANC TTCTCCCTGG GCTCCATGAC 60 ACTGGCCTGG AGTGACTCAT TGCTCTGGTT GGTTGAGAGA GCTCCTTTGC CAACAGGCCT 120 CCAAGTCAGG GCTGGGATTT GTTTCCTTTC CACATTCTAG CAACAATATG CTGGCCACTT 180 CCTGAACAGG GAGGGTGGGA GGAGCCAGCA TGGAACAAGC TGCCACTTTC TAAAGTAGCC 240 AGACTTGCCC CTGGGCCTGT CACACCTACT GATGACCTTC TGTGCCTGCA GGATGGAATG 300 TAGGGGTGAG CTGTGTGACT CTATGGT 327 173 base pairs nucleic acid single linear cDNA Homo sapiens 147 ACATTGTTTT TTTGAGATAA AGCATTGANA GAGCTCTCCT TAACGTGACA CAATGGAAGG 60 ACTGGAACAC ATACCCACAT CTTTGTTCTG AGGGATAATT TTCTGATAAA GTCTTGCTGT 120 ATATTCAAGC ACATATGTTA TATATTATTC AGTTCCATGT TTATAGCCTA GTT 173 477 base pairs nucleic acid single linear cDNA Homo sapiens 148 ACAACCACTT TATCTCATCG AATTTTTAAC CCAAACTCAC TCACTGTGCC TTTCTATCCT 60 ATGGGATATA TTATTTGATG CTCCATTTCA TCACACATAT ATGAATAATA CACTCATACT 120 GCCCTACTAC CTGCTGCAAT AATCACATTC CCTTCCTGTC CTGACCCTGA AGCCATTGGG 180 GTGGTCCTAG TGGCCATCAG TCCANGCCTG CACCTTGAGC CCTTGAGCTC CATTGCTCAC 240 NCCANCCCAC CTCACCGACC CCATCCTCTT ACACAGCTAC CTCCTTGCTC TCTAACCCCA 300 TAGATTATNT CCAAATTCAG TCAATTAAGT TACTATTAAC ACTCTACCCG ACATGTCCAG 360 CACCACTGGT AAGCCTTCTC CAGCCAACAC ACACACACAC ACACNCACAC ACACACATAT 420 CCAGGCACAG GCTACCTCAT CTTCACAATC ACCCCTTTAA TTACCATGCT ATGGTGG 477 207 base pairs nucleic acid single linear cDNA Homo sapiens 149 ACAGTTGTAT TATAATATCA AGAAATAAAC TTGCAATGAG AGCATTTAAG AGGGAAGAAC 60 TAACGTATTT TAGAGAGCCA AGGAAGGTTT CTGTGGGGAG TGGGATGTAA GGTGGGGCCT 120 GATGATAAAT AAGAGTCAGC CAGGTAAGTG GGTGGTGTGG TATGGGCACA GTGAAGAACA 180 TTTCAGGCAG AGGGAACAGC AGTGAAA 207 111 base pairs nucleic acid single linear cDNA Homo sapiens 150 ACCTTGATTT CATTGCTGCT CTGATGGAAA CCCAACTATC TAATTTAGCT AAAACATGGG 60 CACTTAAATG TGGTCAGTGT TTGGACTTGT TAACTANTGG CATCTTTGGG T 111 196 base pairs nucleic acid single linear cDNA Homo sapiens 151 AGCGCGGCAG GTCATATTGA ACATTCCAGA TACCTATCAT TACTCGATGC TGTTGATAAC 60 AGCAAGATGG CTTTGAACTC AGGGTCACCA CCAGCTATTG GACCTTACTA TGAAAACCAT 120 GGATACCAAC CGGAAAACCC CTATCCCGCA CAGCCCACTG TGGTCCCCAC TGTCTACGAG 180 GTGCATCCGG CTCAGT 196 132 base pairs nucleic acid single linear cDNA Homo sapiens 152 ACAGCACTTT CACATGTAAG AAGGGAGAAA TTCCTAAATG TAGGAGAAAG ATAACAGAAC 60 CTTCCCCTTT TCATCTAGTG GTGGAAACCT GATGCTTTAT GTTGACAGGA ATAGAACCAG 120 GAGGGAGTTT GT 132 285 base pairs nucleic acid single linear cDNA Homo sapiens 153 ACAANACCCA NGANAGGCCA CTGGCCGTGG TGTCATGGCC TCCAAACATG AAAGTGTCAG 60 CTTCTGCTCT TATGTCCTCA TCTGACAACT CTTTACCATT TTTATCCTCG CTCAGCAGGA 120 GCACATCAAT AAAGTCCAAA GTCTTGGACT TGGCCTTGGC TTGGAGGAAG TCATCAACAC 180 CCTGGCTAGT GAGGGTGCGG CGCCGCTCCT GGATGACGGC ATCTGTGAAG TCGTGCACCA 240 GTCTGCAGGC CCTGTGGAAG CGCCGTCCAC ACGGAGTNAG GAATT 285 333 base pairs nucleic acid single linear cDNA Homo sapiens 154 ACCACAGTCC TGTTGGGCCA GGGCTTCATG ACCCTTTCTG TGAAAAGCCA TATTATCACC 60 ACCCCAAATT TTTCCTTAAA TATCTTTAAC TGAAGGGGTC AGCCTCTTGA CTGCAAAGAC 120 CCTAAGCCGG TTACACAGCT AACTCCCACT GGCCCTGATT TGTGAAATTG CTGCTGCCTG 180 ATTGGCACAG GAGTCGAAGG TGTTCAGCTC CCCTCCTCCG TGGAACGAGA CTCTGATTTG 240 AGTTTCACAA ATTCTCGGGC CACCTCGTCA TTGCTCCTCT GAAATAAAAT CCGGAGAATG 300 GTCAGGCCTG TCTCATCCAT ATGGATCTTC CGG 333 308 base pairs nucleic acid single linear cDNA Homo sapiens 155 ACTGGAAATA ATAAAACCCA CATCACAGTG TTGTGTCAAA GATCATCAGG GCATGGATGG 60 GAAAGTGCTT TGGGAACTGT AAAGTGCCTA ACACATGATC GATGATTTTT GTTATAATAT 120 TTGAATCACG GTGCATACAA ACTCTCCTGC CTGCTCCTCC TGGGCCCCAG CCCCAGCCCC 180 ATCACAGCTC ACTGCTCTGT TCATCCAGGC CCAGCATGTA GTGGCTGATT CTTCTTGGCT 240 GCTTTTAGCC TCCANAAGTT TCTCTGAAGC CAACCAAACC TCTANGTGTA AGGCATGCTG 300 GCCCTGGT 308 295 base pairs nucleic acid single linear cDNA Homo sapiens 156 ACCTTGCTCG GTGCTTGGAA CATATTAGGA ACTCAAAATA TGAGATGATA ACAGTGCCTA 60 TTATTGATTA CTGAGAGAAC TGTTAGACAT TTAGTTGAAG ATTTTCTACA CAGGAACTGA 120 GAATAGGAGA TTATGTTTGG CCCTCATATT CTCTCCTATC CTCCTTGCCT CATTCTATGT 180 CTAATATATT CTCAATCAAA TAAGGTTAGC ATAATCAGGA AATCGACCAA ATACCAATAT 240 AAAACCAGAT GTCTATCCTT AAGATTTTCA AATAGAAAAC AAATTAACAG ACTAT 295 126 base pairs nucleic acid single linear cDNA Homo sapiens 157 ACAAGTTTAA ATAGTGCTGT CACTGTGCAT GTGCTGAAAT GTGAAATCCA CCACATTTCT 60 GAAGAGCAAA ACAAATTCTG TCATGTAATC TCTATCTTGG GTCGTGGGTA TATCTGTCCC 120 CTTAGT 126 442 base pairs nucleic acid single linear cDNA Homo sapiens 158 ACCCACTGGT CTTGGAAACA CCCATCCTTA ATACGATGAT TTTTCTGTCG TGTGAAAATG 60 AANCCAGCAG GCTGCCCCTA GTCAGTCCTT CCTTCCAGAG AAAAAGAGAT TTGAGAAAGT 120 GCCTGGGTAA TTCACCATTA ATTTCCTCCC CCAAACTCTC TGAGTCTTCC CTTAATATTT 180 CTGGTGGTTC TGACCAAAGC AGGTCATGGT TTGTTGAGCA TTTGGGATCC CAGTGAAGTA 240 NATGTTTGTA GCCTTGCATA CTTAGCCCTT CCCACGCACA AACGGAGTGG CAGAGTGGTG 300 CCAACCCTGT TTTCCCAGTC CACGTAGACA GATTCACAGT GCGGAATTCT GGAAGCTGGA 360 NACAGACGGG CTCTTTGCAG AGCCGGGACT CTGAGANGGA CATGAGGGCC TCTGCCTCTG 420 TGTTCATTCT CTGATGTCCT GT 442 498 base pairs nucleic acid single linear cDNA Homo sapiens 159 ACTTCCAGGT AACGTTGTTG TTTCCGTTGA GCCTGAACTG ATGGGTGACG TTGTAGGTTC 60 TCCAACAAGA ACTGAGGTTG CAGAGCGGGT AGGGAAGAGT GCTGTTCCAG TTGCACCTGG 120 GCTGCTGTGG ACTGTTGTTG ATTCCTCACT ACGGCCCAAG GTTGTGGAAC TGGCANAAAG 180 GTGTGTTGTT GGANTTGAGC TCGGGCGGCT GTGGTAGGTT GTGGGCTCTT CAACAGGGGC 240 TGCTGTGGTG CCGGGANGTG AANGTGTTGT GTCACTTGAG CTTGGCCAGC TCTGGAAAGT 300 ANTANATTCT TCCTGAAGGC CAGCGCTTGT GGAGCTGGCA NGGGTCANTG TTGTGTGTAA 360 CGAACCAGTG CTGCTGTGGG TGGGTGTANA TCCTCCACAA AGCCTGAAGT TATGGTGTCN 420 TCAGGTAANA ATGTGGTTTC AGTGTCCCTG GGCNGCTGTG GAAGGTTGTA NATTGTCACC 480 AAGGGAATAA GCTGTGGT 498 380 base pairs nucleic acid single linear cDNA Homo sapiens 160 ACCTGCATCC AGCTTCCCTG CCAAACTCAC AAGGAGACAT CAACCTCTAG ACAGGGAAAC 60 AGCTTCAGGA TACTTCCAGG AGACAGAGCC ACCAGCAGCA AAACAAATAT TCCCATGCCT 120 GGAGCATGGC ATAGAGGAAG CTGANAAATG TGGGGTCTGA GGAAGCCATT TGAGTCTGGC 180 CACTAGACAT CTCATCAGCC ACTTGTGTGA AGAGATGCCC CATGACCCCA GATGCCTCTC 240 CCACCCTTAC CTCCATCTCA CACACTTGAG CTTTCCACTC TGTATAATTC TAACATCCTG 300 GAGAAAAATG GCAGTTTGAC CGAACCTGTT CACAACGGTA GAGGCTGATT TCTAACGAAA 360 CTTGTAGAAT GAAGCCTGGA 380 114 base pairs nucleic acid single linear cDNA Homo sapiens 161 ACTCCACATC CCCTCTGAGC AGGCGGTTGT CGTTCAAGGT GTATTTGGCC TTGCCTGTCA 60 CACTGTCCAC TGGCCCCTTA TCCACTTGGT GCTTAATCCC TCGAAAGAGC ATGT 114 177 base pairs nucleic acid single linear cDNA Homo sapiens 162 ACTTTCTGAA TCGAATCAAA TGATACTTAG TGTAGTTTTA ATATCCTCAT ATATATCAAA 60 GTTTTACTAC TCTGATAATT TTGTAAACCA GGTAACCAGA ACATCCAGTC ATACAGCTTT 120 TGGTGATATA TAACTTGGCA ATAACCCAGT CTGGTGATAC ATAAAACTAC TCACTGT 177 137 base pairs nucleic acid single linear cDNA Homo sapiens 163 CATTTATACA GACAGGCGTG AAGACATTCA CGACAAAAAC GCGAAATTCT ATCCCGTGAC 60 CANAGAAGGC AGCTACGGCT ACTCCTACAT CCTGGCGTGG GTGGCCTTCG CCTGCACCTT 120 CATCAGCGGC ATGATGT 137 469 base pairs nucleic acid single linear cDNA Homo sapiens 164 CTTATCACAA TGAATGTTCT CCTGGGCAGC GTTGTGATCT TTGCCACCTT CGTGACTTTA 60 TGCAATGCAT CATGCTATTT CATACCTAAT GAGGGAGTTC CAGGAGATTC AACCAGGAAA 120 TGCATGGATC TCAAAGGAAA CAAACACCCA ATAAACTCGG AGTGGCAGAC TGACAACTGT 180 GAGACATGCA CTTGCTACGA AACAGAAATT TCATGTTGCA CCCTTGTTTC TACACCTGTG 240 GGTTATGACA AAGACAACTG CCAAAGAATC TTCAAGAAGG AGGACTGCAA GTATATCGTG 300 GTGGAGAAGA AGGACCCAAA AAAGACCTGT TCTGTCAGTG AATGGATAAT CTAATGTGCT 360 TCTAGTAGGC ACAGGGCTCC CAGGCCAGGC CTCATTCTCC TCTGGCCTCT AATAGTCAAT 420 GATTGTGTAG CCATGCCTAT CAGTAAAAAG ATNTTTGAGC AAACACTTT 469 195 base pairs nucleic acid single linear cDNA Homo sapiens 165 ACAGTTTTTT ATANATATCG ACATTGCCGG CACTTGTGTT CAGTTTCATA AAGCTGGTGG 60 ATCCGCTGTC ATCCACTATT CCTTGGCTAG AGTAAAAATT ATTCTTATAG CCCATGTCCC 120 TGCAGGCCGC CCGCCCGTAG TTCTCGTTCC AGTCGTCTTG GCACACAGGG TGCCAGGACT 180 TCCTCTGAGA TGAGT 195 383 base pairs nucleic acid single linear cDNA Homo sapiens 166 ACATCTTAGT AGTGTGGCAC ATCAGGGGGC CATCAGGGTC ACAGTCACTC ATAGCCTCGC 60 CGAGGTCGGA GTCCACACCA CCGGTGTAGG TGTGCTCAAT CTTGGGCTTG GCGCCCACCT 120 TTGGAGAAGG GATATGCTGC ACACACATGT CCACAAAGCC TGTGAACTCG CCAAAGAATT 180 TTTGCAGACC AGCCTGAGCA AGGGGCGGAT GTTCAGCTTC AGCTCCTCCT TCGTCAGGTG 240 GATGCCAACC TCGTCTANGG TCCGTGGGAA GCTGGTGTCC ACNTCACCTA CAACCTGGGC 300 GANGATCTTA TAAAGAGGCT CCNAGATAAA CTCCACGAAA CTTCTCTGGG AGCTGCTAGT 360 NGGGGCCTTT TTGGTGAACT TTC 383 247 base pairs nucleic acid single linear cDNA Homo sapiens 167 ACAGAGCCAG ACCTTGGCCA TAAATGAANC AGAGATTAAG ACTAAACCCC AAGTCGANAT 60 TGGAGCAGAA ACTGGAGCAA GAAGTGGGCC TGGGGCTGAA GTAGAGACCA AGGCCACTGC 120 TATANCCATA CACAGAGCCA ACTCTCAGGC CAAGGCNATG GTTGGGGCAG ANCCAGAGAC 180 TCAATCTGAN TCCAAAGTGG TGGCTGGAAC ACTGGTCATG ACANAGGCAG TGACTCTGAC 240 TGANGTC 247 273 base pairs nucleic acid single linear cDNA Homo sapiens 168 ACTTCTAAGT TTTCTAGAAG TGGAAGGATT GTANTCATCC TGAAAATGGG TTTACTTCAA 60 AATCCCTCAN CCTTGTTCTT CACNACTGTC TATACTGANA GTGTCATGTT TCCACAAAGG 120 GCTGACACCT GAGCCTGNAT TTTCACTCAT CCCTGAGAAG CCCTTTCCAG TAGGGTGGGC 180 AATTCCCAAC TTCCTTGCCA CAAGCTTCCC AGGCTTTCTC CCCTGGAAAA CTCCAGCTTG 240 AGTCCCAGAT ACACTCATGG GCTGCCCTGG GCA 273 431 base pairs nucleic acid single linear cDNA Homo sapiens 169 ACAGCCTTGG CTTCCCCAAA CTCCACAGTC TCAGTGCAGA AAGATCATCT TCCAGCAGTC 60 AGCTCAGACC AGGGTCAAAG GATGTGACAT CAACAGTTTC TGGTTTCAGA ACAGGTTCTA 120 CTACTGTCAA ATGACCCCCC ATACTTCCTC AAAGGCTGTG GTAAGTTTTG CACAGGTGAG 180 GGCAGCAGAA AGGGGGTANT TACTGATGGA CACCATCTTC TCTGTATACT CCACACTGAC 240 CTTGCCATGG GCAAAGGCCC CTACCACAAA AACAATAGGA TCACTGCTGG GCACCAGCTC 300 ACGCACATCA CTGACAACCG GGATGGAAAA AGAANTGCCA ACTTTCATAC ATCCAACTGG 360 AAAGTGATCT GATACTGGAT TCTTAATTAC CTTCAAAAGC TTCTGGGGGC CATCAGCTGC 420 TCGAACACTG A 431 266 base pairs nucleic acid single linear cDNA Homo sapiens 170 ACCTGTGGGC TGGGCTGTTA TGCCTGTGCC GGCTGCTGAA AGGGAGTTCA GAGGTGGAGC 60 TCAAGGAGCT CTGCAGGCAT TTTGCCAANC CTCTCCANAG CANAGGGAGC AACCTACACT 120 CCCCGCTAGA AAGACACCAG ATTGGAGTCC TGGGAGGGGG AGTTGGGGTG GGCATTTGAT 180 GTATACTTGT CACCTGAATG AANGAGCCAG AGAGGAANGA GACGAANATG ANATTGGCCT 240 TCAAAGCTAG GGGTCTGGCA GGTGGA 266 1248 base pairs nucleic acid single linear cDNA Homo sapiens 171 GGCAGCCAAA TCATAAACGG CGAGGACTGC AGCCCGCACT CGCAGCCCTG GCAGGCGGCA 60 CTGGTCATGG AAAACGAATT GTTCTGCTCG GGCGTCCTGG TGCATCCGCA GTGGGTGCTG 120 TCAGCCGCAC ACTGTTTCCA GAAGTGAGTG CAGAGCTCCT ACACCATCGG GCTGGGCCTG 180 CACAGTCTTG AGGCCGACCA AGAGCCAGGG AGCCAGATGG TGGAGGCCAG CCTCTCCGTA 240 CGGCACCCAG AGTACAACAG ACCCTTGCTC GCTAACGACC TCATGCTCAT CAAGTTGGAC 300 GAATCCGTGT CCGAGTCTGA CACCATCCGG AGCATCAGCA TTGCTTCGCA GTGCCCTACC 360 GCGGGGAACT CTTGCCTCGT TTCTGGCTGG GGTCTGCTGG CGAACGGCAG AATGCCTACC 420 GTGCTGCAGT GCGTGAACGT GTCGGTGGTG TCTGAGGAGG TCTGCAGTAA GCTCTATGAC 480 CCGCTGTACC ACCCCAGCAT GTTCTGCGCC GGCGGAGGGC AAGACCAGAA GGACTCCTGC 540 AACGGTGACT CTGGGGGGCC CCTGATCTGC AACGGGTACT TGCAGGGCCT TGTGTCTTTC 600 GGAAAAGCCC CGTGTGGCCA AGTTGGCGTG CCAGGTGTCT ACACCAACCT CTGCAAATTC 660 ACTGAGTGGA TAGAGAAAAC CGTCCAGGCC AGTTAACTCT GGGGACTGGG AACCCATGAA 720 ATTGACCCCC AAATACATCC TGCGGAAGGA ATTCAGGAAT ATCTGTTCCC AGCCCCTCCT 780 CCCTCAGGCC CAGGAGTCCA GGCCCCCAGC CCCTCCTCCC TCAAACCAAG GGTACAGATC 840 CCCAGCCCCT CCTCCCTCAG ACCCAGGAGT CCAGACCCCC CAGCCCCTCC TCCCTCAGAC 900 CCAGGAGTCC AGCCCCTCCT CCCTCAGACC CAGGAGTCCA GACCCCCCAG CCCCTCCTCC 960 CTCAGACCCA GGGGTCCAGG CCCCCAACCC CTCCTCCCTC AGACTCAGAG GTCCAAGCCC 1020 CCAACCCNTC ATTCCCCAGA CCCAGAGGTC CAGGTCCCAG CCCCTCNTCC CTCAGACCCA 1080 GCGGTCCAAT GCCACCTAGA CTNTCCCTGT ACACAGTGCC CCCTTGTGGC ACGTTGACCC 1140 AACCTTACCA GTTGGTTTTT CATTTTTNGT CCCTTTCCCC TAGATCCAGA AATAAAGTTT 1200 AAGAGAAGNG CAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAA 1248 159 amino acids amino acid single linear protein Homo sapiens 172 Met Val Glu Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg Pro 1 5 10 15 Leu Leu Ala Asn Asp Leu Met Leu Ile Lys Leu Asp Glu Ser Val Ser 20 25 30 Glu Ser Asp Thr Ile Arg Ser Ile Ser Ile Ala Ser Gln Cys Pro Thr 35 40 45 Ala Gly Asn Ser Cys Leu Val Ser Gly Trp Gly Leu Leu Ala Asn Gly 50 55 60 Arg Met Pro Thr Val Leu Gln Cys Val Asn Val Ser Val Val Ser Glu 65 70 75 80 Glu Val Cys Ser Lys Leu Tyr Asp Pro Leu Tyr His Pro Ser Met Phe 85 90 95 Cys Ala Gly Gly Gly Gln Xaa Gln Xaa Asp Ser Cys Asn Gly Asp Ser 100 105 110 Gly Gly Pro Leu Ile Cys Asn Gly Tyr Leu Gln Gly Leu Val Ser Phe 115 120 125 Gly Lys Ala Pro Cys Gly Gln Val Gly Val Pro Gly Val Tyr Thr Asn 130 135 140 Leu Cys Lys Phe Thr Glu Trp Ile Glu Lys Thr Val Gln Ala Ser 145 150 155 1265 base pairs nucleic acid single linear cDNA Homo sapiens 173 GGCAGCCCGC ACTCGCAGCC CTGGCAGGCG GCACTGGTCA TGGAAAACGA ATTGTTCTGC 60 TCGGGCGTCC TGGTGCATCC GCAGTGGGTG CTGTCAGCCG CACACTGTTT CCAGAACTCC 120 TACACCATCG GGCTGGGCCT GCACAGTCTT GAGGCCGACC AAGAGCCAGG GAGCCAGATG 180 GTGGAGGCCA GCCTCTCCGT ACGGCACCCA GAGTACAACA GACCCTTGCT CGCTAACGAC 240 CTCATGCTCA TCAAGTTGGA CGAATCCGTG TCCGAGTCTG ACACCATCCG GAGCATCAGC 300 ATTGCTTCGC AGTGCCCTAC CGCGGGGAAC TCTTGCCTCG TTTCTGGCTG GGGTCTGCTG 360 GCGAACGGTG AGCTCACGGG TGTGTGTCTG CCCTCTTCAA GGAGGTCCTC TGCCCAGTCG 420 CGGGGGCTGA CCCAGAGCTC TGCGTCCCAG GCAGAATGCC TACCGTGCTG CAGTGCGTGA 480 ACGTGTCGGT GGTGTCTGAG GAGGTCTGCA GTAAGCTCTA TGACCCGCTG TACCACCCCA 540 GCATGTTCTG CGCCGGCGGA GGGCAAGACC AGAAGGACTC CTGCAACGGT GACTCTGGGG 600 GGCCCCTGAT CTGCAACGGG TACTTGCAGG GCCTTGTGTC TTTCGGAAAA GCCCCGTGTG 660 GCCAAGTTGG CGTGCCAGGT GTCTACACCA ACCTCTGCAA ATTCACTGAG TGGATAGAGA 720 AAACCGTCCA GGCCAGTTAA CTCTGGGGAC TGGGAACCCA TGAAATTGAC CCCCAAATAC 780 ATCCTGCGGA AGGAATTCAG GAATATCTGT TCCCAGCCCC TCCTCCCTCA GGCCCAGGAG 840 TCCAGGCCCC CAGCCCCTCC TCCCTCAAAC CAAGGGTACA GATCCCCAGC CCCTCCTCCC 900 TCAGACCCAG GAGTCCAGAC CCCCCAGCCC CTCCTCCCTC AGACCCAGGA GTCCAGCCCC 960 TCCTCCNTCA GACCCAGGAG TCCAGACCCC CCAGCCCCTC CTCCCTCAGA CCCAGGGGTT 1020 GAGGCCCCCA ACCCCTCCTC CTTCAGAGTC AGAGGTCCAA GCCCCCAACC CCTCGTTCCC 1080 CAGACCCAGA GGTNNAGGTC CCAGCCCCTC TTCCNTCAGA CCCAGNGGTC CAATGCCACC 1140 TAGATTTTCC CTGNACACAG TGCCCCCTTG TGGNANGTTG ACCCAACCTT ACCAGTTGGT 1200 TTTTCATTTT TNGTCCCTTT CCCCTAGATC CAGAAATAAA GTTTAAGAGA NGNGCAAAAA 1260 AAAAA 1265 1459 base pairs nucleic acid single linear cDNA Homo sapiens 174 GGTCAGCCGC ACACTGTTTC CAGAAGTGAG TGCAGAGCTC CTACACCATC GGGCTGGGCC 60 TGCACAGTCT TGAGGCCGAC CAAGAGCCAG GGAGCCAGAT GGTGGAGGCC AGCCTCTCCG 120 TACGGCACCC AGAGTACAAC AGACCCTTGC TCGCTAACGA CCTCATGCTC ATCAAGTTGG 180 ACGAATCCGT GTCCGAGTCT GACACCATCC GGAGCATCAG CATTGCTTCG CAGTGCCCTA 240 CCGCGGGGAA CTCTTGCCTC GTTTCTGGCT GGGGTCTGCT GGCGAACGGT GAGCTCACGG 300 GTGTGTGTCT GCCCTCTTCA AGGAGGTCCT CTGCCCAGTC GCGGGGGCTG ACCCAGAGCT 360 CTGCGTCCCA GGCAGAATGC CTACCGTGCT GCAGTGCGTG AACGTGTCGG TGGTGTCTGA 420 NGAGGTCTGC ANTAAGCTCT ATGACCCGCT GTACCACCCC ANCATGTTCT GCGCCGGCGG 480 AGGGCAAGAC CAGAAGGACT CCTGCAACGT GAGAGAGGGG AAAGGGGAGG GCAGGCGACT 540 CAGGGAAGGG TGGAGAAGGG GGAGACAGAG ACACACAGGG CCGCATGGCG AGATGCAGAG 600 ATGGAGAGAC ACACAGGGAG ACAGTGACAA CTAGAGAGAG AAACTGAGAG AAACAGAGAA 660 ATAAACACAG GAATAAAGAG AAGCAAAGGA AGAGAGAAAC AGAAACAGAC ATGGGGAGGC 720 AGAAACACAC ACACATAGAA ATGCAGTTGA CCTTCCAACA GCATGGGGCC TGAGGGCGGT 780 GACCTCCACC CAATAGAAAA TCCTCTTATA ACTTTTGACT CCCCAAAAAC CTGACTAGAA 840 ATAGCCTACT GTTGACGGGG AGCCTTACCA ATAACATAAA TAGTCGATTT ATGCATACGT 900 TTTATGCATT CATGATATAC CTTTGTTGGA ATTTTTTGAT ATTTCTAAGC TACACAGTTC 960 GTCTGTGAAT TTTTTTAAAT TGTTGCAACT CTCCTAAAAT TTTTCTGATG TGTTTATTGA 1020 AAAAATCCAA GTATAAGTGG ACTTGTGCAT TCAAACCAGG GTTGTTCAAG GGTCAACTGT 1080 GTACCCAGAG GGAAACAGTG ACACAGATTC ATAGAGGTGA AACACGAAGA GAAACAGGAA 1140 AAATCAAGAC TCTACAAAGA GGCTGGGCAG GGTGGCTCAT GCCTGTAATC CCAGCACTTT 1200 GGGAGGCGAG GCAGGCAGAT CACTTGAGGT AAGGAGTTCA AGACCAGCCT GGCCAAAATG 1260 GTGAAATCCT GTCTGTACTA AAAATACAAA AGTTAGCTGG ATATGGTGGC AGGCGCCTGT 1320 AATCCCAGCT ACTTGGGAGG CTGAGGCAGG AGAATTGCTT GAATATGGGA GGCAGAGGTT 1380 GAAGTGAGTT GAGATCACAC CACTATACTC CAGCTGGGGC AACAGAGTAA GACTCTGTCT 1440 CAAAAAAAAA AAAAAAAAA 1459 1167 base pairs nucleic acid single linear cDNA Homo sapiens 175 GCGCAGCCCT GGCAGGCGGC ACTGGTCATG GAAAACGAAT TGTTCTGCTC GGGCGTCCTG 60 GTGCATCCGC AGTGGGTGCT GTCAGCCGCA CACTGTTTCC AGAACTCCTA CACCATCGGG 120 CTGGGCCTGC ACAGTCTTGA GGCCGACCAA GAGCCAGGGA GCCAGATGGT GGAGGCCAGC 180 CTCTCCGTAC GGCACCCAGA GTACAACAGA CTCTTGCTCG CTAACGACCT CATGCTCATC 240 AAGTTGGACG AATCCGTGTC CGAGTCTGAC ACCATCCGGA GCATCAGCAT TGCTTCGCAG 300 TGCCCTACCG CGGGGAACTC TTGCCTCGTN TCTGGCTGGG GTCTGCTGGC GAACGGCAGA 360 ATGCCTACCG TGCTGCACTG CGTGAACGTG TCGGTGGTGT CTGAGGANGT CTGCAGTAAG 420 CTCTATGACC CGCTGTACCA CCCCAGCATG TTCTGCGCCG GCGGAGGGCA AGACCAGAAG 480 GACTCCTGCA ACGGTGACTC TGGGGGGCCC CTGATCTGCA ACGGGTACTT GCAGGGCCTT 540 GTGTCTTTCG GAAAAGCCCC GTGTGGCCAA CTTGGCGTGC CAGGTGTCTA CACCAACCTC 600 TGCAAATTCA CTGAGTGGAT AGAGAAAACC GTCCAGNCCA GTTAACTCTG GGGACTGGGA 660 ACCCATGAAA TTGACCCCCA AATACATCCT GCGGAANGAA TTCAGGAATA TCTGTTCCCA 720 GCCCCTCCTC CCTCAGGCCC AGGAGTCCAG GCCCCCAGCC CCTCCTCCCT CAAACCAAGG 780 GTACAGATCC CCAGCCCCTC CTCCCTCAGA CCCAGGAGTC CAGACCCCCC AGCCCCTCNT 840 CCNTCAGACC CAGGAGTCCA GCCCCTCCTC CNTCAGACGC AGGAGTCCAG ACCCCCCAGC 900 CCNTCNTCCG TCAGACCCAG GGGTGCAGGC CCCCAACCCC TCNTCCNTCA GAGTCAGAGG 960 TCCAAGCCCC CAACCCCTCG TTCCCCAGAC CCAGAGGTNC AGGTCCCAGC CCCTCCTCCC 1020 TCAGACCCAG CGGTCCAATG CCACCTAGAN TNTCCCTGTA CACAGTGCCC CCTTGTGGCA 1080 NGTTGACCCA ACCTTACCAG TTGGTTTTTC ATTTTTTGTC CCTTTCCCCT AGATCCAGAA 1140 ATAAAGTNTA AGAGAAGCGC AAAAAAA 1167 205 amino acids amino acid single linear protein Homo sapiens 176 Met Glu Asn Glu Leu Phe Cys Ser Gly Val Leu Val His Pro Gln Trp 1 5 10 15 Val Leu Ser Ala Ala His Cys Phe Gln Asn Ser Tyr Thr Ile Gly Leu 20 25 30 Gly Leu His Ser Leu Glu Ala Asp Gln Glu Pro Gly Ser Gln Met Val 35 40 45 Glu Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg Leu Leu Leu 50 55 60 Ala Asn Asp Leu Met Leu Ile Lys Leu Asp Glu Ser Val Ser Glu Ser 65 70 75 80 Asp Thr Ile Arg Ser Ile Ser Ile Ala Ser Gln Cys Pro Thr Ala Gly 85 90 95 Asn Ser Cys Leu Val Ser Gly Trp Gly Leu Leu Ala Asn Gly Arg Met 100 105 110 Pro Thr Val Leu His Cys Val Asn Val Ser Val Val Ser Glu Xaa Val 115 120 125 Cys Ser Lys Leu Tyr Asp Pro Leu Tyr His Pro Ser Met Phe Cys Ala 130 135 140 Gly Gly Gly Gln Asp Gln Lys Asp Ser Cys Asn Gly Asp Ser Gly Gly 145 150 155 160 Pro Leu Ile Cys Asn Gly Tyr Leu Gln Gly Leu Val Ser Phe Gly Lys 165 170 175 Ala Pro Cys Gly Gln Leu Gly Val Pro Gly Val Tyr Thr Asn Leu Cys 180 185 190 Lys Phe Thr Glu Trp Ile Glu Lys Thr Val Gln Xaa Ser 195 200 205 1119 base pairs nucleic acid single linear cDNA Homo sapiens 177 GCGCACTCGC AGCCCTGGCA GGCGGCACTG GTCATGGAAA ACGAATTGTT CTGCTCGGGC 60 GTCCTGGTGC ATCCGCAGTG GGTGCTGTCA GCCGCACACT GTTTCCAGAA CTCCTACACC 120 ATCGGGCTGG GCCTGCACAG TCTTGAGGCC GACCAAGAGC CAGGGAGCCA GATGGTGGAG 180 GCCAGCCTCT CCGTACGGCA CCCAGAGTAC AACAGACCCT TGCTCGCTAA CGACCTCATG 240 CTCATCAAGT TGGACGAATC CGTGTCCGAG TCTGACACCA TCCGGAGCAT CAGCATTGCT 300 TCGCAGTGCC CTACCGCGGG GAACTCTTGC CTCGTTTCTG GCTGGGGTCT GCTGGCGAAC 360 GATGCTGTGA TTGCCATCCA GTCCCAGACT GTGGGAGGCT GGGAGTGTGA GAAGCTTTCC 420 CAACCCTGGC AGGGTTGTAC CATTTCGGCA ACTTCCAGTG CAAGGACGTC CTGCTGCATC 480 CTCACTGGGT GCTCACTACT GCTCACTGCA TCACCCGGAA CACTGTGATC AACTAGCCAG 540 CACCATAGTT CTCCGAAGTC AGACTATCAT GATTACTGTG TTGACTGTGC TGTCTATTGT 600 ACTAACCATG CCGATGTTTA GGTGAAATTA GCGTCACTTG GCCTCAACCA TCTTGGTATC 660 CAGTTATCCT CACTGAATTG AGATTTCCTG CTTCAGTGTC AGCCATTCCC ACATAATTTC 720 TGACCTACAG AGGTGAGGGA TCATATAGCT CTTCAAGGAT GCTGGTACTC CCCTCACAAA 780 TTCATTTCTC CTGTTGTAGT GAAAGGTGCG CCCTCTGGAG CCTCCCAGGG TGGGTGTGCA 840 GGTCACAATG ATGAATGTAT GATCGTGTTC CCATTACCCA AAGCCTTTAA ATCCCTCATG 900 CTCAGTACAC CAGGGCAGGT CTAGCATTTC TTCATTTAGT GTATGCTGTC CATTCATGCA 960 ACCACCTCAG GACTCCTGGA TTCTCTGCCT AGTTGAGCTC CTGCATGCTG CCTCCTTGGG 1020 GAGGTGAGGG AGAGGGCCCA TGGTTCAATG GGATCTGTGC AGTTGTAACA CATTAGGTGC 1080 TTAATAAACA GAAGCTGTGA TGTTAAAAAA AAAAAAAAA 1119 164 amino acids amino acid single linear protein Homo sapiens 178 Met Glu Asn Glu Leu Phe Cys Ser Gly Val Leu Val His Pro Gln Trp 1 5 10 15 Val Leu Ser Ala Ala His Cys Phe Gln Asn Ser Tyr Thr Ile Gly Leu 20 25 30 Gly Leu His Ser Leu Glu Ala Asp Gln Glu Pro Gly Ser Gln Met Val 35 40 45 Glu Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg Pro Leu Leu 50 55 60 Ala Asn Asp Leu Met Leu Ile Lys Leu Asp Glu Ser Val Ser Glu Ser 65 70 75 80 Asp Thr Ile Arg Ser Ile Ser Ile Ala Ser Gln Cys Pro Thr Ala Gly 85 90 95 Asn Ser Cys Leu Val Ser Gly Trp Gly Leu Leu Ala Asn Asp Ala Val 100 105 110 Ile Ala Ile Gln Ser Xaa Thr Val Gly Gly Trp Glu Cys Glu Lys Leu 115 120 125 Ser Gln Pro Trp Gln Gly Cys Thr Ile Ser Ala Thr Ser Ser Ala Arg 130 135 140 Thr Ser Cys Cys Ile Leu Thr Gly Cys Ser Leu Leu Leu Thr Ala Ser 145 150 155 160 Pro Gly Thr Leu 

What is claimed:
 1. An isolated polypeptide comprising an amino acid sequence of SEQ ID NO:
 113. 2. A composition comprising the polypeptide of claim 1 and a physiologically acceptable carrier.
 3. The composition of claim 2, wherein the physiologically acceptable carrier is selected from the group consisting of: water; saline; alcohol; lipids; waxes; buffers and microspheres.
 4. A composition comprising the polypeptide of claim 1 and a non-specific immune response enhancer.
 5. The composition of claim 4, wherein the non-specific immune response enhancer is selected from the group consisting of: adjuvants; microspheres and liposomes.
 6. The composition of claim 5, wherein the adjuvant comprises a component selected from the group consisting of: aluminum hydroxide; mineral oil; lipid A; Bordella pertussis and Mycobacterium tuberculosis.
 7. The composition of claim 5, wherein the adjuvant is selected from the group consisting of: Freund's Incomplete Adjuvant; Freund's Complete Adjuvant and Merck Adjuvant
 65. 8. A fusion protein comprising a polypeptide according to claim 1 and a known prostate antigen.
 9. A fusion protein comprising at least one polypeptide according to claim
 1. 10. A composition comprising a fusion protein according to any one of claims 8 and 9, and a physiologically acceptable carrier.
 11. A composition comprising a fusion protein according to any one of claims 8 and 9, and a non-specific immune response enhancer.
 12. The composition of claim 11 wherein the non-specific immune response enhancer is an adjuvant.
 13. A method for stimulating an immune response in a patient, comprising administering to the patient a polypeptide of claim
 1. 14. A method for stimulating an immune response in a patient comprising administering a composition selected from the group consisting of: (a) compositions comprising a polypeptide according to claim 1; and (b) compositions comprising a fusion protein according to claim
 9. 